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ABSTRACT
Chen, Yafang Ph.D., Purdue University, May 2016. Structural and functional studies
of the papain-like protease 2 from mouse hepatitis virus . Major Professor: Andrew
D. Mesecar.
The global outbreak of the Severe Acute Respiratory Syndrome (SARS) in 2003
caused by SARS coronavirus (SARS-CoV) brought coronaviruses (CoV) to public
attention for the very first time. The ability of SARS-CoV to transmit from human
to human made the virus a great danger at the beginning of the 21st century. To date,
more than ten years have passed since the SARS-CoV outbreak, yet we are still in lack
of approved treatment against CoV infection. To make things worse, a new human
coronavirus, the Middle East Respiratory Syndrome Virus (MERS-CoV), emerged in
2012, and has resulted in 38% case fatality rate. Both SARS-CoV and MERS-CoV
are believed to originate from bats. The zoonotic origin of CoVs renders the future
epidemic, such as the reemergence of SARS and MERS, very likely. Therefore, it is
important to understand the pathogenesis of CoVs and develop therapeutics against
CoV infection.
Non-structural protein 3 (nsp3) is the largest nsp in the coronavirus genome and
it contains multiple functional domains that are required for coronavirus replication,
one of which is the papain-like protease domain (PLP or PLpro). CoV PLPs are
responsible for the processing of the N-terminal region of the viral polyprotein, which
is essential for virus replication. In addition, several CoV PLPs have been shown to
have deubiquitinating (DUB) and deISGylating activities, which may have implica-
tions in the viral evasion of the host innate immune response. Our goal is to establish
a system to investigate how the DUB and deISGylating activities of CoV PLPs are
involved in virus immune evasion. To this end, we chose PLP2 from mouse hepatitis
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virus (MHV) as our target of study because MHV has historically served as a model
system for the study of CoVs, and it has undeniable advantage of ease in culturing
in comparison to human coronaviruses.
Extensive studies have been performed with SARS-CoV PLpro and MERS-CoV
PLpro to investigate the DUB and deISGylating activity of CoV PLPs. The ability
of MHV PLP2 to deubiquitinate protein substrates has also been reported based on
cellular studies. However, no in vitro studies of MHV PLP2 has been published. It is
reported here the expression and purification of a region of MHV nsp3 that contains
the catalytic core of the PLP2 domain and its neighboring domains. More than 20 mg
of pure and active protein could be obtained from 1 L of E. coli cell culture. Further
kinetic characterization of MHV PLP2 using fluorescence-based assays revealed that
PLP2 possesses protease (RLRGG-AMC as the substrate), DUB (Ub-AMC as the
substrate) and deISGylating activities (ISG15-AMC as the substrate). With the
three substrates tested, MHV PLP2 can only be saturated by Ub-AMC with Km of
1.3 mM, but not by RLRGG-AMC or ISG15-AMC where Km is not determinable.
This suggests that PLP2 has a higher binding a nity to Ub than to ISG15 or the
peptide substrate (RLRGG). In addition, MHV PLP2 is a better DUB than SARS-
CoV PLpro and MERS-CoV PLpro, while its deISGylating activity is lower than the
two PLpro’s from human CoVs. Moreover, survey with di-Ubs cleavage revealed that
MHV PLP2 shows promiscuous recognition of the ubiquitin chain linkage, suggesting
that either specific recognition is not required or other host and viral factors are
involved in specific substrate recognition.
Although structures of several CoV PLPs have been reported, no structure of PLP
from betacoronavirus genogroup 2a is available. The 2.6 Å structure of MHV PLP2
determined in Chapter 3 through single-wavelength dispersion method (SAD) with
SeMet-substituted PLP2 presents the very first structure of PLP from a betacron-
avirus 2a group. It reveals a thumb-palm-finger architecture of the PLP2 catalytic
core with a well-aligned Cys-His-Asp catalytic triad, and an ubiquitin-like domain
(Ubl2) at the N-terminus of the PLP2 catalytic core. What is significant about
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this structure is that it uncovers a new MHV nsp3 domain, designated as ”Domain
Preceding Ubl and PLP2” or ”DPUP”. The DPUP domain is structurally similar to
the SARS unique domain (SUD), which raises doubts towards the unique presence
of the SUD domain in SARS-CoV. The kinetic (Chapter 2) and structural (Chapter
3) characterization of the DPUP-Ubl2-PLP2 construct reported in this dissertation
is the largest portion of coronaviral nsp3 that has ever been characterized in vitro.
In order to investigate the interactions between PLP2 and Ub, a computational
model of PLP2–Ub complex was generated through molecular dynamics. X-ray crys-
tal structure of PLP2 in complex with Ub was also determined (1.85 Å), where a
non-covalent complex was generated using PLP2 with a catalytic cysteine to serine
mutation and mono Ub (Chapter 4). Combining the information from the compu-
tational model and the crystal structure of the complex, residues of PLP2 that are
involved in the binding of Ub but are at a distance from the active site were iden-
tified. A series of mutants were then generated targeting these residues in order to
to selectively disrupt the DUB and/or deISGylating activity of PLP2 while main-
tain its protease activity. Further in vitro activity evaluation classified the mutants
into four groups (Chapter 4): mutants with decrease in both DUB and deISGylat-
ing activity (Group I), mutants with decrease only in deISGylating activity (Group
II) or DUB activity (Group III), and unstable mutants (Group IV). Although not
all mutants maintain intact protease activity, there are mutants with good protease
activity in each class, such as F290R and R281A (numbering based on the DPUP-
Ubl-PLP2 construct) in Class 1, R253E/R257A and R253A/R257A in Class 2, and
I249R and D250A in Class 3. Corresponding mutant viruses were then generated
by our collaborators through reverse genetics method to further investigate the ef-
fect of the mutation on virus pathogenesis. Excitingly, mutant viruses containing the
R281A mutation are attenuated and can induce immune responses to protect mice
from WT virus challenge. Preliminary virus studies performed by our collaborators
have suggested that the loss of deISGylating activity in the R281A mutant is critical
in virus attenuation. Extensive studies have been carried out to investigate the role
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of viral DUB activity. For instance, studies with EAV PLP2 and MERS-CoV PLpro
have shown that PLP/PLpro lacking the DUB activity lose its ability to antagonize
IFN-b production, suggesting the importance of viral DUB activity in innate immune
suppression. However, we are in lack of studies about the function of viral deISGy-
lating activity. The R281A mutant generated here is the first example of selectively
knocking out the coronaviral deISGylating activity. On one hand, the R281A mu-
tant virus provides guidance towards the generation of attenuated virus for vaccine
development; on the other hand, this study serves as a proof of principle for the idea
of utilizing virus with deficiency in DUB and/or deISGylating activity as a tool to
study the role of viral DUB and deISGylating during virus infection.
In addition, since CoV nsp3 is a large, membrane-associated, multi-domain pro-
tein, it is very likely that there is crosstalk between the adjacent domains of nsp3.
In order to explore this possibility, mutations were introduced into the Ubl2 domain,
which results in the discovery of a temperature-sensitive mutant (V787S). This mu-
tant contains a valine to serine mutation at position 787 (V787S, numbering based
on MHV nsp3) in the Ubl2 domain that compromises the stability and activity of
the adjacent PLP2 domain (Chapter 5). The V787S mutant has a melting temper-
ature (Tm) approximately 7 C lower than the Tm of WT protein, and the mutant
is gradually inactivated when incubated at elevated temperature. The correspond-
ing mutant virus (AM2 virus) has also been shown to be attenuated and capable of
eliciting protective immune response in mice by our collaborators.
Overall, the studies presented in this dissertation extend our knowledge of MHV
nsp3, and provide valuable tools to further investigate the role of viral DUB and
deISGylating activities during virus infection. Moreover, knowledge learnt from the
MHV system could be applied to other coronavirus systems such as MERS-CoV,
porcine epidemic diarrhea virus (PEDV) or feline infectious peritonitis virus (FIPV)




Coronaviruses (CoVs) are enveloped positive-sense RNA viruses. They belong to
group IV ((+)ssRNA) viruses under the order of Nidovirales (Figure 1.1A). CoVs
have been classified into four genera: alphacoronavirus, betacoronavirus, gamma-
coronavirus, and deltacoronavirus (Figure 1.1). Alpha- and beta-coronaviruses are
believed to originate from bats and can infect mammals, while gamma- and delta-
coronaviruses are associated with birds. The spike proteins protrude from the surface
of the virion give the virus crown-like corona appearance, hence comes the name
”coronavirus” (Figure 1.2A). Figure 1.2B shows the structural organization of coron-
avirus virion particles, where the RNA-nucleocapsid complex is surrounded by viral
envelope consisting of the spike glycoproteins (S), the envelope (E) and membrane
proteins (M).
CoVs can infect a variety of species, including animals and humans, causing
respiratory and gastrointestinal illnesses (1). So far, there have been six human
coronaviruses (HCoVs) identified, including HCoV-229E (1966), HCoV-OC43 (1967),
SARS-CoV (2003), HCoV-NL63 (2004), HCoV-HKU1 (2005) and MERS-CoV (2012).
Physiological consequences of human infection by CoVs are usually mild with cold-
like symptoms, except in immune-compromised individuals, the outcome can be much
more severe and even lead to death [3]. However, emerging CoVs are capable of be-
ing extremely pathogenic. The most serious epidemic caused by an emerging human
coronaviruses occurred in 2002-2003, when the global outbreak of Severe Acute Res-
piratory Syndrome (SARS), caused by SARS-CoV, infected 8000 people worldwide
and resulted in a case-to-fatality rate of approximately 10% [4]. The spread of SARS-
CoV was successfully confined through case isolation. Treatments against SARS-CoV
2
Fig. 1.1.: Coronavirus taxonomy and phylogeny. (A) Taxonomy of coronaviruses according
to the International Committee on Taxonomy of Viruses. (B) Phylogenetic tree of 50
coronaviruses with partial nucleotide sequences of RNA-dependent RNA polymerase. The
figure was modified from reference [1].
infection were mainly supportive treatment to relieve symptoms and boost the im-
mune system. Even though a decade has passed since the outbreak of SARS, no drugs
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Fig. 1.2.: Virion particle of coronaviruses. (A) The appearance of coronavirus virion parti-
cles under electron microscope. The figure was taken from reference [2]. (B) Structure of
coronavirus virion and the associated proteins. The figure was taken from reference [3].
or vaccines are approved for the treatment of coronaviral infections. The emergence
of a novel coronavirus in 2012, the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV), which has infected 1500 people worldwide as of Sep 11th, 2015 and
resulted in a case-to-fatality rate of 38% [5], highlights the need for the discovery of
antiviral drugs and/or vaccines against infections by CoVs.
Studies with SARS-CoV showed that SARS-CoV originates from a bat reservoir
[6]. Then the virus was transmitted to humans through an intermediate reservoir,
civets, where the virus obtained a spike mutation for it to e ciently infect humans [7].
Recently, a SARS-like bat coronavirus was isolated that can directly infect human
cells [8], suggesting that emerging coronaviruses may be transmitted directly from
bats to humans. Studies of MERS-CoV suggest that similar to SARS-CoV, MERS-
CoV also originates from an animal reservoir. A gene fragment that is identical
to MERS-CoV was identified in an Egyptian Tomb bat [9], and it was found that
dromedary camels have neutralizing antibodies against MERS-CoV [10]. However, it
is uncertain as to whether MERS-CoV is transmitted to humans directly from bats
or indirectly through dromedary camels as an intermediate reservoir. Nonetheless,
4
the zoonotic nature of HCoVs makes future global epidemics, such as the emergence
of SARS and MERS, a potential threat to human health.
In addition to human infection, CoVs can infect a variety of live stocks, such as
pigs, cows, and chickens. For example, porcine epidemic diarrhea virus (PEDV) is a
swine coronavirus that has devastated the pork industry worldwide. The outbreak
of PEDV in the United States in 2013/2014 killed over 7 million pigs and resulted in
significant economic loss [11]. Furthermore, the infection of cats by feline infectious
peritonitis virus (FIPV) has been shown to be fatal and incurable, which presents a
great threat to cat-lovers community [12]. Therefore, a better understanding of the
replication and pathogenesis of CoVs is urgently needed to develop e↵ective treat-
ments against coronaviral infections.
1.2 Coronavirus genome
CoVs have the largest genomes (25.5–32kb) among known RNA viruses. The first
two-thirds of the giant coronavirus genome contains two overlapping open reading
frames, ORF1a and ORF1b. These two open reading frames encode two viral replicase
polyproteins, pp1a from ORF1a and pp1ab that results from a -1 frame-shift between
ORF1a and ORF1b. Downstream of ORF1, the structure and accessory proteins are
encoded in the genome. The order of genes for the essential structure proteins, S,
E, M and N, are conserved among coronaviruses, while the accessory proteins are
strain-specific (Figure 1.3).
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Fig. 1.3.: Genome organization of some representative coronaviruses. All coronaviruses
contain ORF1 and genes for spike (S), envelope (E), membrane (M) and nucleocapsid (N)
proteins. The types of accessory proteins and their locations on the genome are strain-
specific. HE: hemagglutinin-esterase. The figure was modified from reference [13].
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1.3 Coronavirus life cycle
The viral spike glycoproteins mediate the entry of the virus into the host cells
through the binding of receptors on the host cells. Since there is substantial vari-
ation on the receptor-binding domain (RBD) of the spike protein among di↵erent
coronaviruses, the type of receptors utilized di↵ers from species to species, which
contributes to the broad host-range of coronaviruses [3]. Table 1.1 summarizes the
receptors utilized by some representative coronaviruses.
Figure 1.4 shows the life cycle of coronavirus. Upon entering the host cell, the
virus releases its positive-sense RNA genome, which encodes two replicase polypro-
teins, pp1a and pp1ab, from the ORF1. These two replicase polyproteins will then
be co- and post-translationally processed by viral papain-like proteases (PLPs) and
3C-like protease (3CLpro or nsp5) into 16 non-structural proteins (nsp) (Figure 1.5).
Table 1.2 summarizes the functions of the 16 nsps. Essentially, these 16 nsps are in-
volved in the rearrangement of host membranes and the assembly of double-membrane
vehicles (DMVs), which serve as the site for virus genome replication and transcrip-
tion [14]. In addition to locating necessary elements for virus replication, DMVs also
protect virus replication from host cell antagonism [15]. Within the DMV, the vi-
ral positive-sense RNA genome serves as a template for the synthesis of full-length
negative-sense RNAs, which in turn act as templates to generate viral RNA genomes.
On the other hand, subgenomic RNAs are synthesized using the RNA genome as a
template. These subgenomic RNAs then serve as templates to generate viral mRNA
for the synthesis of structural proteins [16]. The structural proteins (M, S and E)
are then integrated into the membrane of the endoplasmatic reticulum (ER). Finally,
the nucleocapsid protein (N) associates with newly synthesized genomic RNA in the
cytoplasm and buds into the lumen of the endoplasmmatic reticulum-Golgi interme-
diate compartment (ERGIC). The newly assembled virions are then released from





























































































































































































































































































































































































































































Fig. 1.4.: The life cycle of coronavirus. In the first step, The virus binds the cellular receptor.
Then, it releases its genome into the cytoplasm, where cellular ribosomes will translate the
first open reading frame (ORF1) as two large overlapping polyproteins. Then viral encoded
proteases will process the genome to produce the mature non-structural proteins which
will ensemble in double membrane vesicles originated from the endoplasmic reticulum to
form the replicase complex. The replicase complex is responsible for viral RNA replication
and synthesis of the mRNA for the structural proteins. Finally, the structural proteins
will ensemble in host membranes and will associate with the nucleocaspid and the newly
synthesized viral genome to form the new virion particles which will exit the cell via the
exocytosis pathway. This figure was taken from [18].
Fig. 1.5.: Domain organization of the MHV polyprotein. The location of the di↵erent
non-structural proteins (nsps) resulting from the processing of polyproteins are numbered
1 to 16. The two papain-like protease domains of MHV within nsp3, PLP1 and PLP2, are
represented in orange and red, respectively, while the 3C-like protease (3CLpro) within nsp5
is represented in blue. The corresponding cleavage sites for each protease (PLP1, PLP2 and
3CLpro) are indicated by arrows and are colored according to the protease that performs
the cleavage.
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Table 1.2.: Functions of the 16 coronaviral nsps.
Protein No. of aa1 Function References
Nsp1 247 Induce suppression of host gene expression [19]
Nsp2 585 Dispensable for viral replication [20]
Nsp32 2005 The largest replicase subunit with multiple do-
mains, including the papain-like proteases (PLP),
ADP-ribose-1”-monophosphate (ADRP) , etc
[21, 22]
Nsp4 496 Contains transmembrane domains; may serve as
membrane anchor or sca↵old for the replicase com-
plex; induce DMV formation
[22]
Nsp5 303 3CLpro (main protease), cleaves at 11 sites of the
polyprotein to produce nsp4 to nsp16
[23]
Nsp6 288 Contains transmembrane domains; may serve as
membrane anchor or sca↵old for the replicase com-
plex; induce DMV formation
[22]
Nsp7 92 Involved in RNA replication through specific in-
teractions with other nsps such as nsp1, nsp8 and
nsp10
[24,25]
Nsp8 194 RNA primase, act as processivity factor for nsp12 [24]
Nsp9 110 Binds ssRNA without sequence specificity [26]




Nsp12 928 RNA-dependent RNA polymerase (RdRP) [29]
Nsp13 600 Helicase [29]
Nsp14 519 3’ to 5’ exonuclease and RNA cap N7 methyltrans-
ferase, RNA proofreading
[29,30]
Nsp15 374 Endoribonuclease [29]
Nsp16 299 RNA cap 2’-O-methyltransferase [29]
1 The number of residues as in MHV pp1ab.
2 More details on nsp3 in Section 1.4.
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1.4 Coronavirus nsp3
Coronaviral nsp3 is a large, membrane-associated, multi-domain protein. It is the
largest replicase subunit among the 16 nsps and it contains several domains of func-
tional and structural importance for virus replication (Figure 1.6A). For instance, the
ADRP domain possesses ADP-ribose-1”-monophosphatase activity, and is proposed
to play a role in the regulation of virus replication [31, 32]. The PLP domain has
been shown to be multifunctional with protease, DUB, deISGylating and IFN an-
tagonism activities [33–35]. The NAB domain is capable of binding to ssRNAs [36].
Overall, SARS-CoV nsp3 has been shown to play a crucial role in inducing the forma-
tion of DMV together with nsp4 and nsp6 [22]. Furthermore, a proteomics analysis
of SARS-CoV virions has described nsp3 as the hub of connectivity as it makes the
most interactions with other viral proteins, such as the nucleocapsid protein and nsp2,
implying a critical role of nsp3 in virion assembly and virus replication [21, 37].
Nsp3 of SARS-CoV has been well studied, with two-thirds of nsp3 having been
characterized structurally by either X-ray crystallography or NMR (Figure 1.6) [34,
36, 38–41]. In contrast, there is a paucity of structural information of MHV nsp3,
even though MHV has served for decades as the model system for the study of coron-
aviruses (Figure 1.6). Extensive functional studies of domains within MHV nsp3 have
been conducted [31, 37, 42–44], but little structural information on these domains is
currently available. In fact, with the exception of SARS-CoV, the structural informa-
tion of most CoVs’ nsp3 is still missing (Figure 1.6B). Interestingly, the SARS-unique
domain (SUD), which consists of three domains, the N-terminal domain (SUD-N),
the middle domain (SUD-M) and the C-terminal domain (SUD-C), has been identi-
fied within SARS-CoV nsp3 [41]. It was originally proposed that the SUD domain
is unique to only SARS-CoV [45], and subsequently predicted to exist only in SARS
and bat CoVs within the betacoronavirus genogroups 2b-c [21]. However, the studies
reported in this dissertation provide structural evidence that this is not the case, as
the SUD-C appears to also exist in MHV (Chapter 3).
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Fig. 1.6.: Domain organization of the MHV and SARS-CoV coronavirus nsp3. (A) Do-
main architecture of SARS-CoV nsp3 in comparison to MHV nsp3. Domains with known
structures are shown as ribbons, while domains with unknown structures are represented
as boxes. For SARS-CoV, only one papain-like protease (PLpro) is encoded in nsp3 and
it catalyzes cleavage of the polyprotein at all three cleavage sites. The structures of the
three MHV nsp3 domains determined in this study are underscored with dash lines. PDB
codes: SARS-CoV nsp3 – 2IDY, 2ACF, 2W2G, 2KQW, 2FE8 and 2K87; MHV nsp3 –
2M0A and 4YPT (from this study). (B) A summary of the currently known structures of
various nsp3 domains wihin CoVs studied to date [34, 36, 38–41, 43, 46–50]. The currently
known nsp3 domains are indicated at the top and are shaded in di↵erent colors of red. The
PDB codes for the structures of individual or single domains are listed under the domain
acronym. The PDB codes for the structures of domains that have been determined from a
single polypeptide chain are connected with dashed lines and are shaded according to the
color code of the corresponding domains.
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1.5 Coronavirus papain-like domains
The PLP domains within nsp3 are responsible for proteolytic processing of the N-
terminal polyprotein. The number of PLP domains varies from one to two in di↵erent
groups of CoVs, which gives rise to a variety of N-terminal polyprotein processing
pathways (Figure 1.7) [51]. For example, SARS-CoV has only one enzymatically
active PLP domain (PLpro), thus the processing of the N-terminal polyprotein relies
on a single PLP. When two PLPs are encoded within nsp3 (usually termed PLP1
and PLP2), they can either have specialized or overlapping substrate specificity. In
the case of MHV, while PLP1 processes both the nsp1 |nsp2 and nsp2 |nsp3 sites,
PLP2 specifically cleaves the remaining nsp3 |nsp4 site. Conversely, both PLP1 and
PLP2 from HCoV-229E can process the nsp2 |nsp3 site [52–55]. In addition, even
though IBV also encodes two PLP domains, only PLP2 is enzymatically active but
not PLP1 [56]. Overall, PLP2 is conserved among CoVs, while PLP1 is not, which
has lead to the hypothesis that CoVs initially had only PLP2 and later evolved to
acquire PLP1 through gene duplication [51]. It is still not clear as to why CoVs
evolved to have di↵erent patterns for processing the N-terminal polyprotein.
Fig. 1.7.: Papain-like protease domains in coronaviruses. This figure was taken from refer-
ence [54].
In addition to their ability to process the polyprotein, CoV PLPs have been found
to be multifunctional. Initially, in 2005, Sulea et al. hypothesized that SARS-
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CoV PLpro may have structural similarity to ubiquitin-specific protease 7 (USP7,
or HAUSP, herpesvirus-associated USP) based on a sequence-based prediction of the
SARS-CoV PLpro amino acids in comparison with the crystal structure of USP7 [57].
In the same year, Barretto et al., Lindner et al. and colleagues showed that SARS-
CoV PLpro has deubiquitinating activity in vitro, supporting the hypothesis [33,58].
However, no structure of CoV PLP was available at that time. In 2006, Ratia
from the Mesecar Lab solved the structure of SARS-CoV PLpro, which revealed
that SARS-CoV PLpro adopts a thumb-palm-fingers architecture that is conserved
among USPs [34]. Later on, several other coronaviral PLPs, including NL63 PLP2,
TGEV PLP1, MERS-CoV PLpro and TGEV PLP2, have been shown to possess deu-
biquitinating activity [46, 59–63]. Moreover, SARS-CoV PLpro, MERS-CoV PLpro
and NL63 PLP2 have also been shown to have deISGylating activity [60, 61, 64, 65],
possibly counteracting the antiviral state triggered by ISG15 conjugation [66].
1.5.1 Deubiquitinating and deISGylating activities
Ubiquitination is the conjugation of ubiquitin molecules onto proteins (Figure
1.8C). It is a type of reversible post-translational modification. Three cooperative en-
zymes catalyze this process sequentially, including ubiquitin-activating enzyme (E1),
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). Polyubiquitin chains
are assembled through isopeptide bonds involving di↵erent lysines or the first me-
thionine of ubiquitin. Ubiquitin contains seven lysines at position 6, 11, 27, 29, 33,
48 and 63. Therefore, eight di↵erent linkages of polyubiquitin chains can be formed,
and they are involved in di↵erent cellular processes (Figure 1.8A) [67, 68]. The two
most common linkages occur at K48 and K63. K48-linked polyubiquitin chains target
proteins for proteosomal degradation, while K63-linked ones are involved in kinase
activation and endocytosis. In particular, both K48- and K63-linked polyubiquitin
chains have been shown to play important roles in the regulation of innate immune
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responses [69]. In contrast to ubiquitination, the removal of ubiquitin molecules is
deubiquitination, which is catalyzed by deubiquitinating enzymes (DUB).
Interferon-stimulated gene 15 (ISG15) is an ubiquitin-like molecule (Figure 1.8B).
Similar to ubiquitination, ISGylation is the conjugation of ISG15 molecule onto pro-
teins, which also involves three cooperative enzymes. However, in contrast to ubiq-
uitination, where polyubiquitin chains can be formed, only one ISG15 molecule can
be added to the protein substrates during protein ISGylation. The ISGylation of
cellular proteins have been proposed to establish an antiviral state for the cells [66].
The removal of ISG15 molecule is deISGylation, which is catalyzed by deISGylating
enzymes.
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Fig. 1.8.: Ubiquitination/ISGylation and deubiquitination/deISGylation. (A) Eight di↵er-
ent linkages of ubiquitin chains and their corresponding roles in cellular processes. (B) The
structure of ISG15 (pink, pdb code 1Z2M) superimposed to the structure of Ub (gray, pdb




Coronaviral papain-like proteases are cysteine proteases. The active site consists
of a Cys-His-Asp catalytic triad, where Cys is the nucleophile, His serves as a general
acid-base, and Asp aligns with His to promote the deprotonation of Cys. Figure 1.9
shows the proposed catalytic mechanism for cysteine proteases with a catalytic triad
using MHV PLP2 as an example. In the absence of substrate, ”E”, the catalytic His
is within hydrogen-bonding distance to both the catalytic Cys and Asp. Indeed, an
aligned and functional catalytic triad has been observed in the apo structure of several
CoV PLPs, including SARS-CoV PLpro, MERS-CoV PLpro, MHV PLP2, IBV PLpro
and TGEV PLP1 [34,46–48,70]. Upon binding of the substrate, formation of the ”ES”
complex facilitate the deprotonation of Cys to generate the reactive thiolate. The
thiolate then performs nucleophilic attack on the carbonyl carbon of the substrate,
generating a negative-charged tetrahedral intermediate, ”FP”. The negative charge of
this intermediate is stabilized by an oxyanion hole, which is predicted to be Gln in the
case of MHV PLP2 [70]. However, the oxyanion hole residue in SARS-CoV PLpro is
Trp [71], while the oxyanion hole in MERS-CoV PLpro is deficient [47]. Subsequently,
the first half of the substrate is eliminated, forming the thiol-ester intermediate ”F”.
Next, a water molecule serves as a nucleophile and attacks the carbonyl carbon of the
thiol-ester intermediate, generating a second tetrahedral intermediate, ”FQ”, which is
again stabilized by the oxyanion hole. Then, the catalytic Cys is eliminated, resulting
in regeneration of the thiolate and the second half of the substrate, ”FQ”. Finally,
the N-terminus of the substrate is released and free enzyme ”E” is regenerated.
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Fig. 1.9.: Proposed catalytic mechanism of MHV PLP2. Residues involved in the active
site are shown in black, and the substrate is shown in green. The figure was modified from
reference [72].
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1.5.3 Modulation of host innate immune responses by CoV PLPs
Because ubiquitination and ISGylation are known to play important roles in the
regulation of numerous cellular pathways, including innate immune responses, it has
been proposed that the CoVs may employ the DUB and deISGylating activities of
PLPs to antagonize host innate immune responses to infection (Figure 1.10). Indeed,
several studies have been conducted to investigate the IFN antagonism activity of
CoV PLPs. Initially, Devaraj et al. reported that SARS-CoV PLpro can inhibit IFN
response through the IRF3 pathway by suppressing the phosphorylation, dimerization
and nuclear translocation of IRF3 [73]. Then, Frieman and colleagues showed that
SARS-CoV PLpro can block TNFa-induced NF-kB activation by stabilizing IkBa [74].
After that, it was shown by Clementz and coworkers that NL63 PLP2 and SARS-CoV
PLpro inhibit RIG-I and TLR3-dependent IFNb expression [65]. It was also found
that SARS-CoV PLpro inhibits the type I interferon signaling pathway through inter-
action with the STING-TRAF3-TBK1 complex [75]. MHV PLP2 has also been shown
to inhibit cellular type I interferon production by deubiquitinating TANK-binding
kinase-1 (TBK1) [76, 77]. Most recently, it was discovered that MERS-CoV PLpro
displays IFN antagonism activity and inhibits RIG-I-, MDA5- and MAVS-induced
IFN expression [60–62]. Also, it was observed for the first time that SARS-CoV PL-
pro and MERS-CoV PLpro reduced the endogenous RNA level of proinflammatory
cytokines including CCL5, IFNb, and CXCL10 in activated cells [61]. In addition,
Deng et al. recently demonstrated that infection of alpha/beta interferon receptor
knockout (IFNAR(-/-)) mice with a chimeric Sindbis virus harboring SARS-CoV PL-
pro and ISG15 expression genes suppresses ISG15-mediated protection during viral
infection [78].
However, there have been discrepant results regarding the dependence of IFN
antagonism on the enzyme activity. Initially in 2007, Devaraj et al. reported that
SARS-CoV PLpro-TM active site mutants shows no decrease in its ability to inhibit
IFN expression [73]. On the other hand, Clementz et al. showed that the ability
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of SARS-CoV PLpro to inhibit TNFa-induced NF-kB activation decreased with the
treatment of an active site inhibitor of PLpro [65]. In the case of MERS-CoV PLpro,
it was shown by Mielech et al. that the ability of MERS-CoV PLpro to modulate
IFN production is activity-dependent [61]. Then Bailey-Elkin and coworkers further
reported that the IFN antagonism activity of MERS-CoV PLpro is specifically medi-
ated by the DUB activity, as MERS-CoV PLpro mutants with defective DUB activity
lost their ability to antagonize IFN production [79]. On the other hand, Yang et al.
showed that MERS-CoV PLpro-TM active site mutant displayed no decrease in the
down-regulation of RIG-I-stimulated IFNb promoter activity [62]. However, it needs
to be noted that the PLpro constructs used by Devaraj (SARS-CoV PLpro-TM) and
Yang (MERS-CoV PLpro-TM) both extended into the transmembrane domain (TM)
of nsp3 [62, 73]. Perhaps, in addition to PLpro, other parts of nsp3 can also serve
as IFN antagonists, thus resulting in the activity-independent IFN antagonism as
observed by Devaraj and Yang [62, 73].
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Fig. 1.10.: Proposed sites of action of SARS-CoV PLpro against host innate immune re-
sponses. In the RIG-I pathway, upon sensing of viral uncapped dsRNA or ssRNA, RIG-I is
ubiquitinated with K63-linked ubiquitin chain, which serves as a sca↵old to recruit MAVS.
MAVS then recruits TRAF6 for NF-kB activation or TRAF3 for IRF3 activation. In the
TRAF6 pathway, upon recruitment to MAVS, TRAF6 auto-ubiquitinates itself with K63-
polyubiquitin chains, which then serve as sca↵old to recruit the TAK1 and IKK complexes.
The co-localization of these two complexes enables the phosphorylation of IKK by TAK1.
Activated IKK then phosphorylates IkB, which leads to K48-polyubiquitination and sub-
sequent degradation of IkB, thus allows NF-kB to enter the nucleus to up-regulate IFNb.
Similarly, in the TRAF3 pathway, TRAF3 auto-ubiquitinates itself with K63-polyubiquitin
chains upon activation, which leads to the activation of TBK1 and IKKe. TBK1/IKKethen
phosphorylates and activates IRF3, allowing IRF3 to dimerize and enter the nucleus to
up-regulate the production of IFNb. On the other hand, TRAF3 and TBK1 can inter-
act with ER/mitochondrial-associated STING to form a TRAF3-TBK1-STING signaling
complex, which can further activate IRF3 for IFN production. Produced IFN will then
bind to IFN receptors in surrounding cells, and up-regulate ISGs through the JAK-STAT
signaling pathway. Modification of cellular proteins by ISGs, especially ISG15, establishes
an antiviral state for the cell. CoV PLPs are proposed to act on di↵erent branches in
the signaling pathway to deubiquitinate or deISGylate cellular proteins to antagonism host
innate immune responses. RIG-I: retinoic acid-inducible gene 1; MAVS: mitochondrial
antiviral signaling protein; TRAF: TNF receptor associated factor; TAK1: transforming
growth factor-activated kinase 1; IKKb; inhibitor of kkinase b; TBK1: TANK-binding ki-
nase 1; IkB: inhibitor of kB; IRF3: interferon regulatory factor 3; NF-kB: nuclear factor
kB; STING: stimulator of interferon genes; JAK: Janus kinase; STAT: signal transducer
and activator of transcription. This figure was taken from [72].
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1.5.4 Papain-like protease domains in MHV
As shown in Figure 1.7, MHV nsp3 contains two papain-like protease domains,
PLP1 and PLP2. PLP1 processes both the nsp1|nsp2 and nsp2|nsp3 sites, while PLP2
specifically cleaves the nsp3|nsp4 site [52, 53]. The sequence identity between MHV
PLP1 and PLP2 is only around 20%. Figure 1.11 shows the recognition sequence of
MHV PLP1 and PLP2 on the polyprotein, as well as the recognition sequence for
deubiquitinating and deISGylating enzymes. Interestingly, the sequence that PLP2
recognizes, LKGG, resembles the sequence that is recognized by deubiquitinating and
deISGylating enzymes, which is LRGG. This explains why PLP2 possesses DUB and
deISGylating activities. However, the sequences that PLP1 cleaves are very di↵erent
from PLP2, and PLP1 does not have DUB activity. One possible explanation for the
lack of PLP1 activity towards LXGG is that the S2 and S1 sites within the active site
of PLP1 are too big, thus the di-glycine tail from Ub and ISG15 cannot be locked into
correct orientation for catalysis. Because our goal is to dissect the DUB/deISGylating
activity of CoV PLPs, we chose MHV PLP2 as our target of study instead of MHV
PLP1.
Fig. 1.11.: The recognition sequence of MHV PLP1 and PLP2. The site of cleavage is
indicated with a red arrow.
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1.6 Statement of purpose and significance
It is intriguing that CoV PLPs evolved to possess DUB and deISGylating activi-
ties in addition to their protease activity. Given the importance of ubiquitination and
ISGylation in the regulation of host innate immune responses, it is only reasonable to
speculate that viruses evolve DUB/deISGylating activities to antagonize host innate
immune responses. Indeed, as discussed in Section 1.5.3, previous over-expression
studies with several CoV PLPs provide supports for this hypothesis. However, it is
still not clear yet as to what exactly happens during the course of virus infection. The
cellular substrates of the viral DUB and deISGylating activity remain to be discov-
ered. And it is puzzling regarding the spatial correlation between virus replication and
the innate immune responses. In order to study the role of viral DUB/deISGylating
activity during virus infection, a mutant virus that is capable of replicating nor-
mally in host cells but without its DUB and/or deISGylating activities could serve
as a fantastic tool. The goal of this dissertation is to decouple DUB/deISGylating
activity of MHV PLP2 from its protease activity through structure-guided protein
engineering. Virus containing mutated PLP2 with intact protease activity but de-
creased DUB/deISGylating activity can then be used as a tool for functional studies
of viral DUB/deISGylating activity. On the other hand, if the DUB/deISGylating
activity of CoV PLPs is indeed involved in the antagonism of host innate immune
responses, mutant viruses with low DUB/deISGylating activity may be attenuated,
and therefore may provide guidance towards vaccine development against coronavirus
infection. MHV and its PLP2 are selected as our system of study because MHV has
historically served as the model system for the study of coronaviruses. In addition,
MHV has advantages over human coronaviruses in terms of virus culturing and the
generation of mutant viruses. Moreover, as the most widely used animal model, mice
infected with MHV mutant virus is the most authentic model system for studying
the function of coronaviral DUB/deISGylating activity.
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CHAPTER 2. BIOCHEMICAL AND KINETIC CHARACTERIZATION OF MHV
PLP2
Part of the data and the text in this chapter has been published in the Journal of Bio-
logical Chemistry with the title ”X-ray Structural and Functional Studies of the Three
Tandemly-linked Domains of Nsp3 from Murine Hepatitis Virus Reveal Conserved
Functions” [70].
2.1 Introduction
In this chapter, the biochemical and kinetic characterization of MHV PLP2 is
presented. SARS-CoV PLpro was the first CoV PLP that was shown to have deubiq-
uitinating and deISGylating activities in addition to its ability to process the viral
polyprotein [33, 34, 60]. Since then, many other CoV PLPs, including HCoV-NL63
PLP2, MERS-CoV PLpro and IBV PLpro, have been characterized and shown to
possess both DUB and deISGylating activities [59, 61]. In contrast, although MHV
PLP2 has been shown to deubiquitinate and deISGylate cellular proteins in cell-based
assays [76, 77], the DUB and deISGylating activities of MHV PLP2 have not been
explicitly validated through in vitro characterization using purified recombinant pro-
teins.
Here, two constructs of MHV PLP2 were characterized kinetically and biochem-
ically (Figure 2.1). Both constructs contain the catalytic core of PLP2. We started
with the construct PLP21611-1970, which contains polyprotein residues 1611-1970. Bio-
chemical and kinetic characterization were performed with this construct of PLP2.
However, extensive attempts to crystallize PLP21611-1970 turned out to be unsuccessful.
Therefore, we switched to another construct PLP21525-1911, and performed extensive
biochemical, kinetic and structural characterization of this construct. As demon-
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strated in Chapter 3, we were able to crystallize PLP21525-1911 and solve the structure
of PLP2 catalytic core and its neighboring domains within MHV nsp3.
Fig. 2.1.: Two constructs of PLP2 that were used for this study. PLP21611-1970: residues
1611-1970 from MHV polyprotein 1ab was inserted into vector pET28a. Protein expressed
from this construct has a N-terminal hexa-histidine tag connected to aa 1611-1970 via
a thrombin cleavage site and a T7 tag. PLP21525-1911: residues 1525-1911 from MHV
polyprotein 1ab was inserted into vector pEVL8. Protein expressed from this construct has
a N-terminal octa-histidine tag connected to aa 1525-1911 via a TEV cleavage site. The
DPUP domain was identified in our studies. Please refer to Chapter 3 for details about this
domain.
2.2 Experimental Procedures
2.2.1 Expression and purification of PLP21611-1970
Construct
A region of nsp3 containing PLP2 and the predicted Ubl2 domain (amino acid
1611-1970 of polyprotein 1ab fromMHV strain A59, Appendix A) was codon-optimized
for mammalian cell expression and synthesized by Gene Script (Piscataway, NJ). The
gene was then cloned into pET28a vector via SacI and HindIII sites. The resulting
plasmid pET28a-PLP21611-1970 (Figure A.1) was then given to us from Dr. Susan
Baker’s lab at Loyola University Chicago for protein expression in E. coli cells.
Protein expression
Plasmid pET28a-PLP21611-1970 was transformed into E. coli strain BL21 (DE3)
electro-competent cells for protein expression using Bio-Rad MicroPulser. Upon elec-
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troporation, 500 ml of SOC medium (Corning) was added to the cells. Then the cells
were incubated at 37 C for 45 min with shaking. Finally, cells were streaked on Luria-
Bertani (LB) agar plate with 50 mg/ml kanamycin (kana) through quadrant streaking
to isolate single colony. The next day, the starter culture was prepared by inoculat-
ing 50 ml of LB medium supplemented with 50 mg/ml of kana with a single colony,
followed by incubation at 37 C for overnight. On the next day, 15 ml of the starter
culture was transferred to 1 L of LB medium for protein expression. A total of two
liters of cells were grown at 37 C in the presence of 50 mg/ml kana until the optical
density at 600 nm (OD600) reached 0.6. Protein expression was then induced by the
addition of isopropyl-b-D-thiogalactopyranoside (IPTG) to the final concentration of
0.1 mM and expression was allowed to occur for 6 hours at 25 C. Upon centrifugation
at 4,690 ⇥ g for 20 min at 4 C, the supernatant was removed and approximately 5 g
of cells were harvested. Cells harvested were then directly stored at -80 C.
Protein purification
The cell pellet (5 grams) was then resuspended in 40 ml bu↵er A (25 mM Tris pH
7.0, 500 mM NaCl, 20 mM imidazole, 5 mM b-mercaptoethanol (bME)) containing
flakes of lysozyme and DNase I. The cells were then lysed by sonication on ice-
water using a Branson Digital Sonifier at 65% amplitude for a total of 4 min with
a single cycle of 6.6 sec on and 9.9 sec o↵. The lysed cells were then subjected to
centrifugation at 28,880 ⇥ g for 30 min at 4 C. The clarified lysate (42 ml) was next
decanted from the pellet and filtered through a 0.45 mm membrane (Millipore). The
filtrate was loaded onto a 5 ml Ni2+-charged HisTrap-FF column (GE healthcare) pre-
equilibrated with Bu↵er A. Unbound proteins were washed with 20 column volumes
(CV) of 5% Bu↵er B (25 mM Tris pH 7.0, 500 mM NaCl, 500 mM imidazole, 5 mM
bME). Bound protein was then eluted using a gradient of 5% - 100% Bu↵er B in 30
CV. Fractions (5 ml) were collected and analyzed by specific activity and SDS-PAGE.
Fractions with the highest purity, based on specific activity and SDS-PAGE analysis,
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were pooled and concentrated using a 10K MWCO Millipore Micron centrifuge-based
concentrator. Samples were centrifuged at 2,844 ⇥ g to a volume of around 1.5 ml and
a protein concentration of 35 mg/ml, and loaded onto a Superdex-75 Hiload 26/60
column (GE Healthcare) pre-equilibrated with Bu↵er D (50 mM HEPES, pH 7.0, 100
mM NaCl, 10 mM dithiothreitol (DTT)), and eluted using Bu↵er D at a flow rate of
2 ml/min. Fractions (3 ml) were collected and pooled based on specific activity and
SDS-PAGE purity assessment using 10% gels. The resulting pool was flash-frozen
in the same bu↵er with the addition of glycerol to a final concentration of 5% using
liquid nitrogen. The final frozen enzyme was stored at -80 C. The protein was stable
in -80 C for six months.
Cuvette-based Bio-Rad Bradford Protein Assay
The concentration of protein throughout the purification was measured using a
cuvette-based Bio-Rad Bradford Protein Assay using 1.5 mL polystyrene disposable
cuvettes (1.00 cm light path, Fisherbrand) with 1 ml of Bradford dye. Bovine serum
albumin (BSA) at the concentrations of 0, 0.2, 0.4, 0.7 and 0.9 mg/ml was used to
create a standard curve.
Enzyme specific activity
Throughout the protein purification process, the specific activity of PLP2 was
determined using 250 nM of the Ub-AMC substrate following the procedure de-
scribed below in Section 2.2.5. Specific activity is defined as units per mg of enzyme
(Units/mg), where unit is the mmol of products produced per minute (mmol/min).
SDS-PAGE analysis
4 mg of protein was mixed with 1X of SDS-PAGE loading dye (50 mM Tris pH 6.8,
2% SDS, 10% glycerol, 0.004% bromophenol blue, 143 mM bME). Deionized water
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was added to bring up the volume to 15 ml. The mixture was incubated at room
temperature for 10 min prior to loading to 10% SDS-PAGE gels. The total of 15 ml of
samples were loaded. The gel was ran at 180 V for approximately 50 min in 1X SDS-
PAGE running bu↵er. 10X SDS-PAGE running bu↵er was prepared by dissolving 30
g of Tris base, 144 g of glycine and 10 g of SDS in 1 L of deionized water. Then the gel
was stained for 15 minutes in staining bu↵er with 25% isopropanol, 0.05% coomassie
blue R-250, 10% acetic acid, and destained in 10% acetic acid for overnight. Finally,
the gel was imaged using ProteinSimple FluorChem E system.
2.2.2 Expression and purification of PLP21525-1911
Constructs
A region of nsp3 containing PLP2, the predicted Ubl2 domain and an additional
N-terminal domain (amino acid 1525-1911 of polyprotein 1ab from MHV strain A59,
Appendix A) was codon-optimized and synthesized by Gene Script (Piscataway, NJ).
The gene was then cloned into the pCAGGS-MCS vector for mammalian cell expres-
sion. Plasmid pCAGGS-PLP2 was given to us by our collaborator Dr. Susan Baker
at Loyola University Chicago.
PCR cloning to move the gene of PLP21525-1911 to vector pEVL8. The gene
of PLP21525-1911 was amplified and inserted into ligation-independent cloning vector
pEVL8 (a modified pET30). To amplify the gene, 50 ml of PCR reaction was set up.
Each reaction contains 1 mM of forward and reverse primers, 0.5 mM dNTPs (Fer-
mentas), 5% DMSO, 50 ng of template, 2.5 U of PfuTurbo DNA polymerase (Agilent
Technology), and 1X of the corresponding Pfu reaction bu↵er (Agilent Technology).
Primers used are:
Forward: 5’ GAGAACCTGTACTTCCAATCCAATGAGGTGGAAGCTCTGC 3’
Reverse: 5’ CGGATCCGTTATCCACTTCCAATTTATCACTTCAGGTTTTTCAGATAC 3’
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The temperature cycle for the PCR experiment is shown below.
The PCR products were analyzed using 1% agarose gel. And the amplified genes
were recovered through gel purification using the Wizard SV Gel and PCR Clean-Up
System from Promega. At the same time, the vector pEVL8 was digested with SspI
enzyme in 50 ml of containing 1 mg of pEVL8, 10 U of SspI enyme (ThermoFisher
Scientific), and 1X of the corresponding Bu↵er G (ThermoFisher Scientific). The
reaction was incubated at 37 C for an hour. Digested pEVL8 was analyzed on 1%
agarose and recovered in the same way as the PCR products. Next, the amplified gene
was mixed with digested pEVL8 vector in a mass ratio of 2:1. Then the mixture was
transformed to 10 ml of XL1-Blue Supercompetent Cells (Agilent Technology) via heat
shock transformation method. All cells were plated on a LB agar plate supplemented
with 50 mg/ml of kana. The agar plate was incubated at 37 C for overnight.
The next day, colony PCR experiment was performed to confirm the insertion
of the gene. Briefly, 20 ml of PCR reaction was set up, which contains 0.25 mM of
T7 primers and T7-term primers, 0.2 mM dNTPs, 2 mM MgCl2, 1 U of Taq DNA
polymerase (ThermoFisher Scientific), 1X of the corresponding Taq Bu↵er with KCl
(ThermoFisher Scientific), and some cells from colonies on the plate as the template.
The temperature cycle for the colony PCR experiment is shown as below:
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The PCR products were then analyzed on 1% agarose gels. If there are PCR
products of the gene size, the corresponding colony will be inoculated and subjected
to plasmid extraction using a High Pure Plasmid Isolation Kit from Roche. The
resulting plasmid was then sequenced to verify the insertion of the correct gene to the
plasmid. Finally, plasmid pEVL8-PLP21525-1911 (Figure A.1) was transformed into
Escherichia coli cells for protein expression.
Protein expression
The expression of PLP21525-1911 followed the procedure described for PLP21525-1911
in Section 2.2.1. Plasmid pEVL8-PLP21525-1911 was transformed into E. coli strain
BL21 (DE3) electro-competent cells for protein expression. Approximately 5 g of cells
from 2 L of cell culture were harvested by centrifugation. Harvested cells were then
directly stored at -80 C.
Protein purification
Cell lysis and the first Ni2+-charged HisTrap-FF column were carried out following
the procedure described for PLP21525-1911 in Section 2.2.1. Based on specific activity
and SDS-PAGE analysis (according to the procedure described in Section 2.2.1),
fractions eluted from the Ni column that were with the highest purity were pooled
(total volume of 30 ml) and then treated with His-tagged TEV(S219V)–Arg5 protease
(mass ratio of PLP2 to TEV protease is 50:1) to remove the His-tag from PLP2 (please
refer to Appendix B for the expression and purification of His6-TEV(S219V)-Arg5).
The TEV protease treatment was performed overnight at 4 C while dialyzing against
one liter of Bu↵er C (25 mM Tris pH 7.0, 100 mM NaCl, 10 mM bME). To remove
the free His-tag and uncleaved PLP2 from cleaved PLP2, the dialyzed sample was
passed over the same Ni2+-charged HisTrap-FF column that was freshly equilibrated
with Bu↵er A. The flowthrough collected (35 ml) was concentrated using a 10K
MWCO Millipore Micron concentrators at 2,844 ⇥ g to a volume of 1.5 ml and a
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protein concentration of 43 mg/ml. The protein was then loaded onto a Superdex-
75 Hiload 26/60 column (GE Healthcare) pre-equilibrated with Bu↵er D (50 mM
HEPES, pH 7.0, 100 mM NaCl, 10 mM DTT), and eluted using Bu↵er D at a flow
rate of 2 ml/min. Fractions (3 ml) were collected and pooled based on specific activity
and SDS-PAGE purity assessment. Purified PLP2 was concentrated to 5 mg/ml for
protein crystallization or flash-frozen in the same bu↵er with the addition of glycerol
to a final concentration of 5% using liquid nitrogen. The final frozen enzyme was
stored at -80 C. The protein was stable in -80 C for a year.
Protein concentration determination
The concentration of protein throughout the purification was measured through
the cuvette-based Bio-Rad Bradford Protein Assay (Section 2.2.1). The concentra-
tion of final pure PLP21525-1911 was determined through the NanoDrop assay (Take3
Multi-Volume Plate with wavelength of 0.5 mm) by measuring the absorbance at 280
nm using a Synergy Multi-Mode Microplate Reader (BioTek). The extinction coef-
ficient of PLP21525-1911 was experimentally determined using the protocol described
in [80]. Briefly, the absorbance of PLP2 at 280 nm in either bu↵er (25 mM Tris,
pH 7.0, 100 mM NaCl, 5 mM bME) or 6M Gdn·HCl was measured as Anat and





where ✏Gdn·HCl = (#Trp)(5, 500) + (#Tyr)(1, 490) = 5 ⇥ 5, 500 + 14 ⇥ 1, 490 =
46, 870 M-1 cm-1. Using this method, the extinction coe cient of PLP21525-1911 was
experimentally determined to be 50, 033± 7, 350 M-1 cm-1 (1.14 L/(g · cm)), which is
close to the value predicted by the Expasy protein server (46,870 M-1 cm-1).
31
2.2.3 SEC-MALS analysis
This experiment was performed in Purdue Bindley Bioscience Center using a
MiniDawn Treos/Optilab TrEX (Wyatt Technology) with the assistance from Dr.
Lake Paul. Briefly, freshly purified protein in Bu↵er D at three di↵erent concen-
trations (0.7, 1.4, and 2.8 mg/ml for PLP21611-1970; 1.5, 3.0 and 6.0 mg/ml for
PLP21525-1911) was passed through a Superdex 75 10/300 GL analytical gel filtra-
tion column (GE Healthcare) at a flow rate of 0.5 ml/min. The column was coupled
to a MiniDawn Treos/Optilab TrEx instrument (Wyatt Technology). The molecular
weight of the eluted protein was calculated based on the Rayleigh scattering using
the ASTRA software (Wyatt Technology). SEC-MALS analysis was also performed
using BSA protein as a positive control.
2.2.4 MALDI analysis
To analyze the molecular weight of PLP21611-1970 through MALDI, 4 mg/ml of
purified PLP21611-1970 in a bu↵er of 50 mM HEPES, pH 7.0, 100 mM NaCl, 10 DTT
and 2% glycerol was used. Matrix was prepared by dissolving 10 mg of sinapic acid
in 1ml of 80% acetonitrile solution in deionized water with 0.1% TFA. The protein
sample was mixed with the matrix at a ratio of 1:1 or 1:2. 1 ml of the protein-
matrix mixture was loaded to the MALDI sample plate and allowed to dry completely.
Then the plate was loaded into the mass-spectrometer for MALDI analysis in linear
mode on an Applied Biosystems 4700 Proteomics analyzer (Framingham, MA). The
experiment was performed in the Purdue Proteomics Facility with the assistance from
Dr. Lake Paul.
2.2.5 Steady-state kinetic studies of PLP2
The substrate Z-RLRGG-AMC, where Z is the carboxybenzyl (cbz) protecting
group and RLRGG is the C-terminal peptide of Ub and ISG15, was purchased
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from BaChem America. The substrates Ub-AMC and ISG15-AMC were purchased
from Boston Biochem. For each of these substrates, AMC stands for 7-amino-4-
methylcoumarin. Ub-AMC and ISG15-AMC assays were performed at 25 C in trip-
licate in a final volume of 50 ml using the 96-well Corning Costar black half-volume
microplates, while the Z-RLRGG-AMC assay was performed at 25 C in triplicate in
a final volume of 100 ml using the 96-well Corning Costar black microplates. Assay
bu↵er contained 50 mM HEPES, pH 7.0, 0.1mg/ml bovine serum albumin (BSA)
and 2 mM DTT. Assays were initiated by the addition of enzymes. The final en-
zyme concentrations were as follows for each assay: 3 mM for the Z-RLRGG-AMC
assay, 5 nM for the Ub-AMC assay, and 10 nM for the ISG15-AMC assay. Rates
of hydrolysis of the substrates by PLP2 were monitored by recording the increase in
fluorescence intensity of the released AMC group (excitation l: 340 ± 40 nm, emis-
sion l: 460 ± 40 nm) as a function of time using a Synergy Multi-Mode Microplate
Reader (BioTek). The initial slope of the reaction in arbitrary fluorescence units
(AFU) per unit time (AFU/min) was converted to the amount of product produced
per unit time (mM/min) using the extinction coe cient of the product (AFU/mM).
The extinction coe cient of the product was determined from the slope of a standard
curve that was generated from the maximum fluorescence intensity upon complete
hydrolysis of the substrate versus the corresponding substrate concentration. For the
Ub-AMC substrate, the initial velocities were plotted against Ub-AMC concentrations
and the data were fit to the Michaelis-Menten equation v/[E] = kcat[S]/(Km + [S]),
where v is the initial velocity (mM/min), [E] is the enzyme concentration (mM), kcat
is the turnover number in reciprocal minutes (min-1) and represents the maximum
number of substrate molecules converted to products per enzyme molecule per min,
[S] is the substrate concentration, Km is the substrate concentration (mM) at which
the reaction rate is half of the maximum rate. For the substrates ISG15-AMC and
Z-RLRGG-AMC, where no saturation of the enzyme was observed, plots of initial
velocities versus substrate concentrations were fit to the equation v/[E] = kapp[S],
where kapp represents the apparent rate constant (kcat/Km) in units of mM-1 min-1.
33
When [S] ⌧ Km, kapp approximates kcat/Km. The error in kcat/Km (4kcat/Km) was














2.2.6 Inhibition of PLP21611-1970 by free ubiquitin
Inhibition of PLP21611-1970 by free ubiquitin was performed using the Ub-AMC
assay as described above. Either 200 nM or 400 nM of Ub-AMC was used as the
substrate. The rate of substrate hydrolysis by PLP21611-1970 was measured at the
presence of increasing concentration of free ubiquitin ranging from 1 mM to 100 mM.
The reciprocal of the reaction rate was plotted against the concentration of ubiquitin
at di↵erent [Ub-AMC] to generate the Dixon plot. According to the modified velocity













when 1/v = 1/Vmax, [I] =  Ki. Therefore, the Ki value of Ub could be estimated.
2.2.7 Polyubiquitin chains processing assay
A di-ubiquitin (di-Ub) panel including all eight ubiquitin linkage types: K6, K11,
K27, K29, K33, K48, K63 and linear, K48-linked tetra-ubiquitin and K63-linked hexa-
ubiquitin were purchased from Boston Biochem. Ubiquitin chain cleaving reactions
were performed by incubating 2 mM of each ubiquitin chain listed above with 20
nM of recombinant PLP2 in bu↵er (50 mM HEPES, pH 7.0, 100 mM NaCl, 0.1
mg/ml BSA and 2 mM DTT) at 25 C for various times ranging from 5 min to 2
hr. At the end of each time point, except for the panel of di-Ub substrates where
only one time point was taken at 2h, the reactions were quenched by the addition of
NuPAGE LDS sample bu↵er (Invitrogen). As a control, the same amount of ubiquitin
chains was incubated at 25 C without any enzyme. Samples were then analyzed by
SDS-PAGE using NuPAGE Novex 4-12% Bis-Tris mini gels (Invitrogen), which were
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subsequently stained with Coomassie Brilliant blue and destained with 10% acetic
acid for visualization. Each gel was then photographed using a FluoroChem E System
from Protein Simple.
2.3 Results
2.3.1 Expression, purification and characterization of PLP21611-1970
Expression and purification of PLP21611-1970
Plasmid pET28a-PLP21611-1970 was transformed to E. coli cells for protein expres-
sion. Purification of PLP21611-1970 started with a Ni2+-charged HisTrap-FF column
because the expressed protein contained a hexa-histidine tag. Next, the pooled frac-
tions obtained after the Ni column was concentrated and then passed through a sec-
ond size exclusion column Superdex-75 for further purification. The protein purity
throughout the purification process was assessed via specific activity (Table 2.1) and
SDS-PAGE analyses (Figure 2.2). The final purified PLP21611-1970 is a 398-amino-acid
protein, with a hexa-histidine tag followed by a thrombin cleavage site and a T7 tag at
the N-terminus. From the SDS-PAGE analysis shown in Figure 2.2A, the molecular
weight of the purified protein is determined to be slightly above 37 kDa according
to the molecular weight of the markers. Matrix-assisted laser desorption/ionization
(MALDI) analysis of the purified protein shows that the MW is around 44.7 kDa
(Figure 2.3), which is close to the theoretical MW of tagged PLP21611-1970 (44.7 kDa).
SEC-MALS analysis of PLP21611-1970
The quaternary structure of PLP2 in solution was investigated via size-exclusion
chromatography coupled with multi-angle light scattering (SEC-MALS) analysis (Fig-
ure 2.4). The molecular weight of the protein under the elution peak was determined
to be 46.1± 0.3 kDa, which is close to the predicted molecular weight of PLP2 (44.7
kDa), suggesting that PLP2 is present as a monomer in solution. In addition, the
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Fig. 2.2.: SDS-PAGE analysis of PLP21611-1970 throughout purification. 10% SDS-PAGE
gels were used for analysis. Molecular weight of the markers are the same between each gel.
Left: fractions after Ni2+-charged HisTrap column; right: fractions after S75 column.
Fig. 2.3.: MALDI analysis of PLP21611-1970. The peak of PLP21611-1970 with one added
proton ([M+H]+) is indicated with red arrow.
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Table 2.1.: Summary of PLP21611-1970 purification.
Sample
Total Protein Total Specific Activity Fold Yield
(mg)1 Units2 (Units/mg) Purification (%)
Lysate 294 14.8 0.05 1.00 100
HisTrap Pool 60 8.5 0.14 2.82 58
Superdex-75 Pool 36 7.9 0.22 4.36 53
1 The amount of protein obtained from 2 L of cell culture.
2 Unit (mmol/min): mmol of products produced per minute under following assay
conditions - 250 nM Ub-AMC, 5 nM enzyme in assay bu↵er containing 50 mM
HEPES, pH 7.0, 0.1 mg/ml BSA and 2mM DTT.
horizontal traces of molar mass under the peaks indicate that the PLP2 is mono-
dispersed.
Fig. 2.4.: SEC-MALS analysis of PLP21611-1970. Three di↵erent concentrations of protein
were used – 0.7, 1.4 and 2.8 mg/ml.
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Kinetic characterization of PLP21611-1970
Kinetic characterization of PLP21611-1970 was performed with two di↵erent fluoro-
genic substrates, Ub-AMC and Z-RLRGG-AMC. Scheme of the enzymatic assays is
shown in Figure 2.5. The kinetic response of PLP21611-1970 to increasing concentra-
tions of each of these substrates is shown in Figure 2.6. Plots of initial rates versus
increasing concentrations of Z-RLRGG-AMC up to the highest substrate concentra-
tions tested show no signs of substrate saturation (Figure 2.6, left panel). Therefore,
the data were fit to a line to derive the apparent rate constant, kcat/Km, from the
slope (Table 2.2). On the other hand, PLP2 is readily saturated by the substrate
Ub-AMC (Figure 2.6, right panel) so data were fit to the Michaelis-Menten equation
resulting in a Km value of 0.42 ± 0.04 mM, a kcat value of 34.2 ± 1.5 min-1 and a
kcat/Km value of 81.4± 8.5 mM-1 min-1. The kinetic parameters for the PLP21611-1970
catalyzed hydrolysis of both substrates are summarized in Table 2.2 in comparison
to other CoV PLPs.
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Fig. 2.5.: Scheme of the enzymatic assays employed to characterize the kinetic properties
of PLP2. From top to bottom: protease activity (RLRGG-AMC as the substrate), deubiq-
uitinating activity (Ub-AMC as the substrate), and deISGylating activity (ISG15-AMC as
the substrate).
Fig. 2.6.: Kinetics of PLP21611-1970-catalyzed hydrolysis of substrates. Cleavage of RLRGG-
AMC (left) and Ub-AMC (right) by PLP21611-1970 was measured at di↵erent substrate
concentrations. For each substrate, initial velocities were calculated at every substrate
concentration and then fit to equations (see Section 2.2.5 for details).
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Table 2.2.: Comparison of kinetic parameters of CoV PLPs with substrates




kcat/Km (mM-1 min-1) 0.00231 81.4± 8.5 ND2
kcat (min-1) – 34.2± 1.5 ND2
Km (mM) – 0.42± 0.04 ND2
PLP21525-1911
kcat/Km (mM-1 min-1) 0.00161 38.3± 6.3 2.30± 0.071
kcat (min-1) – 49.8± 2.9 –
Km (mM) – 1.3± 0.2 –
SARS PLpro3
kcat/Km (mM-1 min-1) 0.28± 0.111 1.5± 0.3 28.9± 5.3
kcat (min-1) – 75.9± 8.1 436± 40
Km (mM) – 50.6± 7.4 15.1± 2.4
MERS PLpro3
kcat/Km (mM-1 min-1) 0.0031 1.3± 0.2 9.9± 1.6
kcat (min-1) – 18.8± 1.2 32.6± 1.8
Km (mM) – 14.3± 2.0 3.3± 0.5
NL63 PLP24
kcat/Km (mM-1 min-1) 0.193± 0.0011 880± 90 59± 5
kcat (min-1) – 8.8± 0.2 3.2± 0.1
Km (mM) – 0.010± 0.001 0.054± 0.004
1 For non-saturating substrates, kcat/Km is the apparent value (kapp) de-
rived from the slope of rate versus substrate concentration plots.
2 ND: not determined.
3 The kinetic parameters of SARS-CoV PLpro and MERS-CoV PLpro are
from Baez-Santos et al. [60].
4 The kinetic parameters of HCoV-NL63 PLP2 was generated by Dr. Kiira
Ratia [18].
40
Inhibition of PLP21611-1970 by mono ubiquitin




E · S k2 ! E + P
where k1 is the rate constant for the association of E and S to ES, k 1 is the rate
constant for the disassociation of ES to E and S, and k2 is the rate constant for the
dissociation of ES to E and P. Under the steady-state assumption, the Michaelis con-
stant Km = (k2 + k 1)/k1. When k2 ⌧ k 1, where the catalysis of the reaction is the
rate-limiting step, the Michaelis constant Km simplifies to k 1/k1, which reflects the
substrates a nity for the enzyme (Kd). However, in complicated enzyme-catalyzed
reactions where Km 6= k 1/k1, Km does not represent the Kd value. To determine the
a nity of the product ubiquitin for PLP21611-1970, which will provide some insight into
the binding strength of the Ub-AMC, the inhibition of PLP21611-1970 by mono ubiqui-
tin with di↵erent concentration of Ub-AMC (200 nM and 400 nM) as substrates was
measured. A Dixon plot was then generated by plotting the reciprocal of the reaction
rate (1/v) against varying concentrations of ubiquitin (inhibitor) at each Ub-AMC
concentration. A horizontal line at the height of 1/Vmax was also included in the
plot to represent infinite [S]. Ubiquitin is considered as a competitive inhibitor in the
Ub-AMC assay. Assuming the concentration of Ub-AMC is infinite, the reaction rate
would remain constant at the level of Vmax regardless of the concentration of ubiq-
uitin. According to the modified velocity equation for competitive inhibitor (Section
2.2.6), the x-axis value of the intersection of any one line (the line of 200 nM or 400
nM Ub-AMC) with the horizontal line represents the -Ki value. As shown in Figure
2.7, the line of 200 nM Ub-AMC intersects with the horizontal line at an x-axis value
of -5.87 mM, indicating a Ki value of 5.87 mM. On the other hand, the line of 400 nM
Ub-AMC intersects with the horizontal line at an x-axis value of -5.62 mM, suggesting
a Ki value of 5.62 mM. Therefore, the average Ki value is approximately 5.7 mM. It
is more than 10 times higher than the Km value, indicating that the catalysis rate
constant k2 is not small compared to k 1. Since only two substrate concentrations
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(200 nM and 400 nM) were evaluated here, the data was not adequate to fit to the
competitive inhibition equation for more comprehensive analysis.
Fig. 2.7.: Inhibition of PLP21611-1970 by mono ubiquitin. The experiment was performed
using the Ub-AMC assay. Reciprocal of the reaction rate (1/Rate) was plotted against the
concentration of Ub (inhibitor) for di↵erent concentration of Ub-AMC (blue: 200 nM; red:
400 nM). The green horizontal line at y=1/Vmax represents the theoretical situation where
[Ub-AMC] is infinite. According to equation 2.1, the x-axis value of the intersect between
the blue/red line and the green line equals to -Ki.
Processing of ubiquitin chains by PLP21611-1970
The ability of PLP21611-1970 to act as deubiquitinating enzyme and catalyze the
hydrolysis of isopeptide bonds was explored by testing its activity towards di↵er-
ent ubiquitin chains. Since K48- and K63-linked polyubiquitin chains are the most
characterized chain types and the most ubiquitous in cell signaling pathways, we de-
termined the time course for hydrolysis of K48-linked tetra-ubiquitin (K48-Ub4) and
K63-linked hexa-ubiquitin (K63-Ub6) by PLP21611-1970. Briefly, K48-Ub4 and K63-
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Ub6 were incubated with PLP2 and the reaction products were analyzed by SDS-
PAGE. As shown in Figure 2.8, PLP2 processes K48-Ub4 and K63-Ub6 to mono-Ub
at nearly equal rates without the build-up of the intermediate Ub2 or Ub3 species.
Fig. 2.8.: PLP21611-1970-mediated processing of ubiquitin chains. 20 nM PLP2 and 2 mM
ubiquitin chains were incubated at 25 C with samples being taken out at five di↵erent
time points. Polyubiquitin chains incubated without PLP2 serve as negative controls (ctrl).
Markers (molecular weight, from top to bottom): 50, 37, 25, 20, 15, 10 kDa.
2.3.2 Expression, purification and characterization of PLP21525-1911
Expression and purification of PLP21525-1911
The PLP21525-1911 construct containing the catalytic core of PLP2, the predicted
Ubl2 domain and an additional N-terminal domain was expressed and purified from E.
coli following the procedure described in Section 2.2.2. The purity of the protein was
assessed throughout purification via SDS-PAGE (Figure 2.9A) and specific activity
analyses (Table 2.3). The final purified PLP21525-1911 is a 389-amino-acid protein (43.5
kDa), with two additional residues at the N-terminus resulting from removal of the
octa-histidine tag after TEV protease cleavage. A total of 45 mg of highly pure PLP2
can be obtained from 2 L of culture.
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Fig. 2.9.: Purification and SEC-MALS analysis of PLP21525-1911. (A) Protein SDS-PAGE
gel throughout the purification of PLP21525-1911. 1–markers, 2–clear lysate, 3–post Ni His-
Trap column pool, 4–FT of reverse Ni HisTrap column post TEV cleavage, 5–Superdex 75
pool. (B) SEC-MALS analysis of PLP21525-1911 at three di↵erent concentrations – 1.5, 3
and 6 mg/ml.
Table 2.3.: Summary of PLP21525-1911 purification.
Sample
Total Protein Total Specific Activity Fold Yield
(mg)1 Units2 (Units/mg) Purification (%)
Lysate 390 0.62 0.0016 1.00 100
HisTrap Pool 105 0.30 0.0029 1.81 49
Superdex-75 Pool 45 0.14 0.0031 1.94 22
1 The amount of protein obtained from 2 L of cell culture.
2 Unit (mmol/min): mmol of products produced per minute under following assay
conditions - 50 mM RLRGG-AMC, 3 mM enzyme in assay bu↵er containing 50 mM
HEPES, pH 7.0, 0.1 mg/ml BSA and 2mM DTT.
SEC-MALS analysis of PLP21525-1911
The quaternary structure of PLP21525-1911 in solution was investigated via SEC-
MALS analysis (Figure 2.9B). The molecular weight of eluted protein was calculated
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to be 43.4 ± 0.6 kDa, which is consistent with the predicted molecular weight of
43.5 kDa, suggesting that PLP21525-1911 exists as a monomer in solution. In addition,
the horizontal traces of molar mass across the peaks indicate that PLP21525-1911 is
mono-dispersed.
Kinetic characterization of PLP21525-1911
Three di↵erent fluorogenic substrates, Ub-AMC, ISG15-AMC and Z-RLRGG-
AMC were used to characterize the kinetic properties of PLP21525-1911. A scheme
of the enzymatic assays is shown in Figure 2.5. The kinetic response of PLP2 to
increasing concentrations of each of these substrates is shown in Figure 2.10. Plots
of initial rates versus increasing concentrations of either Z-RLRGG-AMC or ISG15-
AMC up to the highest substrate concentrations tested show no signs of substrate
saturation (Figures 2.10 A and C). Therefore, data were fit to a line to derive the
apparent rate constant, kapp, from the slopes. On the other hand, PLP2 is readily sat-
urated by the substrate Ub-AMC so data were fit to the Michaelis-Menten equation
(Figure 2.10B) resulting in a Km value of 1.3± 0.2 mM and a kcat value of 49.8± 2.9
min 1. The resulting kinetic parameters of PLP21525-1911 catalyzed hydrolysis of all
three substrates are summarized in Table 2.2 where they are compared to the kinetic
parameters of SARS-CoV PLpro, MERS-CoV PLpro and HCoV-NL63 PLP2, which
were determined previously [18, 60].
Recognition and processing of polyubiquitin chains by PLP21525-1911
The ability of PLP2 to act as deubiquitinating enzyme and catalyze the hydrolysis
of isopeptide bonds was explored next by testing its specificity towards ubiquitin
chains. Di-ubiquitins (di-Ub’s) with di↵erent isopeptide linkages (K6, K11, K27,
K29, K33, K48, K63) or a peptide linkage (linear-Ub) were incubated with PLP2 and
the reaction products were analyzed by SDS-PAGE (Figure 2.11). The results show
that MHV PLP2 is capable of cleaving all di-ubiquitins with isopeptide bonds into
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Fig. 2.10.: Kinetics of PLP21525-1911-catalyzed hydrolysis of substrates. Cleavage of
RLRGG-AMC (A), Ub-AMC (B) and ISG15-AMC (C) by PLP21525-1911 was measured
at di↵erent substrate concentrations. For each substrate, initial velocities were calculated
at every substrate concentration and then fit to equations (see Section 2.2.5 for details).
monoubiquitins but not linear-Ub, which contains a peptide bond (Figure 2.11A).
In addition, the e ciency of di-ubiquitin cleavage by PLP2 appears to be linkage
dependent as hydrolysis of K11-, K48- and K63-linked di-Ubs are the most e cient.
After two hours, these di-Ubs have been completely processed to mono-Ub whereas
unreacted substrate still remains for K6-, K27-, K29- and K33-linked di-Ubs.
Since K48- and K63-linked polyubiquitin chains are the most characterized chain
types and the most ubiquitous in cell signaling pathways, we determined the time
course for hydrolysis of K48-linked tetra-ubiquitin (K48-Ub4) and K63-linked hexa-
ubiquitin (K63-Ub6) by PLP21525-1911 (Figures 2.11 B and C). The data show that
PLP2 processes K48-Ub4 and K63-Ub6 with nearly equal rates.
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Fig. 2.11.: PLP21525-1911-mediated processing of ubiquitin chains. (A) Survey of the hydrol-
ysis of di-Ub by PLP21525-1911. 0.5 mg of di-Ub with di↵erent linkages (K6, K11, K27, K29,
K48, K63 and linear) was incubated at 25 C with 20 nM PLP2 for 2 hours, respectively.
Di-Ub incubated without PLP2 serves as the negative control. (B and C) The time-resolved
hydrolysis of K48-Ub4 (B) and K63-Ub6 (C) by PLP21525-1911. The reaction was incubated
at 25 C with samples being taken at five di↵erent time points. Polyubiquitin chains incu-
bated without PLP2 serves as negative control (ctrl). Marker (KDa, from top to bottom):
50, 37, 25, 20, 15, 10.
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2.4 Discussion
Here, two protein constructs, PLP21611-1970 and PLP21525-1911 (Figure 2.1), that
both contain the catalytic core of MHV PLP2 were characterized. As shown in Ta-
ble 2.2, the kcat/K m value of PLP21611-1970 and PLP21525-1911 with RLRGG-AMC
is comparable. As for the activity with Ub-AMC, the kcat value of PLP21525-1911
(49.8 min-1) is slightly higher than that of PLP21611-1970 (34.2 min-1), while the Km
value of PLP21611-1970 (0.42 mM) with Ub-AMC is only half of that for PLP21525-1911
(0.42 mM), resulting in a kcat/Km value of PLP21611-1970 (81.4 mM-1 min-1) approx-
imately 2 times of that for PLP21525-1911 (38.3 mM-1 min-1). This could be due to
the premature determination of the Km and kcat value for PLP21611-1970 since the
highest concentration of Ub-AMC used is only 1 mM for PLP21611-1970, in contrast to
the highest concentration of 4 mM used for PLP21525-1911 characterization. In addi-
tion, SEC-MALS analyses of the two constructs reveal that both PLP21611-1970 and
PLP21525-1911 exist as monomers in solution. Therefore, given the comparable activ-
ity between PLP21611-1970 and PLP21525-1911, the same oligomeric properties between
these two constructs, and the fact that PLP21525-1911 was able to be crystallized but
not PLP21611-1970, PLP21525-1911 was chosen for further kinetic and structural charac-
terization.
Based on the kcat/Km values shown in Table 2.2, MHV PLP21525-1911 catalyzes the
hydrolysis of Ub-AMC approximately 17-fold more e ciently than ISG15-AMC and
24,000-fold more e ciently than Z-RLRGG-AMC. This order of substrate preference
for MHV PLP21525-1911 (Ub-AMC > ISG15-AMC >>> Z-RLRGG-AMC) is the same
as HCoV-NL63 PLP2, but stands in contrast to the SARS-CoV and MERS-CoV
PLpro enzymes, which prefer ISG15-AMC over Ub-AMC by about 19-fold and 8-
fold, respectively (Table 2.2). SARS-CoV PLpro and MERS-CoV PLpro also highly
prefer ISG15-AMC by 96-fold and 3,300-fold over the Z-RLRGG-AMC substrate. The
significant di↵erence between the PLP2 and PLpro-mediated hydrolysis of Ub-AMC
or ISG15-AMC and Z-RLRGG-AMC suggests that there are additional and important
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interactions between PLP2 and Ub/ISG15 outside of the enzyme’s catalytic center,
i.e. beyond the reactive cysteine and substrate recognition subsites for ”RLRGG”.
The survey with di-Ub’s showed that MHV PLP2 can process di-Ub’s of all linkage
types, except the linear one (Figure 2.11A). It should be noted that Lys-linked polyu-
biquitin chains are formed through isopeptide bonds between the C-terminal glycine
of the distal Ub and the e-amino group of lysine’s from the proximal Ub, while linear
ubiquitin chains are formed via peptide bonds between the C-terminal glycine of the
distal Ub and the N-terminal methionine of the proximal Ub (Figure 2.12). The rea-
son that MHV PLP2 could not process the linear ubiquitin chains probably is because
the substrate binding pocket (S1’ subsite) of MHV PLP2 is too small to accommo-
date the bulky side chain from Met. It has been shown that SARS-CoV PLpro and
MERS-CoV PLpro could not process linear ubiquitin chains either [60]. On the other
hand, the observation that MHV PLP2 can process all Lys-linked di-Ub’s indicates
that this enzyme displays promiscuous recognition surrounding the environment of
the lysine residue of the proximal ubiquitin molecule in ubiquitin chains. What is not
clear is whether or not there are specific substrate recognition mechanisms associated
with MHV PLP2 that are mediated through the interactions with specific ubiquiti-
nated substrates instead of the attached ubiquitin chains. Alternatively, MHV PLP2
may require external assistance, such as other domains in nsp3, to achieve substrate
discrimination, or MHV PLP2 may indiscriminately deubiquitinate multiple host cell
proteins.
Moreover, the observation that MHV PLP2 can process both K48- and K63-linked
polyubiquitin chains to mono-ubiquitin with nearly equal rate di↵ers from that of
SARS-CoV PLpro. In the case with SARS-CoV PLpro, K48-linked ubiquitin chains
are cleaved much more rapidly than the K63-linked ones, and K48-diUb is processed
much slower than the longer ubiquitin chains [60,71]. Our results here indicate that,
unlike SARS-CoV PLpro which has two ubiquitin binding sites, MHV PLP2 most
likely has only one ubiquitin binding site, which is the same as MERS-CoV PLpro
(Figure 2.13B). Di↵erent mechanisms to process K48-linked ubiquitin chains have
49
Fig. 2.12.: Isopeptide bond versus peptide bond. Lys-linked polyubiquitin chains are linked
via isopeptide bonds, while linear ubiquitin chains are formed through peptide bond. ”R”
is the side chain of methionine.
been proposed for SARS-CoV PLpro and MERS-CoV PLpro, where the processing
of K48-Ub2 to mono Ub is the rate-limiting step for SARS-CoV PLpro, but not for
MERS-CoV PLpro [60] (Figure 2.13). The observation here suggests that MHV PLP2
process K48-linked polyubiquitin chains in a manner similar to MERS-CoV (Figure
2.13). On the other hand, a mechanism of how K63-linked tetra-ubiquitin chains
are processed by these three CoV PLPs is proposed in Figure 2.14. For MHV PLP2
and MERS-CoV PLpro, since they only have one Ub-binding site, the processing of
K63-linked Ub chains shows no di↵erence to the processing of K48-linked Ub chains,
where the cleavage occurs in a stepwise manner. As for SARS-CoV PLpro, since
K63-linked Ub chains adopt an extended and linear conformation (Figure 2.14A),
only the SUb1 site is involved in the binding of K63-linked Ub chains, revealing a
similar binding mode as MHV PLP2 and MERS-CoV PLpro. However, the binding
a nity of K63-linked Ub chains to the three CoV PLPs may varies, resulting in the
di↵erent rates in the hydrolysis of the Ub chains.
Although the DUB and deISGylating activity of MHV PLP2 has been demon-
strated in several cell-based studies [44, 76], here these activities of MHV PLP2 are
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Fig. 2.13.: Model of K48-linked Ub4 cleavage by MHV PLP2, MERS-CoV PLpro and SARS-
CoV PLpro. (A) Diagram of K48-linked Ub4. (B) The Ub-binding sites on MHV PLP2,
MERS-CoV PLpro, and SARS-CoV PLpro. MHV PLP2 and MERS-CoV PLpro have only
one distal Ub-binding site (SUb1) at the zinc finger, while SARS-CoV PLpro has two distal
Ub-binding sites, SUb1 at the zinc finger and SUb2 at the ridge region. The position of the
substrate’s scissile bond in the active site is indicated with a red arrow. (C) MHV PLP2
and MERS-CoV PLpro hydrolyze K48-linked Ub4 in a stepwise manner with no di↵erence
in the processing of K48-linked Ub chains of di↵erent length. Other possible processing
routes are indicated with blue arrows. In the case of SARS-CoV PLpro, since it has two
Ub-binding sites, it favors the binding of di-Ub instead of mono-Ub. Thus the inhibition
of SARS-CoV PLpro by K48-Ub2 occurs, resulting in the accumulation of K48-Ub2. This
figure was modified from [60].
explicitly validated through in vitro characterization using purified recombinant pro-
teins. Overall, the characterization of MHV PLP2 revealed significant distinctions
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Fig. 2.14.: Model of K63-linked Ub4 cleavage by MHV PLP2, MERS-CoV PLpro and
SARS-CoV PLpro. (A) Diagram of K63-linked Ub4. (B) The Ub-binding sites on MHV
PLP2, MERS-CoV PLpro, and SARS-CoV PLpro, same as what is shown in Figure 2.13.
(C) All three CoV PLPs process K63-linked Ub4 in a stepwise manner with equal rates in
the hydrolysis of di↵erent species. This figure was modified from [60].
in the deubiquitination and deISGylation activities of MHV PLP2 and other CoV
PLPs, including SARS-CoV PLpro and MERS-CoV PLpro. The results suggest that
these viral proteins may target di↵erent cellular substrates to facilitate viral evasion
of the host innate immune responses.
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Antagonizing the host innate immune responses through viral deubiquitinating
or deISGylating enzymes seems to be a common strategy employed by viruses. Be-
sides coronaviruses, other species, such as adenovirus, nairovirus, arterivirus, and
herpesvirus, have also been found to encode proteases that have deubiquitinating
and deISGylating activities, and these proteases are proposed to assist in evading
ubiquitin- or ISG15-dependent host innate immune responses (Table 2.4, reviewed
in [81,82]. Extensive protein over-expression studies performed on cellular levels have
to some extent supported this hypothesis [65, 74, 77]. And it has recently been re-
vealed that MERS-CoV PLpro mutant with deficient DUB activity failed to inhibit
IFN-b promoter activation in cell-based assay [79]. Moreover, studies with equine ar-
teritis virus (EAV) PLP2 have shown that cells infected with DUB activity-deficient
EAV virus display significantly enhanced innate immune responses compared to cells
infected with WT EAV virus [83]. However, a detailed mechanism of how viral DUBs
suppress host immune responses is still not fully clear. The continuous emergence
of severe epidemics caused by new CoVs requires better understanding of the infec-
tion and pathogenesis mechanisms. MHV is the best-studied coronavirus model, and
it has an undeniable advantage of ease in culturing in comparison to HCoVs. The
discovery that PLP2 has deubiquitinating/deISGylating activities enables the use of















































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. STRUCTURE DETERMINATION OF MHV PLP2
Part of the data and the text in this chapter has been published in the Journal of Bio-
logical Chemistry with the title ”X-ray Structural and Functional Studies of the Three
Tandemly-linked Domains of Nsp3 from Murine Hepatitis Virus Reveal Conserved
Functions” [70].
3.1 Introduction
The first crystal structure of CoV PLPs reported was the structure of SARS-CoV
PLpro (betacoronavirus genogroup 2b), which was solved in 2006 by Ratia and col-
leagues in the Mesecar Lab [34]. The structure of SARS-CoV PLpro revealed that
the catalytic core of SARS-CoV PLpro adopts a thumb-palm-fingers architecture
that is conserved in ubiquitin-specific proteins (USPs) (Figure 3.1) [98–101], which
is consistent with the observation that SARS-CoV PLpro possesses DUB activity.
Additionally, the structure shows that the active site of SARS-CoV PLpro contains
a Cys-His-Asp catalytic triad that is well-aligned for catalysis, in contrast to the cat-
alytic core of USP7 where its active site is misaligned in the absence of substrate [98].
Moreover, the structure of SARS-CoV PLpro revealed for the first time the presence
of an ubiquitin-like domain (Ubl) in nsp3 preceding the catalytic core of PLpro. Since
then, the X-ray structures of several other CoV PLPs have been determined, including
TGEV PLP1 (alphacoronavirus genogroup 1a) and MERS-CoV PLpro (betacoron-
avirus genogroup 2c) [46, 47]. The structure of IBV PLpro (gammacoronavirus) was
also published recently [48]. However, no structural information of a PLP from the
betacoronavirus genogroup 2a has been reported, which is surprising since MHV, a
virus in betacoronavirus genogroup 2a, has served as the model system for the study
of coronaviruses for decades. It is even more surprising since there is a large amount
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of functional studies conducted with MHV nsps. Despite this, the structures of MHV
nsps have been poorly characterized (Figure 1.6 and [102]).
Fig. 3.1.: Structural superposition of SARS-CoV PLpro (blue) with USP7 (yellow) and
USP14 (red). The thumb, palm and fingers domains are indicated. This figure was modified
from [34].
In order to determine the structure of MHV PLP2, crystallization of di↵erent
regions of MHV nsp3 containing the catalytic domain of PLP2 was attempted. For-
tunately, the PLP21525-1911 construct crystallized and allowed the collection of a na-
tive dataset. However, extensive attempts to determine the structure through the
method of molecular replacement turned out to be unsuccessful. Therefore, di↵erent
approaches of experimental phasing were pursued, and eventually the structure of
PLP21525-1911 was determined via the single-wavelength anomalous dispersion (SAD)
method using SeMet-substituted protein. As expected, the structure reveals a thumb-
palm-fingers architecture of the PLP2 catalytic core and a preceding Ubl domain.
Surprisingly, we also discovered a new domain in MHV nsp3 at the N-terminus of
PLP2 that we call the ”Domain Preceding Ubl and PLP2 (DPUP)” domain. Fur-
ther analysis reveals that DPUP has close structural similarity to the Severe Acute
Respiratory Syndrome coronavirus unique domain C (SUD-C), suggesting that the
SUD may not be unique to SARS-CoV. Attempts to crystallize PLP2 without the
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N-terminal DPUP domain (PLP21608-1911) were unsuccessful. Throughout the rest
of this dissertation, PLP21525-1911 (DPUP-Ubl2-PLP2) will be referred as PLP2 for
simplicity.
3.2 Experimental Procedures
3.2.1 Crystallization of PLP2
PLP21525-1911 (PLP2) was purified as described in Section 2.2.2. Initial crystal-
lization conditions for PLP2 were first identified after performing a high-throughput
crystallization screen using a series of commercial crystallization screens from Qiagen.
Briefly, 1 ml of freshly purified PLP2 at three concentrations (6 mg/ml, 12 mg/ml and
24 mg/ml) was pipetted into the three sub-wells of a 96-3 well sitting drop plate
(Greiner CrystalQuick crystallization plate), and 1 ml of reservoir solution was then
added to the drop. The plates were then incubated at 20 C. An initial crystallization
hit was identified after 2 days of growth in a solution containing 100 mM HEPES, pH
7.5, 2% PEG400, and 2 M (NH4)2SO4. Initial crystals were small with the longest
dimension of only 0.05 mm. Further optimization of the crystallization conditions
was then carried out manually using 24-well sitting drop plates at 20 C using a fine
grid of 0.1 M HEPES between pH 6.8 and pH 8.3, and PLP2 microseeds of serial
dilutions between 10 4 and 10 10. Microseeds of PLP2 were prepared by adding a
crystallization drop (from a plate setup previously without the adding of microseeds)
containing an abundance of small PLP2 crystals to 20 ml of the corresponding reser-
voir solution followed by serial dilutions in the same reservoir solution. To set up the
crystallization plate, 2 ml of purified PLP2 at 6 mg/ml was pipetted into the sub-well
of the plate. To the sub-well, 0.5 ml of reservoir solution, and 0.5 ml of fresh prepared
PLP2 microseeds were then added. Di↵raction quality PLP2 crystals grew within two
days with dimensions of approximately 0.09 mm by 0.12 mm. The optimal crystal-
lization condition consisted of 100 mM HEPES pH 8.0, 4% PEG400, 2 M (NH4)2SO4
and 5 mM DTT. Crystals of PLP2 were harvested using nylon loops and then placed
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into reservoir solution supplemented with 20% glycerol for seconds before they were
mounted to nylon loops by flash-frozen in liquid nitrogen. Crystals were then stored
in a dewar under liquid nitrogen until data collection.
3.2.2 PLP2 heavy atom derivatives
Native gel shift experiment
A series of heavy atom screens were obtained from colleagues at Purdue. Hampton
Research Heavy Atom Screen Pt (Cat No. HR2-442) and Hg (Cat No. HR2-446)
were gifts from Dr. Michael Rossmann’s Lab (Purdue University), while Hampton
Research Heavy Atom Screen Au (Cat No. HR2-444) was a gift from Dr. Jue Chen’s
Lab (Purdue University). 1 ml of stock heavy atom (Table 3.1) in H2O was added
to 1 ml of 8 mg/ml PLP2, and the mixture was incubated at RT for 30 min before
running the native gel (see below). Samples that resulted in heavy precipitation after
incubation were not analyzed.
McLellan continuous native gel of PLP2 To run McLellan continuous native
gel of PLP2, 600 ml 1X gel bu↵er (30 mM Histidine, 30 mM MES, pH 6.1) was first
prepared. Note that upon dissolving the above ingredients in H2O, the pH of the
bu↵er should be around 6.1 ± 0.1 and no pH adjustment is required. To make two
6% gels, a 20 ml gel mixture was prepared by combining 16 ml of 1X gel bu↵er, 4
ml of 30% acrylamide, 100 ml 10% APS (fresh made in H2O, 10 mg of APS in 100 ml
of H2O) and 20 ml TEMED (added last). Prior to loading the samples, the gel was
run at 300 V for 15 min at 4 C to get rid of the catalyst. 1 ml of sample bu↵er (0.5X
gel bu↵er, 10% glycerol, 0.01% bromophenol blue) was added to the samples prior to
loading. The gel was then run at 300 V for 60 min at 4 C.
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Table 3.1.: Stocks of heavy atoms from Hampton Research





























To optimize the soaking condition for [Pt2I2(H2NCH2CH2NH2)2](NO3)2 deriva-
tives, PLP2 crystals were soaked in cryo-solution with di↵erent concentrations of
heavy atom for various amount of time prior to freezing. Then the di↵raction quality
of the Pt derivatives were evaluated in Purdue University X-ray Lab. On the other
hand, in an attempt to use bromide as the source of anomalous signals, PLP2 crystals
were soaked in cryo-solution containing di↵erent concentrations of NaBr (10 mM, 250
mM, 500 mM, 750 mM and 1 M) for 30-60 seconds prior to freezing.
3.2.3 Expression, purification and crystallization of SeMet PLP2
To express SeMet-substituted PLP2, pEVL8-PLP21525-1911 was transformed into
E. coli strain B834 (DE3) cells. Overnight culture was prepared by inoculating a
colony in 1X M9 simple media (Table 3.2) supplemented with 5% LB media and
50 mg/ml kanamycin. The next day, an overnight culture was centrifuged to remove
residual LB media. The cell pellet was then resuspended in 1 ml 1X M9 simple media
and added to 1 L 1X M9 complete media (Table 3.2) supplemented with Kana. Two
liters of cells were grown at 37 C until the A600 reached 0.6. At this point, protein
expression was induced by the addition of IPTG to a final concentration of 1 mM,
and cells were grown overnight at 18 C with constant shaking. The procedure for
purification of SeMet PLP2 was the same as described in Chapter 2 for unlabeled
PLP21525-1911. As for the crystallization of SeMet PLP2, di↵raction-quality crystals
were obtained in the same way as unlabeled PLP21525-1911 with fresh SeMet PLP2
crystals as mircroseeds.
3.2.4 MALDI analysis of SeMet PLP2 and native PLP2
To analyze the molecular weight of SeMet PLP21525-1911 and native PLP21525-1911
through MALDI, 4 mg/ml of proteins in a bu↵er of 50 mM HEPES, pH 7.0, 100 mM
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Table 3.2.: Recipe for M9 media
Ingredient Amount Ingredient Amount
5X M9 salts (1 L) 1X M9 complete media (1 L)
Na2HPO4 33.9 g 5X M9 salts 200 ml
KH2PO4 15 g 20% glucose 20 ml
NaCl 2.5 g 1 M MgSO4 2 ml
NH4Cl 5 g 1 M CaCl2 100 ml
1X M9 simple media (1 L) 1 mg/ml thiamine 1 ml
5X M9 salts 200 ml 1000X trace metal mix1 1 ml
20% glucose 20 ml 10X soluble amino acids2 100 ml
1 M MgSO4 2 ml 100X insoluble amino acids3 10 ml
1 M CaCl2 100 ml Selenomethionine 50 mg
1 1000X trace metal mix: 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2,
10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiSO4, 2 mM
Na2MoO4, 2 mM Na2SeO3 and 2 mM H3BO3. To prepare the mixture,
add all the reagents except iron chloride to 80 ml H2O, then add iron
chloride, followed by the addition of 500 ml of 10 N HCl; last adjust
the volume to 100 ml with H2O.
2 10X soluble amino acids: Dissolve 0.5 g of the following L-amino acids
to 1 L H2O: Arg, Asp, Asn, Ala, Glu, Gln, Gly, His, Ile, Leu, Lys, and
Pro.
3 100X insoluble amino acids: Dissolve 0.5 g of L-Trp and L-Tyr in 10
ml 2 N HCl. Slowly add H2O to 100 ml.
NaCl, 10 DTT were used. Matrix was prepared by dissolving 10 mg of sinapic acid
in 1ml of 50% acetonitrile solution in deionized water with 0.1% TFA. The protein
sample was mixed with the matrix at a ratio of 1:1. MALDI analysis was performed
following the procedure described in Section 2.2.4.
61
3.2.5 Data collection and structure determination
For data collection, flash-cooled crystals were placed on the goniostat under a
stream of dry N2 at 100
 K. Several complete datasets were collected from native
PLP2 crystals, SeMet PLP2 crystals, platinum derivatives and bromide derivatives.
The settings for data collection are shown in Table 3.3. All datasets were processed
and scaled using HKL2000 [103]. Ultimately, one native dataset and one SeMet
peak dataset were used to determine the structure of PLP2. The native dataset and
the SeMet peak dataset were collected at the National Institutes of General Med-
ical Sciences and Cancer (GM/CA) 23-ID-B and Life Science-Collaborative Access
Team (LS-CAT) 21-ID-D beamlines, respectively, at the Advanced Photon Source
Synchrotron (APS), Argonne National Laboratory (ANL). The native dataset and
the SeMet peak dataset were processed and scaled to 2.60 Å and 2.80 Å, respectively.
Initial phases were determined by using the single-wavelength anomalous dispersion
(SAD) method and the SeMet peak dataset. An initial model of PLP2 was generated
using the AutoSol module in Phenix [104]. Phases were further extended using the
2.60 Å native dataset. However, the initial model resulting from AutoSol was incom-
plete as the first 90 residues at the N-terminus were not built into density by the pro-
gram. Through the iteration of manual model building in Coot [105], structure refine-
ment with Phenix Refine [106], and automatic model building in ARP/wARP [107],
the majority of the missing residues were built. The improved model was then further
refined using Phenix Refine. Data collection and refinement statistics are shown in
Table 3.7. Figures were generated using PyMOL (The PyMOL Molecular Graphics
System, Schrödinger LLC.).
3.2.6 Inhibition of MHV PLP2 with synthesized compounds
Inhibition assays were performed in the presence of 100 mM compounds using
the Z-RLRGG-AMC assay (50 mM Z-RLRGG-AMC as the substrate) as described in
Section 2.2.5. The initial rates were then determined and compared to the no-inhibitor
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Crystals (Å) Time Width Images
Native 0.97872 Rayonix MX-225 225 mm 2 sec 1  100
SeMet 0.97932 Mar 300 CCD 350 mm 1 sec 0.5  1801
Pt derivative 1.07180 Mar 300 CCD 350 mm 2 sec 0.5  1801
Br derivative 0.92017 Mar 300 CCD 350 mm 1 sec 1  902
1 The inverse beam method was applied, with 90 images collected for each 45  angular
wedge.
2 The inverse beam method was applied, with 45 images collected for each 45  angular
wedge.
control to calculate the percentage inhibition. The inhibition of SARS-CoV PLpro by
compound 3k was determined to serve as the positive control. Final concentrations of
the enzymes are 3 mM for MHV PLP2 and 0.14 mM for SARS-CoV PLpro. All assays
were performed in triplicate. Compounds were obtained from various collaborators
and their synthesis was described in [108].
3.2.7 PLP21608-1911 (PLP2-4DPUP)
The construct of pEVL8-PLP21608-1911 (PLP2-4DPUP)
The gene of pEVL8-PLP21610-1911 was amplified from plasmid pEVL8-PLP21525-1911
and inserted to empty pEVL8 vector following the procedure described in Section
2.2.2. Primers used to PCR amplification are:
Forward: 5’ GAGAACCTGTACTTCCAATCCAATGCCAATAAGGTCGATGTGC 3’
Reverse: 5’ CGGATCCGTTATCCACTTCCAATTTATCACTTCAGGTTTTTCAGATAC 3’
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Expression, purification and crystallization of PLP2-4DPUP
The expression and purification of pEVL8-PLP21608-1911 (PLP2-4DPUP) followed
the procedure described in Chapter 2 for pEVL8-PLP21525-1911 (Section 2.2.2). Initial
crystallization conditions for PLP2-4DPUP were identified after performing a high-
throughput crystallization screen using a series of commercial crystallization screens
from Qiagen. Briefly, 0.012 ml of purified PLP2-4DPUP at three concentrations (6,12
and 24 mg/ml) was pipetted into the three sub-wells of a 96-3 well sitting drop plate
(INTELLI-PLATE), and 0.012 ml of reservoir solution was then added to the drop.
The screen was set up using a mosquito Crystal liquid handling system. The plates
were then incubated at 20 C. An initial crystallization hit was identified after 2 days
of growth in a solution containing 1.4 M sodium malonate pH 7.0, and 0.1 M Bis-
Tris propane pH 7.0. Further optimization of the crystallization conditions was then
carried out manually using 96-well sitting drop plates (Corning) using a fine grid of
sodium malonate between 1.0 M and 2.0 M, and 0.1 M Bis-Tris propane between pH
6.5 and pH 8.0. To set up the crystallization plate, 1 ml of purified PLP2-4DPUP
at di↵erent concentrations (3, 6, 12, and 16 mg/ml) was pipetted into the sub-well
of the plate. To the sub-well, 1 ml of reservoir solution was then added. The plates
were then incubated at 20 C. Crystals of PLP2-4DPUP grew within two days with
dimensions of approximately 0.2 mm by 0.2 mm. Crystals were then harvested using
nylon loops and placed into reservoir solution supplemented with 20% glycerol (or
20% ethylene glycol or 15% PEG 400) for seconds before they were mounted to nylon
loops by flash-cooling in liquid nitrogen.
3.2.8 Vertical zone-interference gel electrophoresis
1% agarose gels were made in 1X electrophoresis bu↵er (TBE bu↵er without the
addition of EDTA, pH adjusted to 8.7), and casted in a vertical apparatus where
ice-cold water was running through the tubings built in the front and back plates for
cooling. PLP2 was incubated with oligonucleotides ((dG)10, (dA)10, (dC)10, (dT)10)
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at room temperature for an hour in binding bu↵er consisting of 50 mM HEPES pH 7.0,
100 mM KCl, 3,5 mM MgCl2 and 10 mM bME in a sample volume of 10 ml. The final
concentrations of protein and oligonucleotides are 25 mM and 100 mM, respectively.
After incubation, the samples were mixed with DMSO (final concentration of 10%)
and a trace of bromophenol blue (BPB) as the tracing dye. The zone solutions were
prepared in the same way as the samples in a volume of 100 ml but in the absence of
protein. Prior to loading, DMSO and BPB were loaded to the zone solutions. The
100 ml zone solutions were first loaded into the well. Then the sample solutions were
layered to the bottom of the well underneath the zone solutions using long and thin
gel loading tips. Electrophoresis was performed at 4 C for an hour with a constant
voltage of 300 V for 80 min. The gel was then stained in bu↵er consisting of 0.25%
coomassie blue, 15% ethanol, 8% acetic acid and 10% methanol for 30 min. Finally,
the gel was destained in bu↵er consisting of 15% ethanol and 8% acetic acid for
overnight before imaging.
3.3 Results
3.3.1 Crystallization of PLP2
High-throughput crystallization screens of purified PLP2 yielded a condition that
supported the crystallization of PLP2 (Figure 3.2A). The resulting condition consisted
of 100 mM HEPES, pH 7.5, 2% PEG400, and 2 M (NH4)2SO4. Initial optimization
was performed using 24-well hanging drop plates where 1 ml of 6 mg/ml PLP2 was
mixed with 1 ml of reservoir solution. A grid of reservoir solution was prepared
based on the hit condition with variation of the pH, concentrations of PEG400 and
(NH4)2SO4. However, under the above condition, the nucleation of crystals happened
too fast resulting in a large number of small cubic crystals with the longest dimension
of only 0.05 mm (Figure 3.2B). Unfortunately, these crystals did not continue to grow
after two days. Therefore, further optimization was pursued in order to slow down the
nucleation process and increase the size of crystals. Such attempts included perform-
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ing micro-seeding and additive screens (Hampton Research HR2-428), changing the
temperature for crystal growth (4 C, 12 C and 20 C), using the sitting-drop vapor
di↵usion method instead of the hanging-drop method, and varying the concentration
of protein or precipitant. Through this process of optimization, it was noticed that
the utilization of the sitting-drop vapor di↵usion method instead of the hanging-drop
one, together with implementation of the micro-seeding procedure, greatly slowed
down the nucleation process. Crystallization trays with optimized conditions were
set up following the procedure described in Section 3.2.1. Eventually, crystals of
PLP2 (150 microns in the longest dimension) were obtained after two days of growth
(Figure 3.2C). A complete X-ray dataset on a PLP2 crystal was then collected and
processed to 2.60 Å resolution (Table 3.7).
Fig. 3.2.: Crystallization of PLP2. Initial crystals obtained from high-throughput screens
are shown in (A). Crystals resulting from the initial (B) and final (C) rounds of optimization
are also shown.
3.3.2 Heavy atom derivatives of PLP2
With the dataset of PLP2 obtained as described above, the method of molecular
replacement was first attempted to determine the structure of PLP2. However, multi-
ple attempts through numerous molecular replacement approaches using the available
SARS-CoV PLpro structures (PDB codes: 2FE8, 3E9S, 3MJ5) or the TGEV PLP1
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structure (3MP2) proved unsuccessful. Therefore, experimental phasing using SeMet-
substituted PLP2 and heavy-atom derivatives was pursued.
Preparation of SeMet PLP2
SeMet PLP2 was expressed in the methionine auxotroph E. coli strain B834 (DE3)
cells. Cells were grown in M9 minimal media supplemented with glucose, thiamine,
trace metal mix, L-SeMet, and all amino acids except unlabeled methionine for protein
expression. It was observed that inclusion of the trace metal mix was important for the
expression of soluble SeMet PLP2 (data not shown), which supports the critical role of
the zinc fingers domain in maintaining structure integrity of the protein. Purification
of SeMet PLP2 followed the procedure described for PLP2 (Section 2.2.2). SDS-
PAGE and specific activity analyses of the protein were performed throughout the
purification (Figure 3.3 and Table 3.4). MALDI analysis on the pure SeMet PLP2
protein suggested a molecular weight of 43,787 Da (Figure 3.4A). Given the di↵erence
in atomic mass between sulfur and selenium, which is 47, the di↵erence of 242 Da
in molecular weight between SeMet PLP2 and native PLP2 (MW: 43,545 Da, Figure
3.4B) indicated that purified SeMet PLP2 contained five Se atoms. Pure SeMet
PLP2 was then crystallized following the crystallization procedure for native PLP2
(Section 3.2.1). Fluorescence-energy scans at the selenium X-ray absorption edge
further confirmed that incorporation of Se atoms in SeMet PLP2, and at the same
time determined the anomalous scattering coe cients, f’ and f”, of Se (Figure 3.5).
A platinum derivative of PLP2
To determine the type of heavy atoms that can specifically bind to PLP2, native
gel shift experiments were performed to screen a variety of heavy atoms available from
Hampton Research Heavy Atom Screens. When heavy atoms bind to a protein, they
cause a change in the electrical charge of the protein–heavy atom complex, which
can be resolved on native gels as heavy atoms that specifically bind to a protein
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Fig. 3.3.: SDS-PAGE analysis of SeMet PLP2 throughout purification. (A) Clarified lysate,
flowthrough (FT) and fractions (A9-B6) from the Ni HisTrap column were analyzed on 10%
SDS-PAGE gel. 4 mg of protein was loaded into each lane. (B) Pool after the Ni HisTrap
column, the pool after TEV cleavage, the concentrated protein prior to S75 column and
fractions (A5-A11) from the S75 column were analyzed on 10% SDS-PAGE gel.
Table 3.4.: Summary of SeMet PLP2 purification.
Sample
Total Protein Total Specific Activity Fold Yield
(mg)1 Units2 (Units/mg) Purification (%)
Lysate 850 0.34 0.0004 1.00 100
HisTrap Pool 74 0.08 0.0011 2.75 24
Superdex-75 Pool 21 0.04 0.0020 5.00 12
1 From two liters of cell culture.
2 Unit (mmol/min): mmol of products produced per minute under following assay
conditions - 50 mM RLRGG-AMC, 3 mM enzyme in assay bu↵er containing 50
mM HEPES, pH 7.0, 0.1 mg/ml BSA and 2mM DTT.
will cause a gel shift or laddering of the protein. In contrast, heavy atoms that
denature the protein will prevent the protein from entering the gel. The McLellan
continuous gel system was used to run native gel of PLP2 since the theoretical pI of
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Fig. 3.4.: MALDI analysis of SeMet PLP21525-1911 and native PLP21525-1911.
PLP2 is 8.3. The standard acidic native gel system did not work with PLP2 (data
not shown). Among all the heavy atoms tested, one Pt-containing heavy atom was
found to cause a gel shift of PLP2 on native gel (Figure 3.6, lane 8). This heavy atom
is [Pt2I2(H2NCH2CH2NH2)2](NO3)2. No Au- or Hg-containing heavy atom tested
caused a gel shift of PLP2 (Figure 3.7).
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Fig. 3.5.: Plot of the anomalous scattering factors f0 and f00 calculated from the fluores-
cence scan of SeMet PLP2. Scans were produced on the LS-CAT 21-ID-D beamline at the
Advanced Photon Source Synchrotron, Argonne National Laboratory.
To prepare Pt derivative of PLP2, PLP2 crystals were soaked in a cryo-solution
containing varied concentrations of [Pt2I2(H2NCH2CH2NH2)2](NO3)2 prior to flash-
cooling. Screens to find the best soaking time and the concentration of the Pt heavy
atom in the cryo-solution were performed to optimize the soaking condition for PLP2
Pt derivatives. PLP2 crystals were soaked in 2 mM or 4 mM of the Pt heavy atom
for various amount of time prior to flash-cooling, then the di↵raction quality of the
soaked crystals was evaluated for the best resolution in Purdue University X-ray Lab.
Given the di↵erences in di↵raction ability among crystals, one condition would only be
considered as bad when weak di↵raction (resolution lower than 9 Å) or no di↵raction
was observed for at least two crystals. Tested conditions and the di↵raction quality of
soaked crystals are summarized in Table 3.5. Overall, PLP2 crystals can be soaked in
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2 mM of the Pt heavy atom for at most 8 hours or 4 mM for at most 30 min without
being damaged. Multiple datasets of PLP2 Pt derivative were collected, with the
best one shown in Table 3.6.
Fig. 3.6.: Native gel shift experiment with platinum heavy atoms. The text on the right
lists the heavy atom used in each lane (from lane 1 to lane 9). The heavy atom used in lane
8 caused gel shift of PLP2.
Fig. 3.7.: Native gel shift experiment with Hg or Au heavy atoms. Ctrl, no heavy atom
control; Pt12, [Pt2I2(H2NCH2CH2NH2)2](NO3)2, 2.25 mM; Hg1, C13H17HgNO6, 3.06 mM;
Hg6, C8H8HgO2, 2.97 mM; Hg7, K2HgI4, 1.27 mM; Hg8, C7H5ClHgO2, 2.8 mM; Hg9,
C2H5HgCl, 3.78 mM; Hg10, HgBr2, 3.77 mM; Hg11, HgI2, 2.2 mM; Hg14, HgO, 4.62
mM; Hg15, C(HgOOCCH3)4, 1 mM; Au1, KAu(CN)2, 4 mM; Au2, KAuCl4, 4 mM; Au3,
NaAuCl4, 4 mM; Au4, AuCl3, 4 mM; Au5, HAuCl4, 4 mM; Au6, KAuBr4, 4 mM.
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Table 3.5.: Screen of soaking conditions for Pt12 derivative of PLP2
[Pt12]
Soaking Highest resolution (Å)
time Crystal 1 Crystal 2 Crystal 3 Crystal 4
2 mM
20 min 5 3.6
1 h 4 11 6.5
3 h 3.5
4 h 3.8
6.5 h 3.8 5
8 h 4.5 4 3.9
O/N ND1 WD2 WD WD
4 mM
30 min 3.5
1 h 7 7.5 ND
1.25 h WD 7
2.5 h WD WD ND
5 h WD WD
8 h WD WD
1 ND: no di↵raction
2 WD: weak di↵raction, resolution lower than 9 Å
Bromide derivative of PLP2
In an attempt to use bromide as the source of anomalous signals, PLP2 crystals
were soaked in cryo-solution containing di↵erent concentrations of NaBr (ranging
from 10 mM to 1M) for 30-60 seconds prior to flash-cooling. One dataset of PLP2
bromide derivative was collected. However, the anomalous signal from the bromide
derivative is not as strong as that from SeMet PLP2, as judged from the lower value
in figure of merit using the single-wavelength anomalous dispersion method for the
bromide derivative.
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3.3.3 Experimental phasing and structure determination of PLP2
Multiple datasets were collected for di↵erent types of PLP2 heavy atom deriva-
tives (Table 3.6). Ultimately, experimental phases were determined via the single-
wavelength anomalous dispersion (SAD) approach from a 2.80 Å dataset collected
from a SeMet PLP2 crystal at peak energy (Table 3.6). Both native and SeMet
PLP2 proteins crystallized in the I 213 space group with one PLP2 monomer in the
asymmetric unit. Since PLP2 was determined to be monomer in solution based on
SEC-MALS analysis, the asymmetric unit contains the biologically relevant monomer.
The final structure was determined and refined against the native dataset to a res-
olution of 2.60 Å with final R-values of Rwork = 17.1% and Rfree = 22.1%. The
final X-ray data collection and refinement statistics are summarized in Table 3.7.
The atomic coordinates and structure factors of PLP2 have been deposited in the
Protein Data Bank and assigned code 4YPT. The final PLP2 structural model had
observable electron density for residues 11-388. The first ten N-terminal and the last
one C-terminal residues had weak or unobservable electron density. Therefore, these
amino acids are absent from the final structural model.
In fact, dataset at peak, infection and high remote energy was collected respec-
tively from a SeMet PLP2 crystal, and the multi-wavelentgh anomalous dispersion
(MAD) method was attempted to determine the phase of PLP2. However, due to
the inconsistent origins chosen for indexing, initial attempts of MAD turned to be
unsuccessful. Upon re-indexing of the three datasets, the MAD method resulted in a
figure of merit (fom) value of 0.56, which is higher than the value obtained from SAD.
Nonetheless, since the experimental phases determined from SAD were adequate to
solve the structure of PLP2, no further attempt was pursued to solve the structure
utilizing phases determined from MAD.
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Table 3.6.: PLP2 X-ray datasets for experimental phasing
Crystals
Wavelength Highest Completeness SAD MAD
(Å) (Å) (%) fom1 fom1
SeMet2
0.979317 Peak 2.80 98.8 (100) 0.43
0.560.979451 Inflection 2.85 99.5 (100) 0.36
0.964187 High 2.93 99.4 (100) 0.35
Pt 1.071802 Peak 3.35 99.6 (100) 0.222
Br 0.920173 Peak 3.10 99.9 (100) 0.213
1 fom: figure of merit. SAD and MAD fom was determined using the
”AutoSol” module in Phenix.
2 Initial phases were determined through SAD using the SeMet 5-8 peak
dataset
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Table 3.7.: X-ray data collection and refinement statistics
Data collection SeMet Native
Beamline 21ID-D 23 ID-B
Wavelength (Å) 0.98 1.03
Space group I 213 I 213
Unit cell dimensions:
a, b, c (Å) a = b = c = 154.94 a = b = c = 155.58
↵, ,   ↵ =   =   = 90 ↵ =   =   = 90
Resolution (Å) 50.00–2.80 (2.85–2.80)1 50.00–2.60 (2.64–2.60)
No. of reflections observed 472931 537164
No. of unique reflections 15419 19350
Rmerge2(%) 7.9 (77.8) 5.7 (74.9)
I/ I 21.9 (2.4) 38.2 (4.5)
% Completeness 98.8 (100.0) 99.7 (100.0)
Redundancy 5.8 (5.8) 10.2 (10.2)
Phasing
Resolution (Å) 49.00–3.10 (3.21–3.10)
Figure of merit 0.43
Sites 5 Se
Refinement
Resolution range (Å) 49.00–2.60 (2.74–2.60)
No. of reflections in working set 18388 (2612)
No. of reflections in test set 998 (136)
Rwork3(%) 17.1 (21.0)
Rfree4(%) 22.2 (28.5)
Wilson B factor (Å) 30.9
Average B factor (Å) 54.5
RMSD from ideal geometry
Bond length (Å) 0.008
Bond angle (deg) 1.138
Ramachandran plot
Most favored (%) 95.0
Allowed (%) 4.2
Disallowed (%) 0.8
1 Values in parentheses are for the last (highest resolution) shell.
2 Rmerge = ⌃hkl⌃i
  Ii(hkl)  hI(hkl)i
  /⌃hkl⌃iIi(hkl), where Ii(hkl) is the intensity of
a given reflection, and hI(hkl)i is the mean intensity of symmetry-related reflections.
3 Rwork = ⌃hkl
  |Fobs|   |Fcalc|
  /⌃hkl|Fobs|, where Fobs and Fcalc are the observed and
calculated structure factors, respectively.
4 Rfree was calculated using 5% of the data set chosen at random that were excluded
from the refinement.
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3.3.4 X-ray crystal structure of PLP2
The crystal structure of the MHV PLP2 catalytic core and flanking N-terminal
and Ubl2 domains consists of five domains–Fingers, Palm, Thumb, Ubl2 and DPUP
(Figure 3.8A). The thumb, palm and fingers domains form the catalytic core of PLP2,
which has an architecture resembling a right hand. The thumb domain (aa 146-264
in the expression construct) is primarily made up of six helices (a4-a9), with two
short anti-parallel strands (b11-b12) in between helices a5 and a6. The palm domain
(aa 320–387) is formed by six anti-parallel strands (b18-b23). Finally, the fingers
domain contains two short helices, one short strand, and one b-sheet consisting of
four anti-parallel twisted strands. At the tip of the fingers domain, four cysteines
(C272, C274, C306, C308) coordinate a metal ion in a tetrahedral geometry (Figure
3.9). The identity of the metal was determined to be zinc via a fluorescence-energy
scan at the zinc X-ray absorption edge (Figure 3.10). An energy scan over a wide
energy range that included the X-ray absorption edges for iron, cobalt, nickel and
copper was also performed and no other visible fluorescence peaks, except the one for
the zinc ion, were observed.
The MHV ubiquitin-like (Ubl2) domain (aa 86-145) is composed of a b-grasp
fold [109]. The Ubl domain was first identified in nsp3 after the determination of the
X-ray structure of SARS-CoV PLpro [34]. Subsequently, a second Ubl domain was
identified in nsp3 after determination of the NMR structure of the first 183 residues
of the SARS-CoV nsp3 N-terminus [38]. The Ubl domain associated with PLpros and
PLP2 is now designated as Ubl2 and the N-terminal Ubl domain is now designated
as Ubl1 since it comes first in the primary sequence. The relative orientations of the
Ubl2 and DPUP domains and the PLP2 catalytic core, as observed in the structure,
are likely influenced by the compact crystallographic packing surrounding the DPUP
domain (Figure 3.11).
The X-ray structure of PLP2 also reveals an unpredicted domain at the N-terminus
of MHV PLP2 that is formed by 85 residues. The domain consists of two helices (a1-
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a2) that are connected by five anti-parallel b-strands (b1-b5). A DALI search [110]
of this unpredicted domain against the Protein Data Bank (PDB) identified the C-
domain of the SARS Unique Domain (SUD-C) as the top match with a Z-score of
7.3. Structural superposition of this MHV PLP2 domain with the SUD-C domain,
using DaliLite server [111], shows that the root-mean-square-deviation (RMSD) is
2.1 Å over 63 aligned backbone Ca atoms, while the sequence identity is only 13%
(Figure 3.8B). Although the SUD has been proposed to be unique to SARS-CoV, the
presence of this unpredicted domain in MHV nsp3 questions its exclusivity (more in
Discussion). This new domain in nsp3 is designated as the Domain Preceding Ubl2
and PLP2 (DPUP) domain because it doesn’t engender exclusivity and it allows for
DPUP to be identified in other coronavirus nsp3s.
The active site of PLP2, which consists of a C194-H351-D365 catalytic triad,
sits between the thumb and palm domains (Figure 3.8A). C194 and D365 are both
within a H-bonding distance to H351 (3.1 Å and 3.0 Å, respectively, Figure 3.8C),
indicating that the active site is readily arranged, even in the absence of a substrate.
Unlike SARS-CoV PLpro, where a tryptophan side chain forms part of the oxyanion
hole [34], Q189 occupies the same position in PLP2 and appears to be involved in the
oxyanion hole stabilization (Figure 3.8C). N192, which is conserved among coronaviral
PLPs, may also participate in stabilizing the oxyanion hole [34]. Interestingly, after
structural refinement of PLP2, residual electron density surrounding the reactive
cysteine (C194) was observed suggesting that it is partially oxidized to cysteic acid
(Figure 3.8C, left panel). X-ray refinement with a partially occupied cysteic acid
(occupancy was set to be 0.5) was able to account for the residual electron density
(Figure 3.8C, right panel). Partial or complete oxidation of the catalytic cysteine is
commonly observed in crystal structures of cysteine proteases due to both the highly
reactive nature of the side chain thiol group, and its ability to coordinate thiophilic
transition metals capable of oxidation [112]. Complete, partial and no oxidation
of the reactive cysteine has been observed in SARS-CoV PLpro X-ray structures
[34, 108,113,114].
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Fig. 3.8.: X-ray crystal structure of PLP2. (A) Ribbon representation of the overall struc-
ture of PLP2. The zinc atom at the fingers domain is shown as a gray sphere. The catalytic
triad residues and the four zinc-coordinating cysteines from the fingers domain are repre-
sented as sticks. (B) Structural superposition of PLP2 DPUP domain (wheat) with SARS
SUD-C domain (cyan, PDB code 2KQW). RMSD is 2.1 Å over 63 aligned Ca at 13% se-
quence identity. (C) Electron density map covering the catalytic triad before (left) and after
(right) refinement of the sulfonic group at the catalytic Cys. In the right panel, occupancy
of oxygen atoms in the sulfonic group was set to 0.5, same for the atoms in the imidazole
ring of H351. Blue density is the Fo-Fc map, and green density is the 2Fo-Fc di↵erence
map.
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Fig. 3.9.: Stereoview of the zinc atom tetrahedrally coordinated by four cysteines. The zinc
atom is shown as a gray sphere, and side chains of the coordinating cysteines are shown as
sticks. Electron density surrounding the zinc atom is shown in blue for the 2Fo-Fc map,
contoured at 1s, and red for an anomalous map, contoured at 3s.
Fig. 3.10.: Plot of f0 and f00 calculated from the fluorescence scan of native PLP2 at the
X-ray absorption edge for zinc. Scans were produced on the GM/CA 23-ID-B beamline at
the Advanced Photon Source Synchrotron, Argonne National Laboratory.
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Fig. 3.11.: Crystal packing of PLP2 within the I 213 space group. (A) Stereoview of the
packing around the 2-fold axis. The four domains in di↵erent colors are from di↵erent
molecules. Domains in lightblue and wheat are the fingers domains, with the zinc atom
shown as a gray sphere. Domains in green and salmon are the DPUP domains. (B) Stereo
view of the packing around the 3-fold axis. The three domains are the DPUP domains from
di↵erent molecules.
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3.3.5 Structural comparison of MHV PLP2 to known structures of coro-
naviral PLPs
To help elucidate the function of coronaviral PLPs, the catalytic core of PLP2
(thumb-palm-fingers) was superimposed with that of SARS-CoV PLpro, TGEV PLP1
and MERS-CoV PLpro. The overall architectures of these proteins are similar: the
RMSDs of PLP2 to SARS-CoV, TGEV PLP1 and MERS-CoV PLpro are 1.7 Å (217
aligned Ca atoms at 32% sequence identity), 2.8 Å (189 aligned Ca atoms at 17%
sequence identity), and 1.8 Å (217 aligned Ca atoms at 28% sequence identity), re-
spectively. For the sake of clarity, only the structural superpositions of MHV PLP2 on
SARS-CoV PLpro and MERS-CoV PLpro are shown (Figure 3.12A). Furthermore,
the Cys-His-Asp catalytic triads from these PLPs are well aligned (Figure 3.12B).
However, several di↵erences in the structures are observed from the overlay. First,
while the local geometry of the zinc-binding site is maintained in all these structures,
the fingertip regions have di↵erent curvatures and extents of opening/closure with
respect to the palm domains. In contrast with SARS-CoV PLpro, TGEV PLP1 and
MERS-CoV PLpro, the fingertips in PLP2 collapse towards the palm, rendering the
canonical surface for ubiquitin binding too compact to accommodate the typical ubiq-
uitin structure without some conformational changes. Extensive flexibility within the
fingers domain has been observed in the X-ray structure of the free enzyme form,
i.e. with no substrates or ligands bound, of SARS-CoV PLpro (PDB code 2FE8),
where an overlay of the three protomers within one asymmetric unit shows signifi-
cant variations in the positions of the atoms in the fingers domain (up to 4.6 Å for
zinc atoms) [34]. The conformational flexibility of the fingers domain may regulate
substrate binding and, hence, the activity of PLPs. However, given the tight packing
of the crystal around the fingers domain (Figure 3.11A), there is the possibility that
crystal packing may influence the conformation of the collapsed fingers domain in
MHV PLP2.
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Another region with significant di↵erences among the PLPs is the Lb19-b20 loop
in PLP2 (sequence: 346GGSVG350) (Figure 3.12 A and C), referred to as the BL2
loop in ubiquitin-specific proteases (USPs). Here we will refer to it as the substrate
loop, because this region has been shown to be involved in binding to substrates
and inhibitors. The length of the substrate loop varies in di↵erent CoVs (Figure
3.12C and 4.15). Flanked with glycine residues, this loop is expected to be highly
flexible. Indeed, this loop has been observed in di↵erent conformations in various
structures of coronaviral PLPs (Figure 3.12C). In the case of SARS-CoV PLpro,
the loop (267GNYQCG272) is found in a closed arrangement when there is a bound
inhibitor, whereas an open state is observed when the enzyme is crystallized as the
free enzyme form (Figure 3.12C). The corresponding loop in the structure of the free
enzyme form of TGEV PLP1 (177GTTQNG182) is found to adapt an intermediate
state between the open and closed conformations of SARS-CoV PLpro. However,
the loop in PLP2 is one residue shorter, and it is observed in an extended open
conformation.
3.3.6 MHV PLP2 is not a↵ected by SARS-CoV PLpro inhibitors
A series of potent inhibitors of SARS-CoV PLpro has been developed [108], and
recently it was shown that a number of these compounds could also inhibit HCoV-
NL63 PLP2 to a significant level [60]. To explore the possibility that these compounds
could be further developed as broad-spectrum inhibitors against di↵erent CoV PLPs,
the inhibition of MHV PLP2 by 28 of these compounds was tested (Figure 3.13).
However, none of these inhibitors shows any inhibition of MHV PLP2 above 10% at
100 mM (Figure 3.13). The lack of inhibition is most likely due to the amino acid
di↵erences within the substrate loop of MHV PLP2. The side chain benzyl group of
Y269 in the substrate loop of SARS-CoV PLpro has been shown to play an important
role in the binding of compounds 15g, 3k and 3j [108,114]. The corresponding residue
is a phenylalanine in NL63 PLP2, which can also be inhibited by a number of these
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Fig. 3.12.: Structural comparison among coronaviral PLPs. (A) Structural superposition of
unbound PLP2 (lightblue), unbound SARS-CoV PLpro (lightpink, PDB code 2FE8), and
unbound MERS-CoV PLpro (lightgreen, PDB code 4P16). Areas with major di↵erence
are indicated with black arrows. (B) Close-up view of the active site alignments. The
Cys-His-Asp catalytic triad is conserved among the three proteins, while the oxyanion hole
residues are di↵erent. The color code is the same as A. The catalytic cysteine in MERS-CoV
PLpro was covalently modified by b-mercaptoethanol. (C) Conformations of the BL2 loops
in di↵erent CoV PLPs. The color code is the same as A with the additional structure of
inhibitor-bound SARS-CoV PLpro shown in cyan (PDB code 3E9S). The loop from MERS-
CoV PLpro is omitted because it is not visible in the structure. (D) Sequences of the BL2
loops in di↵erent CoV PLPs.
compounds. However, no phenylalanine or tyrosine residues exist in the MHV PLP2
substrate loop. Consistent with this possible explanation, it has been shown that
MERS-CoV PLpro which also lacks an aromatic residue in this loop, is not inhibited
by these compounds [60].
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Fig. 3.13.: SARS-CoV PLpro inhibitors show no inhibition of MHV PLP2. The inhibition
of SARS-CoV PLpro by compound 3k is used as the positive control.
3.3.7 Purification and crystallization of PLP2-4DPUP
To investigate whether the ”collapsed” fingers domain in the structure of PLP2
was the result of crystal packing, crystallization of PLP2 without the N-terminal
DPUP domain (PLP21608-1911 or PLP2-4DPUP or Ubl2-PLP2) was attempted. First,
PLP2-4DPUP was purified following the procedure described in Section 2.2.2 for
PLP21525-1911. Figure 3.14 shows the SDS-PAGE analysis of the proteins throughout
the purification. A high-throughput crystallization screen of purified PLP2-4DPUP
was performed and yielded a condition that supported the crystallization of PLP2-
4DPUP after two days’ of growth at 20 C (Figure 3.15). This condition consists of
1.4 M sodium malonate pH 7.0, and 0.1 M Bis-Tris propane pH 7.0. Optimization
was then performed using 96-well sitting drop plates where 1ml of PLP2-4DPUP at
di↵erent concentrations (3, 6, 12, and 16 mg/ml) was mixed with 1 ml of reservoir so-
lution. The grid of reservoir solution was constructed based on the hit condition with
variation in pH and the concentration of sodium malonate. After two days of growth,
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the X-ray di↵raction quality of the crystals was evaluated in Purdue University X-ray
Lab. Unfortunately, the di↵raction quality of crystals obtained from the above condi-
tion was weak (resolution lower than 7 Å), regardless of what cryoprotectant was used
(Figure 3.16). Further optimization was carried out by changing the temperature for
crystal growth (12 C instead of 20 C), using the hanging-drop vapor di↵usion method
rather than the sitting-drop one, or performing additive screen (Hampton Research).
Crystals obtained were flash-cooled and sent to LRL-CAT beamline at the Advanced
Photon Source, Argonne National Laboratory for remote data collection. However,
no dataset was collected because no crystal could di↵ract at resolution higher than 4
Å (data not shown).
Fig. 3.14.: SDS-PAGE analysis of PLP2-4DPUP throughout purification. MW of tagged-
PLP2-4DPUP and untagged-PLP2-4DPUP are 36.7 kDa and 34.1 kDa, respectively.
3.3.8 Functional studies of the DPUP domain
Zone-interference gel electrophoresis (ZIGE) studies with the SARS-CoV SUD do-
main have shown that the SUD can bind specifically to oligo(G)-strings [115]. SUD-
C adopts a frataxin-like fold and is structurally similar to DNA-binding domains of
DNA-modifying enzymes. SUD-C has also been shown to have RNA-binding abil-
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Fig. 3.15.: Crystals of PLP2-4DPUP.
Fig. 3.16.: Di↵raction quality of PLP2-4DPUP crystals. Crystals of PLP2-4DPUP were
soaked in di↵erent cryoprotectants, such as 20% glycerol (A), 20% ethylene glycol (B) and
15% PEG400 (C) prior to di↵raction under X-ray. The highest resolutions are 9.7 Å (A),
7.8 Å (B), and 7.4 Å (C).
ity [41]. SUD-NM and its individual subdomains can bind oligonucleotides that form
G-quadruplexes [40]. Here, the ability of the DPUP domain to bind ssDNA, includ-
ing (dG)10, (dA)10, (dC)10 and (dT)10 was tested. In the vertical ZIGE experiment,
PLP21525-1911 (the construct with the DPUP domain) by itself does not show up or
enter into the gel. However, when it was incubated with (dG)10 but not other oligonu-
cleotides, PLP21525-1911 starts to show up in the gel (Figure 3.17A). Thus, it suggests
that the DPUP domain can specially bind to (dG)10, but not other oligonucleotides.
However, when we used proteins that do not have the DPUP domain, including
PLP21611-1970 (PLP2-4DPUP), SARS-CoV PLpro and USP7 as negative controls,
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we observed some shift in the gel of SARS-CoV PLpro and USP7 upon incubation
with (dG)10, although PLP2-4DPUP did seem to be di↵erent from PLP21525-1911 in
the binding of (dG)10 (Figure 3.17B). Therefore, we could not conclude that the gel
shift of PLP21525-1911 upon incubation with (dG)10 is due to the specific binding of
(dG)10 to the DPUP domain.
Fig. 3.17.: Functional studies of the DPUP domain via vertical ZIGE method. (A)
PLP21525-1911 was incubated with (dG)10, (dA)10, (dC)10 and (dT)10, respectively, prior
to the gel electrophoresis. Negative controls without the addition of the oligonucleotides
are included. (B) PLP21525-1911, PLP21611-1970, SARS-CoV PLpro and USP7 are incubated
with (dG)10, respectively. PLP21611-1970, SARS-CoV PLpro and USP7 are used as negative
controls because they do not contain the DPUP domain.
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3.4 Discussion
Here we report the first crystal structure of the MHV PLP2 catalytic core together
with two of its N-terminal adjacent domains as part of nsp3. Besides the expected
thumb-palm-finger architecture of the PLP2 catalytic core and the Ubl2 domain at its
N-terminus, the X-ray structure reveals a domain preceding the Ubl2 domain in MHV
nsp3 that is so far only similar to the SARS-CoV SUD-C domain. We designate this
domain as the Domain Preceding Ubl2 and PLP2 or DPUP domain. As discussed in
Chapter 2, nsp3 is the largest subunit in the replicase complex with multiple domains.
It is not clear yet as to how the multiple domains of nsp3 work in concert to support
virus replication. To understand potential cross-talk among the domains within nsp3,
it would be important to characterize nsp3 in its entirety. The structure of DPUP-
Ubl2-PLP2 determined here moves us closer towards this goal as it is the largest
portion of any coronaviral nsp3 that has ever been structurally determined (Figure
1.6).
The discovery of the DPUP domain is of significant importance. Initially, the SUD
domain, including SUD-N, SUD-M and SUD-C, was believed to be unique to SARS-
CoV, and, perhaps, responsible for its extreme pathogenicity [45]. Subsequently, Neu-
man et al. performed a bioinformatics analysis of nsp3s from multiple coronaviruses
and proposed that the SUD-C exists only in the betacoronavirus genogroups 2b, 2c
and 2d but not in genogroup 2a, to which MHV belongs [21]. In addition, the SUD-C
is predicted to be absent in the alpha- and gammacoronaviruses. X-ray and NMR
structural studies show that subdomains SUD-N and SUD-M adopt macrodomain
folds, while SUD-C adopts a frataxin-like fold [40,41]. Interestingly, SUD-NM and its
individual subdomains can bind oligonucleotides that form G-quadruplexes [40,115].
SUD-C has also been shown to have RNA-binding ability, and concerted actions by
the subdomains of SUD have been proposed to ensure specific RNA binding [41]. The
ability of the DPUP domain to bind oligonucleotides was investigated, however, the
results were inconclusive. Nonetheless, the presence of the DPUP domain in MHV
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nsp3 and the bioinformatics prediction suggest that SUD should no longer be con-
sidered ’unique’ to SARS-CoV. Therefore, it is intriguing to investigate the presence
of similar domains in other CoVs, and their roles in virus infection, replication and
pathogenesis.
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CHAPTER 4. STRUCTURE-GUIDED MUTAGENESIS OF PLP2 TO
DECOUPLE ITS MULTIPLE ENZYMATIC ACTIVITIES
4.1 Introduction
Coronaviral PLPs are enzymes with multiple enzymatic activities, including the
protease, DUB and deISGylating activities. The protease activity of coronaviral PLPs
is required for the processing of the viral polyprotein. As for the DUB and deISGy-
lating activities, it has been proposed that CoVs employ their DUB and deISGylating
activities to antagonize host innate immune responses during virus infection. This
hypothesis has been, to some extent, supported by several cellular-level overexpres-
sion studies [61, 65, 73, 74]. However, a lot of information is still missing regarding
what exactly happens during virus infection and what are the substrates of the vi-
ral DUB and deISGylating activity. It is also puzzling as to the spatial relationship
between virus replication and the innate immune responses within cells. The conven-
tional approach to study the function of an enzymatic activity is to knock out this
particular activity by mutating residues at the active site, and then to evaluate the
consequences with the absence of the activity. However, since all the three activities
of PLPs (protease, DUB and deISGylating) rely on the exact same active site, if
the active site residues were mutated, all three activities will be gone. Without the
protease activity, the viruses won’t be able to replicate in cells. As a consequence, it
would not be possible to evaluate the role of the viral DUB or deISGylating activity
in the context of virus infection. Therefore, it is important to maintain the protease
activity of PLP2 by keeping its active site intact while selectively disrupting the DUB
or deISGylating activity of PLP2 by targeting residues that are far away from the
active site but involved in the binding of Ub or ISG15. By disrupting the interac-
tion between PLP2 and Ub/ISG15, the DUB or deISGyalting activity of PLP2 will
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be diminished. Interestingly, this approach has been applied to MERS-CoV PLpro,
where they found that DUB-deficient PLpro mutants lost their ability to antagonize
IFN production [79]. However, their results are mostly based on cellular level studies.
Due to the di culty in culturing MERS-CoV viruses and the requirement of special
animal models for MERS-CoV studies, they were not able to move the interesting
DUB-deficient MERS PLpro mutant forward to the generation and study of mutant
viruses. Importantly, most human coronaviruses are either di cult to culture, or are
human pathogens requiring specialized biosafety labs. In contrast, MHV is an excel-
lent model system for the study of coronaviruses because it is much easier to culture
and only infect mice. Therefore, we are interested in identifying DUB/deISGylating-
deficient PLP2 mutants in MHV that could potentially serve as tools to study the
role of viral DUB or deISGylating activities during virus infection in the MHV model
system. Towards this goal, the first need is to identify residues of PLP2 that are
involved in the binding of Ub. To help identify these residues, a computational model
of PLP2 in complex with Ub was pursued as was solving the crystal structure of the
PLP2–Ub complex. Both approaches were implemented in the following studies.
There are di↵erent approaches for generating PLP2–Ub complex. The most pop-
ular one is to covalently modify the catalytic Cys with Ub derivatives, such as Ub-
aldehyde (Ubal), Ub-vinyl methyl ester (Ub-VME), Ub-bromopropylamine (Ub-Br3),
Ub-Propargylamine (Ub-Prg), etc [116, 117]. Structures of multiple DUB-Ub com-
plexes have been solved by using complexes that were generated through these meth-
ods [71, 98, 99, 117–119]. Recently, Chou and colleagues reported another approach
to generate a stable, non-covalent SARS-CoV PLpro–Ub complex [120]. They used a
catalytic Cys to Ser mutant of SARS-CoV PLpro to form a tightly associated complex
with free ubiquitin. Since the the side chain of Ser has a higher pKa than Cys, by
mutating Cys to Ser, a stronger H-bonding interaction would be formed between ac-
tive site Ser and the C-terminal carboxylate group of Ub compared to the one formed
between Cys and Ub. Also, with the active site Cys being mutated to Ser, the het-
erogeneous species issue resulting from the oxidation of the active site Cys would no
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longer be a problem. Additionally, the non-covalent PLP–Ub complex mimics the
enzyme form ’EP’ prior to product release. In our study, we were able to crystallize
the non-covalent MHV PLP2–Ub complex generated from PLP2 catalytic Cys to Ser
mutant (PLP2-CS) and mono Ub.
This structure and a computationally derived structure of a PLP2–Ubal complex
were used to identify residues that are involved in the binding of Ub. Extensive
mutagenesis studies were then performed on these residues and for each mutant,
all three activities (protease, DUB and deISGylating) were evaluated through in
vitro enzymatic assays. Since the mutants were designed to disrupt the PLP2–Ub
interaction, it was expected that mutants that maintain intact protease activity, but
display decreased DUB activity would be obtained. Excitingly, a mutant, R281A, was
discovered that has intact protease activity, but is deficient in deISGylating and DUB
activity. The corresponding mutant virus was found by our collaborator, Professor
Susan Baker, Loyola University Chicago, to be viable and attenuated. This mutant
virus can serve as a tool to study the role of viral DUB and deISGylating activity in
virus infection. More importantly, it could be of great importance to the development
of vaccine against coronavirus infection.
4.2 Experimental Procedure
4.2.1 Generation of a structural model for MHV PLP2 bound with Ubal
by computational method
The following experiments were done in collaboration with Dr. Sergey Savinov,
University of Massachusetts Amherst. The X-ray crystal structure of SARS-CoV PL-
pro in complex with Ubal (PDB code 4MM3) was used as a structural template to
generate a model of the MHV PLP2–Ub complex [71]. Since the Ub structure could
not be embedded directly into the ubiquitin binding site of the unliganded structure of
MHV PLP2 without severe clashes of Ub with the fingers region, the crystal structure
of unbound MHV PLP2 was subjected to a 1.2-ns isothermal (300K) molecular dy-
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namics simulation with explicit water molecules and NaCl ions (150 mM) (Desmond
Molecular Dynamics System, Schrödinger LLC.). Remarkably, the trajectory of the
simulation indicated an immediate opening of the collapsed fingers regions of MHV
PLP2 beyond the positions observed in various liganded and unliganded SARS-CoV
PLpro structures, as judged by the distance between the zinc atom and Ca carbon of
the active site catalytic cysteine. Subsequently, the zinc ion and the associated fin-
gertip oscillated between open and collapsed states with decreasing amplitude. Next,
a conformational state was identified that is most similar to the one found in the
SARS-CoV PLpro–Ubal complex and it was used to generate a structural model of a
MHV PLP2–Ubal complex. The preliminary model was refined further by a secondary
molecular dynamics simulation of the PLP2–Ubal non-covalent complex. This simu-
lation allowed for extra flexibility at the C-terminal of Ub, which produced a number
of structurally similar conformational states. A state with optimal interaction ener-
getics, characterized by a comparatively high number of H-bonding, hydrophobic and
favorable electrostatic contacts was used as the model for the PLP2-Ubal complex
thereafter. The persistence of the interactions between PLP2 and Ubal during the
simulation was calculated. For comparison, the structure of SARS-CoV PLpro–Ubal
complex was also subjected to a 1.2 ns MD simulation.
4.2.2 Generation of PLP2-4DPUP-C194S mutant
Site-directed mutagenesis to create the catalytic cysteine 194 to serine
mutation
Site-directed mutagenesis was performed on pEVL8-PLP21610-1911 (PLP2-4DPUP)
plasmid to mutate the catalytic cysteine 194 to serine (CS) following the QuikChange
protocol (Stratagene). Designed primers for the mutagenesis are listed as below:
Forward: 5’ CAAACAACAACTCCTACATCAACGTGGCATGTCTG 3’
Reverse: 5’ CGTTGATGTAGGAGTTGTTGTTTGACTGCTTAAAAGC 3’
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Briefly, 50 ml of PCR reaction was set up , which contains 1 mM of forward and
reverse primers, 0.2 mM dNTPs (Fermentas), 1 U of Phusion High-Fidelity DNA
polymerase (New England BioLabs Inc.), 1X of the corresponding Phusion HF bu↵er,
and 50 ng of pEVL8-PLP21610-1911 as the template. The temperature cycle for the
PCR experiment is shown below with a gradient of annealing temperatures:
After the PCR reaction, 5 ml of samples from each reaction was analyzed on 1%
agarose gel to evaluate the results of the PCR experiment. Reactions with the right
size of PCR products were then combined, followed with PCR clean-up using the Wiz-
ard SV Gel and PCR Clean-Up System from Promega, where the DNA was eluted
with 45 ml of elution bu↵er. Eluted DNA was then subjected to DpnI digestion,
where 50 ml of reaction was set up with 5 U of DpnI enzyme (Promega), 1X of the
corresponding Bu↵er B (Promega), and 45 ml of the eluted DNA. The reaction was
incubated at 37 C for 2 hours. Next, 4 ml of DpnI digested sample was transformed to
10 ml of XL1-Blue Supercompetent Cells (Agilent Technology) via heat shock trans-
formation method. All cells were plated on a LB agar plate supplemented with 50
mg/ml of kana. The agar plate was incubated at 37 C for overnight. The next day,
colonies were inoculated for plasmid extraction using the High Pure Plasmid Isolation
Kit from Roche. The resulting plasmids were subjected to DNA sequencing of the
entire insert using the DNA Sequencing Shared Resource at Purdue University to
verify the introduced mutation.
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Expression and purification of PLP2-4DPUP-C194S
The expression and purification of PLP2-4DPUP-C194S followed the same pro-
cedure described in Section 3.2.7, with the bu↵er composition being: Bu↵er A – 25
mM Tris pH 7.5, 500 mM NaCl, 20 mM Imidazole, 5 mM bME; Bu↵er B – 25 mM
Tris pH 7.5, 500 mM NaCl, 500 mM Imidazole, 5 mM bME; Bu↵er C – 50 mM Tris
pH 7.5, 100 mM NaCl, 5 mM bME; Bu↵er D – 50 mM Tris pH 7.5, 100 mM NaCl, 5
mM DTT.
4.2.3 Expression and purification of human ubiquitin
Human ubiquitin inserted into pET-11a was expressed in E. coli BL21 (DE3)
cells. One liter of cells was grown in 2X YT medium supplemented with 50 mg/ml
carbenicillin at 37 C until the optical density at 600 nm (A600) reached 0.6. Protein
expression was then induced by the addition of IPTG to the final concentration of 0.4
mM and expression was allowed to occur for 4 hours at 37 C. Approximately 5 g of
cells were harvested by centrifugation at 4,690 ⇥ g for 20 min at 4 C. Cells harvested
were then directly stored at -80 C.
To purify ubiquitin, the cell pellet was resuspended in 50 ml of lysis bu↵er (50 mM
Tris pH 7.5) containing one protease inhibitor tablet (Roche) and flakes of lysozyme
and DNase I. The cells were then lysed by sonication using a Branson Digital Sonifier
at 70% amplitude for 7 min with 5 sec on and 5 sec o↵ pulses, followed by centrifu-
gation at 28,880 ⇥ g for 30 min at 4 C. Next, 70% percholric acid was slowly added
to the clarified lysate with constant stirring until the pH dropped to 4.5. The lysate
was then left to stir for ten more minutes before it was centrifuged at 28,880 ⇥ g
for 30 min at 4 C. The resulting supernatant was then dialyzed against 4 liters of
ammonium acetate (50 mM, pH 4.5) overnight at 4 C. The next day, the dialyzed
supernatant was loaded onto a 8 ml MonoS column pre-equilibrated with Bu↵er A (20
mM CH3COONH4 pH 4.5, 1 mM EDTA, 5 mM DTT) at a flowrate of 0.5 ml/min.
Unbound proteins were washed with 5 column volumes (CV) of Bu↵er A. Bound pro-
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tein was then eluted through a gradient of 0% - 100% Bu↵er B (20 mM CH3COONH4
pH 4.5, 1 mM EDTA, 5 mM DTT, 0.6 M NaCl) in 20 CV at a flowrate of 3 ml/min.
Fractions (3 ml) were collected and analyzed by SDS-PAGE using 12.5% gel. Pure
fractions were pooled and dialyzed against 4 L of 15 mM Tris pH 7.5 at 4 C overnight.
The concentration of ubiquitin was calculated using a NanoDrop plate by measuring
the absorbance at 280 nm using a Synergy Multi-Mode Microplate Reader (BioTek)
(Section 2.2.2). The extinction coe cient of ubiquitin has been determined to be 0.16
(mg/ml)-1 cm-1 at 280 nm [121].
4.2.4 Crystallization of PLP2-4DPUP-C194S-Ub complex
Purified PLP2-4DPUP-C194S at three di↵erent concentrations (4, 8, 16 mg/ml,
or 117, 234, 468 mM) was incubated with ubiquitin at 1:1 molar ratio for 6 hours at
4 C prior to crystallization. A high-throughput crystallization screen of the PLP2-
4DPUP-C194S-Ub complex was performed using a series of commercial crystalliza-
tion screens from Qiagen a Mosquito liquid handling system (TTP Labtech). Briefly,
0.12 ml of the PLP2–Ub complex at di↵erent concentrations was pipetted into the
three sub-wells of a 96-3 well sitting drop plate (Greiner CrystalQuick crystallization
plate), respectively, and 0.12 ml of reservoir solution was then added to the drop. The
plates were then incubated at 20 C. A crystallization hit was identified the next day
from the PEGs screen in a solution containing 0.2 M potassium formate and 20 w/v
PEG 3350.
4.2.5 Data collection and structure determination
Crystals of PLP2-4DPUP-C194S-Ub from the crystallization hit described above
were harvested using nylon loops and placed into reservoir solution supplemented with
20% glycerol for seconds before they were mounted to nylon loops by flash-cooling
in liquid nitrogen. Crystals were then stored in a dewar filled with liquid nitrogen
until data collection. For data collection, flash-cooled crystals were mounted under a
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stream of dry N2 at 100 K. A complete X-ray dataset was collected at the Life Science-
Collaborative Access Team (LS-CAT) 21-ID-G beamlines at the Advanced Photon
Source Synchrotron (APS), Argonne National Laboratory (ANL). The settings for
data collection were: detector of MAR 300 CCD at 200 mm with the exposure time
of 2 seconds and 1 C of step width. A total of 180 images were collected. The
dataset was then processed and scaled using HKL2000 [103] to 1.85 Å. The structure
was solved through the molecular replacement method using the Phaser-MR module
in Phenix [122] with the structure of PLP2 solved in Chapter 3 as the search model.
Manual model rebuilding was carried out in Coot [105]. Refinement of the structure
was performed with Phenix Refine [106]. Data collection and refinement statistics are
shown in Table 4.3. Figures were generated using PyMOL (The PyMOL Molecular
Graphics System, Schrödinger LLC.).
4.2.6 Generation and characterization of PLP2 mutants
Mutagenesis of PLP2
Constructs for PLP2 mutants were generated by site-directed mutagenesis follow-
ing the procedure described in Section 4.2.2. Primers used for the mutagenesis are
summarized in Table 4.1. Mutagenesis was performed on the construct of pEVL8-
PLP21525-1911 containing the DPUP domain, the Ubl2 domain and the PLP2 domain.
The introduced mutations were verified by Sanger-based sequencing of the entire gene
using the DNA Sequencing Shared Resource at Purdue University.
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Table 4.1.: Primers for site-directed mutagenesis




















































1 Use plasmid R253E/R257A as the template.
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Expression and purification of PLP2 mutants
Expression of PLP2 mutants followed the procedure for WT PLP21525-1911 (Section
2.2.2), except the induction with 0.1 mM IPTG was performed at 18 C for overnight
instead of at 25 C for 6 hr. The PLP2 mutants along with WT PLP2 as a control were
purified through one-step immobilized metal a nity chromatography (IMAC) using
20 ml gravity columns (Bio-Rad) packed with 2 ml Ni-NTA resin (Thermo scientific).
Briefly, the cell pellet from a 500 ml culture (the weight of cell pellet varies between
mutants, ranging from 1.2 g to 2 g) was resuspended in 40 ml Bu↵er A (25 mM Tris
pH 7.0, 500 mM NaCl, 20 mM imidazole, 5 mM bME) supplemented with lysozyme
and DNase I. Cells were then lysed by sonication, and clarified with centrifugation
following the procedures described above. Clarified lysate was next loaded onto the
column pre-equilibrated with Bu↵er A. Unbound proteins were washed with 20 CV of
Bu↵er A, bound proteins were then eluted with 7 ml of 100% Bu↵er B (25 mM Tris
pH 7.0, 500 mM NaCl, 500 mM imidazole, 5 mM bME). Eluted samples were then
dialyzed in Bu↵er C (25 mM Tris pH 7.0, 100 mM NaCl, 10 mM bME) for overnight.
The resulting purified proteins were used directly for further kinetic characterization.
Kinetic characterization of PLP2 mutants
The fluorescence-based assays described in Section 2.2.5 were used to characterize
the kinetic properties of PLP2 mutants. The protease, DUB, and deISGylating activ-
ities of PLP2 mutants were measured with 50 mM RLRGG-AMC, 500 nM Ub-AMC,
and 500 nM ISG15-AMC as the substrate, respectively. The kinetic rates of the PLP2
mutants were standardized to that of WT PLP2. Steady-state kinetic studies of se-




WT PLP2 and PLP2 mutants Y302F, Y302A, R281E and R281A were incubated
at 30 C for di↵erent time periods (0-60 min). At each time point, the specific activity
of enzymes was measured at 25 C using a Synergy Multi-Mode Microplate Reader
(BioTek) with 50 mM RLRGG-AMC as the substrate and 3 mM of each enzyme. The
assay bu↵er used contained 50 mM HEPES, pH 7.0, 0.1 mg/ml BSA and 2 mM DTT.
The experiments were performed in triplicate in a final volume of 100 ml using the 96-
well Corning Costar black microplates. To analyze the data, the remaining activity
(the ratio of the reaction rate at time=t to the rate at time=0) was plotted against
incubation time.
Ubiquitin chains processing assay with PLP2 mutants
The ability of the PLP2 mutants to process K48- and K63-linked polyubiqui-
tin chains was evaluated through the ubiquitin chains cleavage assay as described
in Section 2.2.7. K48- and K63-linked tetra-ubiquitin were purchased from Boston
Biochem.
Thermal melting temperature analysis using circular dichroism (CD)
Thermal melting analyses of WT PLP2 and the R281A mutant were carried
out with a Chirascan circular dichrosim (CD) spectrometer (Applied Photophysics)
equipped with a temperature control system (Quantum Northwest Inc.) by monitor-
ing the CD signal at 220 nm while increasing the temperature at a step interval of
0.4 C and at a rate of 0.5 C/min. 2.4 ml of protein samples at 1.5 mM in bu↵er with
0.1 M potassium phosphate (pH 7.5) was contained in a 10 mm quartz cell (Starna
Cells) with magnetic stirring. Thermal scans were performed in three independent
experiments for both WT and the R281A mutant. The melting temperatures (Tm)
were calculated as the first derivative peak using the program SigmaPlot.
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4.2.7 Synthesis of Ub-propargylamine (Ub-Prg)
Expression and purification of Ub1-75-Intein-CBD fusion protein
Expression vector of pTYB2-Ub1-75-Intein-CBD was a gift from Professor Keith
Wilkinson’s lab in Emory University. The Ub-Intein-CBD fusion protein was ex-
pressed in BL21(DE3) RIPL cells. 3 liters of cells were grown in super LB media (3
g KH2PO4, 6 g Na2HPO4, 20 g Tryptone, 5 g Yeast Extract, 5 g NaCl, pH 7.2, 0.2 %
lactose, 0.6 % glycerol, 0.05 % glucose) supplemented with 50 mg/ml of carbenicillin
(carb) and 34 mg/ml chloramphenicol (cam) at 25 C for overnight. The next day,
around 11 g of cells were harvested by centrifugation at 4,690 ⇥ g for 20 min at 4 C.
Cells harvested were then directly stored at -80 C.
The column for protein purification was packed a day before. Briefly, 60 ml of
chitin beads (New England Biolabs) stored in 20% ethanol was poured into a 120 ml
gravity column (2.5 ⇥ 30 cm, Econo-column, BioRad), and was then washes with 300
ml of ddH2O. The resin was then equilibrated with 180 ml of column bu↵er (50 mM
HEPES pH 6.5, and 350 mM NaOAc). The packed column was stored at 4 C prior to
use. To purify the protein, the cell pellet was resuspended in 40 ml of column bu↵er
containing 1 mM MgCl2 and DNase I. The cells were then lysed by sonication using
a Branson Digital Sonifier at 65% amplitude for 10 min with 5 sec on and 5 sec o↵
pulses, followed by centrifugation at 28,880 ⇥ g for 30 min at 4 C. Next, the clarified
lysate was loaded into the pre-packed column with chitin beads, then the lysate-chitin
beads mixture was transferred to a glass beaker and incubated at 4 C with gentle
stirring for 2 hours . During this period of time, the Ub-Intein-CBD fusion protein
will bind to the chitin beads. After that, the mixture was poured back to the gravity
column and washed extensively with 300 ml of column bu↵er to remove unbound
proteins. The washes were collected and evaluated through SDS-PAGE analysis.
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Generation of Ub-MESNa and Ub-Prg
To generate Ub-MESNa, 50 ml of 180 mMMESNa (sodium 2-sulfanylethanesulfonate,
Sigma) fresh made in column bu↵er was passed through the column, and the flow was
stopped when the solution is around 1 cm above the chitin beads. Then, the beads
were mixed with another 50 ml of 180 mM MESNa, and the mixture was transferred
to a beaker and incubated at 4 C for overnight with gentle stirring. The next day,
the incubated mixture was loaded onto the gravity column and eluted with 100 ml
of column bu↵er while the eluted Ub-MESNa was being collected. The purity of Ub-
MESNa was assessed by running SDS-PAGE with 12.5% gels, and its concentration
was determined by measuring the absorbance at 280 nm using Take 3 (BioTek). To re-
act Ub-MESNa with propargylamine (Prg), 4.05 g of Prg powder (Sigma) was slowly
added to the eluted Ub-MESNa solution, then the pH of the solution was adjusted to
7.7 with NaOH. The reaction was incubated for 4 hours at RT. The reaction products
were then dialyzed against 1 L of 50 mM Tris pH 7.5 using SnakeSkin dialysis tubing
with 3K MWCO (ThermoFisher Scientific). The next day, the dialyzed solution was
filtered and the concentration was determined by measuring the absorbance at 280
nm using the experimentally calculated extinction coe cient of Ub [121]. Finally, the
protein was divided into 1ml aliquots and directly stored at -80 C.
4.2.8 Modification of PLP21525-1911 by Ub-Prg
Modification
To perform a small scale modification study, 1 ml of PLP21525-1911 (3.5 mg/ml or
80 mM) was incubated with Ub-Prg at varied molar ratios, ranging from 1:0.125 to
1:4 (PLP2 : Ub-Prg). A reaction with no Ub-Prg was also included as a control.
The mixture was incubated at room temperature for 10 min prior to analysis on 10%
SDS-PAGE gel. From the small scale modification study, the optimal molar ratio of
PLP2 to Ub-Prg for maximum modification could be decided, which is 1:1. Then
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large scale modification was set up by incubating 24 ml of PLP21525-1911 (3.5 mg/ml
or 80 mM) with Ub-Prg (molar ratio of 1:1) at room temperature for 30 min with
gentle shaking on a rocker. During the incubation period, the mixture was covered in
foil to avoid from light. Since PLP2 was not 100% modified, further purification was
needed in order to separate Ub-modified PLP2 from unmodified PLP2 (see below).
Ion-exchange chromatography to separate PLP2–Ub complex from un-
modified PLP2
Cation exchange chromatography – Mono S. Prior to purification, the reac-
tion mixture was dialyzed against Bu↵er A (25 mM Tris pH 7.0, 5 mM bME) at 4 C
overnight using SnakeSkin dialysis tubing with 10K MWCO (ThermoFisher Scien-
tific). The next day, the dialyzed mixture was loaded onto a 8 ml Mono S column
(GE Healthcare) pre-equilibrated with Bu↵er A at a flow rate of 1 ml/min. Unbound
proteins were washed away with Bu↵er A until the UV came back to zero. Bound
protein was then eluted using a gradient of 0% - 60% Bu↵er B (25 mM Tris pH 7.0,
500 mM NaCl, 5 mM bME) in 30 CV at a flow rate of 2 ml/min. The gradient was
held constant when proteins started to come out. 3 ml fractions were collected and
analyzed by SDS-PAGE using a 10% gel. Fractions with high purity of PLP2–Ub
were pooled and dialyzed against bu↵er with 50 mM HEPES pH 7.0 and 100 mM
NaCl prior to crystallization.
Anion exchange chromatography – Mono Q. The reaction mixture was dia-
lyzed against Bu↵er A (25 mM Tris pH 9.0, 5 mM bME) at 4 C overnight prior to
purification. The next day, the dialyzed mixture was loaded onto a 8 ml Mono Q
column (GE Healthcare) at a flow rate of 1 ml/min. Unbound proteins were washed
away with Bu↵er A until the UV came back to zero. Bound protein was then eluted
using a gradient of 0% - 100% Bu↵er B (25 mM Tris pH 9.0, 500 mM NaCl, 5 mM
bME) in 45 CV at a flow rate of 2 ml/min. 3 ml fractions were collected and analyzed
by SDS-PAGE using a 10% gel. Fractions with high purity of PLP2–Ub were pooled
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and dialyzed against bu↵er with 50 mM HEPES pH 7.0 and 100 mM NaCl prior to
crystallization.
4.3 Results
4.3.1 Computationally derived model of PLP2 in complex with Ub
Before crystals were obtained for the PLP2–Ub complex, the structure of the
SARS-CoV PLpro–ubiquitin aldehyde (Ubal) complex (PDB code 4MM3) [71] was
used as a template to generate a model of PLP2 in complex with Ubal via molecu-
lar dynamics (Section 4.2.1). A computational model was pursued in order to gain
insights into potential interactions between PLP2 and ubiquitin, in case crystals of
the complex could not be obtained. The resulting computational model of the MHV
PLP2–Ubal complex reveals that the Ubal molecule is stabilized by numerous inter-
actions at the canonical surface formed by the thumb-palm-fingers domains of PLP2,
while the C-terminal residues of Ubal extend into the narrow opening of the active
site, as expected. Henceforth, to di↵erentiate the enzyme residues from Ub residues,
the Ub residues will be shown in italics, while the PLP2 residues will be represented
in the regular font.
Extensive H-bonding interactions between the C-terminal residues of Ubal and
the active site of PLP2 are observed in the model (Figure 4.1A). This observation is
consistent with the fact that PLP2 can hydrolyze the peptide substrate Z-RLRGG-
AMC, albeit more than 20,000 times less e ciently than Ub-AMC. A similar network
of H-bonding interactions has also been discovered in the structure of SARS-CoV
PLpro–Ubal complex (Figure 4.1B) [71]. In SARS-CoV PLpro, the side chain of Y265
interacts with the backbone of R74 (Figure 4.1B). A similar interaction is absent in
PLP2 due to the substitution of Y265 with F344. However, the loss of this H-bonding
interaction may not have a significant e↵ect on the enzymatic activity, as the Y265F
mutant of SARS-CoV PLpro possesses activity comparable to WT [120]. On the other
hand, a potentially stable salt-bridge interaction between the side chain of R74 and
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E244 is observed in the PLP2–Ubal model (Figure 4.1A, Table 4.2). In the SARS-CoV
PLpro–Ubal complex, however, a similar interaction is absent as suggested by both
the crystal structure [71,120] and the 1.2 ns MD analysis of the complex (Table 4.2).
Overall, the di↵erences in the interaction profiles between the C-terminal residues of
Ubal and the active sites of MHV PLP2 and SARS-CoV PLpro do not adequately
justify why the activity of PLP2 with Z-RLRGG-AMC is significantly lower than that
of SARS-CoV PLpro. Perhaps, the additional salt bridge between E244 and R74 in
PLP2–Ubal model is detrimental to the activity of PLP2 with Z-RLRGG-AMC as
it could lead to substantial product inhibition. Alternatively, additional interactions
between PLP2 and Ub that were not predicted by the MD run may play an important
role in the reduction of MHV PLP2 activity against Z-RLRGG-AMC when compared
to that of SARS-CoV PLpro.
In addition to the interactions near the active site, extensive contacts are predicted
between MHV PLP2 and the Ubal core (residues 1-71) (Figure 4.1C). Specifically,
side chains of Y302 and R281 interact with the backbone carbonyl of A46 through
H-bonding, while there is a backbone-backbone interaction between the amide of F290
and the carbonyl of G47. Side chain of F290 interacts with the I44-V70 hydrophobic
patch of Ub, and residues D250, R253 and D285 each engage in salt-bridge interactions
with R42, E51 and K48, respectively. Importantly, it is found that there are more
complimentary charge contacts between MHV PLP2 in the MHV PLP2–Ubal complex
compared to the SARS-CoV PLpro–Ubal complex (Table 4.2). This may account for
the much lower Km of PLP2 (1.3 mM) with Ub-AMC compared to that of SARS-CoV
PLpro (50.6 mM).
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Fig. 4.1.: Computationally-derived model of PLP2 in complex with Ubal. (A and B)
Potential interactions between PLP2 and the C-terminal residues of Ubal (A) in comparison
to the identified interactions between SARS-CoV PLpro and the C-terminal residues of Ubal
(B) as observed in the structure of SARS-CoV PLpro–Ubal complex (PDB code 4MM3).
PLP2 is colored as in Figure 3: Orange thumb, lightblue palm, green fingers. Ubal is
shown in yellow, and SARS-CoV PLpro in cyan. H-bonding and salt bridge interactions
are represented as dash lines. Red dash line in A indicates that a similar interaction is
not observed in B, and vice versa. (C) Potential interactions between PLP2 and Ubal
(yellow). Only the interactions that persist for more than 50% of the simulation time are
shown. Magenta dashed line indicates that the interaction persists for more than 50% of
the simulation time, but is not present in the current analyzed frame.
106
Table 4.2.: Persistence of potential interactions during MD simulation
MHV SARS-CoV Interaction
Ub PLP2 % Time Ub PLpro % Time Preference Type
with Ub C-terminal residues
G76-NH⇤ G350-CO 91 G76-NH G272-CO 96 ⇡ HB
G75-CO S246-NH 83 G75-CO G164-NH 59 PLP2 HB
G75-NH S246-CO 96 G75-NH G164-CO 100 ⇡ HB
R74-CO G350-NH 79 R74-CO G272-NH 81 ⇡ HB
R74 S348-CO 24 R74 Q270-CO 78 PLpro HB
R74 E244 100 PLP2 SB
R74-NH Y265 90 PLpro HB
L73-NH D165 90 PLpro HB
R72 D247 100 PLP2 SB
R72 D250 100 R72 E168 100 ⇡ SB
with Ub core
R42 D250 100 R42 E168 74 ⇡ SB
Q49 I249-CO 47 Q49 R167-CO 8 PLP2 HB
Q49 R253 12 PLP2 HB
E51 R253 100 PLP2 SB
E51 R257 35 PLP2 SB
G47-CO F290-CO 97 G47-CO M209-CO 92 ⇡ HB
G47-CO R281 11 PLP2 HB
K48 D285 58 K48 E204 6 PLP2 SB
A46-CO R281 100 PLP2 HB
A46-CO Y302 72 A46-CO Q233 84 ⇡ HB
⇤ This format indicates that the backbone atom is involved in the interaction. In this case, it
means that the backbone amide of G76 is involved in the interaction.
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4.3.2 Crystallization of PLP2-4DPUP-C194S in complex with Ub
PLP2-4DPUP-C194S and mono Ub were purified according to the procedure
described in Section 4.2.2 and 4.2.3 respectively. Figure 4.2 shows the purity of PLP2-
4DPUP-C194S and Ub after purification. The molecular weight of PLP2-4DPUP-
C194S and Ub are 34.1 kDa and 8.6 kDa, respectively. PLP2-4DPUP-C194S was
fresh purified for crystallization, while frozen Ub was dialyzed into Bu↵er D (50 mM
Tris pH 7.5, 100 mM NaCl, 5 mM DTT) prior to incubation with PLP2-4DPUP-
C194S.
Fig. 4.2.: Purification of PLP2-4DPUP-C194S and mono Ub. (A and B) SDS-PAGE
analysis of PLP2-4DPUP-C194S throughout the purification. (C) SDS-PAGE analysis of
mono Ub after purification.
Purified PLP2-4DPUP-C194S at 4 mg/ml (117 mM), 8 mg/ml (234 mM) and 16
mg/ml (468 mM) was incubated with Ub at 1:1 molar ratio in a 4 C for 6 hours prior
to setting up the crystallization screens. Crystals started to appear after one day of
incubation at 20 C in a condition consisting of 0.2 M potassium formate and 20 w/v
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PEG 3350 (Figure 4.3). Crystals obtained from this hit condition were directly used
for data collection.
Fig. 4.3.: Crystal of PLP2-4DPUP-C194S in complex with Ub. PLP2-4DPUP-C194S-Ub
grew in space group C121 with two molecules in the asymmetric unit.
4.3.3 Structure of PLP2-4DPUP-C194S–Ub complex
Overall structure
The X-ray crystal structure of the PLP2-4DPUP catalytic cysteine-to-serine mu-
tant (PLP2-4DPUP-C194S) in complex with Ub was determined through the method
of molecular replacement using the structure of PLP2 determined in Chapter 3 as the
search model. The structure of the complex was determined to 1.85 Å resolution
(Table 4.3). The final refined structure has R
work
of 15.8% and R
free
of 19.6%. The
complex of PLP2-CS-Ub crystallized in space group C121. The crystal packing of
molecules within one unit cell is shown in Figure 4.4A. There are two sets of com-
plexes (two PLP2-CS molecules and two Ub molecules) in an asymmetric unit. The
Ub molecule binds to PLP2-CS via the canonical pocket formed by the thumb-palm-
fingers domains. The two sets of complexes are structurally similar with RMSD of
0.9 Å over 375 aligned Ca atoms. The structural variation between the two sets of
complexes exists mainly in the Ubl2 domain (Figure 4.4B). This is not surprising be-
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cause the Ubl domains of CoV PLPs have been shown to be flexible [34]. Nonetheless,
detailed analysis of the interactions between PLP2 and Ub in both complexes reveals
the same interaction pattern. Therefore, only one of the complexes will be analyzed
from here on as representative. Ub residues are shown in italics, and PLP2 residues
are represented in the regular font.
Fig. 4.4.: Crystal packing of the PLP2-4DPUP-C194S-Ub structure and the structural
di↵erence of molecules within an ASU. (A) Crystal packing of the PLP2-4DPUP-C194S-
Ub complex within the C121 unit cell. PLP2 is shown in gray and blue, while the Ub
molecules are shown in orange. There are two sets of complexes, including two PLP2 and
two Ub, in an ASU. (B) Structural superposition of the two sets of complexes in an ASU.
PLP2 is shown in magenta and green, while the corresponding bound Ub molecules are
shown in yellow and blue, respectively.
Analysis of the interactions between PLP2 and Ub
In order to identify residues of PLP2 as mutagenesis targets to decouple the en-
zyme’s multiple activities, the interactions between PLP2 and the Ub core (residues
1-71) was analyzed. As shown in Figure 4.5A, the Ub core interacts with PLP2
mainly through three regions, the tip and the base of the fingers domain and the
thumb domain. First, at the fingers tip, the backbone atoms of E64 and T66, and
side chains of T66 and H68 indirectly interact with the main-chain atoms of T307
and A305 via a network of water-mediated H-bonds (Figure 4.5B). Second, the side
chain atom of R42 forms ion-pair interactions with D247 and D250 from the thumb
domain of PLP2, while the side chain of E51 interacts with R253 and R257 (Figure
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a, b, c (Å) a = 199.5, b = 43.4, c = 110.2
↵,  ,   ↵ =   = 90,   = 114.8
Resolution (Å) 100.00–1.85 (1.88–1.85)a
No. of reflections observed 916110
No. of unique reflections 73697
Rmergeb(%) 5.2 (63.8)
I/ I 25.3 (1.9)
% Completeness 99.9 (99.8)
Redundancy 3.7 (3.7)
Refinement
Resolution range (Å) 37.58–1.85 (1.90–1.85)
No. of reflections in working set 73602 (5055)
No. of reflections in test set 1999 (141)
Rworkc(%) 15.8 (23.0)
Rfreed(%) 19.6 (29.8)
Wilson B factor (Å) 26.5
Average B factor (Å) 34.8
RMSD from ideal geometry
Bond length (Å) 0.012
Bond angle (deg) 1.23
Ramachandran plot
Most favored (%) 98.2
Allowed (%) 1.8
Disallowed (%) 0
a Values in parentheses are for the last (highest resolution) shell.
b Rmerge = ⌃hkl⌃i
  Ii(hkl)   hI(hkl)i
  /⌃hkl⌃iIi(hkl), where Ii(hkl)
is the intensity of a given reflection, and hI(hkl)i is the mean
intensity of symmetry-related reflections.
c Rwork = ⌃hkl
  |Fobs|   |Fcalc|
  /⌃hkl|Fobs|, where Fobs and Fcalc are
the observed and calculated structure factors, respectively.
d Rfree was calculated using 5% of the data set chosen at random
that were excluded from the refinement.
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4.5C). Next, at the base of the fingers domain, the side chain of K48 interacts with
E279 via salt-bridge interaction. The backbone atom of A46 forms H-bond interac-
tion with the side chain of R281, while the backbone carbonyl of G47 forms a similar
interaction with the backbone amide of F290. Additionally, the main-chain atoms of
G47 and Q49 indirectly interact with R281, D285, M288 and R253 via a network of
water-mediated H-bonds (Figure 4.5D).
Within the active site of PLP2, the C-terminal residues of Ub (RLRGG) have
clearly defined electron density. The BL2 loop (346GGSVG350), which has been shown
to play an important role in substrate/inhibitor binding also has clearly observable
density (Figure 4.6A). The backbone or side chain atoms of the C-terminal residues
of Ub interact with PLP2 through a total of 19 direct H-bonds (Figure 4.6B). Specif-
ically, the side chain guanidinium group of R72 interacts with the side chain carboxy-
late of D250; the backbone carbonyls of L73 interact with the backbone carbonyl and
amide of S246; the backbone carbonyl of R74 interacts with the backbone amide of
G350; the backbone amide and carbonyl of G75 forms several H-bond interactions
with the backbone atoms of S246; and the backbone amide of G76 interactes with
both the side of C194S and the backbone of G350. One of the two O atoms of the
G76 C-terminal carboxylate interacts with the side chain and backbone of C194S, the
backbone of N193 and the side chain of Q189, while the other O atom interact with
the side chain of C194S, the backbone of G350 and the side chain of H351. In addi-
tion, the backbone carbonyl of R74 and the backbone amide of R72 interact with the
backbone carbonyls of G347 and S348 from the BL2 loop via water-mediated H-bonds
(Figure 4.6B), which has not been observed in previously published PLP–Ub com-
plex structures [34, 79, 120]. Interestingly, the two O atoms of the G76 carboxylate
form extensive H-bonds with PLP2 (Figure 4.6B). It is suggested from the structure
that the side chain of Q189 and the backbone amides of N193 and C194S form the
oxyanion hole during catalysis.
Notably, most of the interactions between PLP2 and Ub observed from the crys-
tal structure of the PLP2-4DPUP-C194S–Ub complex, except those water-mediated
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Fig. 4.5.: Structure of PLP2–Ub complex. (A) Overall structure of PLP2-C194S-Ub com-
plex. Domains are color coded: Ub in yellow, Ubl2 domain of PLP2 in purple, thumb
domain in orange, palm domain in blue, and fingers domain in green. Interacting residues
of PLP2 and Ub are shown in sticks. Interactions between PLP2 and Ub mainly exist in
three regions, which are circled in di↵erent colors - red (B), cyan (C), and black (D).
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Fig. 4.6.: Interactions between PLP2 and the C-terminal residues of Ub. (A) The C-terminal
residues of Ub (RLRGG) and the BL2 loop of PLP2 have clear electron density. Ub and
PLP2 are shown in yellow and wheat, respectively. A Fo-Fc omit map with Ub omitted
from the map calculated is colored green and contoured at 3s. A 2Fo-Fc map is colored in
light blue and is contoured at 1s. (B) Detailed interactions between the C-terminal residues
of Ub and the active site of PLP2. Ub is shown in yellow. PLP2 is color coded as: thumb –
orange, palm – light blue, fingers – green. Water molecules are represented in red spheres.
H-bonding interactions are shown in dashes.
ones, have been predicted through the computational model of the complex derived
through molecular dynamics as discussed in Section 4.3.1. On the one hand, this
observation supports the potential power of MD simulation in predicting potential H-
bonding and salt-bridge interactions; on the other hand, it revealed the weakness of
MD simulation in predicting water-mediated interactions. Water molecules are found
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ubiquitously at protein-protein interfaces [123]. It is suggested that water-mediated
interactions could be as important as direct interactions in protein-protein recogni-
tion [123]. In the structure of MHV PLP2-4DPUP-C194S–Ub complex, the water
molecules are found to be consistent in both complexes within the ASU. However,
more studies are needed to determine the importance of the water-mediated interac-
tions as revealed by the crystal structure of the PLP2-4DPUP-C194S–Ub complex.
For example, multiple datasets could be collected from crystals grown under di↵er-
ent conditions to evaluate if the water molecules. Also, residues with side chains
involved in water-mediated interactions could be mutated to test the importance of
these interactions in the binding of Ub in the complex.
4.3.4 Conformational changes of MHV PLP2 upon ubiquitin binding
In order to investigate the conformational changes of MHV PLP2 upon the binding
of ubiquitin, the catalytic core of PLP2 from the PLP2–Ub complex was superimposed
with the catalytic core of PLP2 from the unbound structure (Figure 4.7). The RMSD
is approximately 1.6 Å over 292 aligned Ca atoms. The Ubl2 domain was omitted
from the superimposition given its inherent flexibility. The conformational changes
exist mainly in two regions: the fingertips region and the BL2 loop. In the unbound
structure of PLP2, possibly due to the e↵ect of crystallization (Figure 3.11), the
fingertips collapse towards the palm domain, rendering the pocket formed by the
thumb-palm-fingers domains too compact to accommodate the ubiquitin molecule.
To bind ubiquitin, the fingertips must open up to allow the ubiquitin molecule to fit.
The zinc atom in the fingers domain shows a shift of 4.9 Å upon ubiquitin binding.
As supported by the kinetics data (Table 2.2), the binding of ubiquitin a↵ects the
arrangement of residues in the active site, which thereby increases catalysis. The
BL2 loop adopts a more closed conformation upon the binding of ubiquitin. Several
backbone to backbone H-bonding interactions are observed between the BL2 loop
115
and the C-terminal residues of Ub (Figure 4.6B). The BL2 loop has been shown to
play an important role in the binding of substrates or inhibitors [71, 113].
Fig. 4.7.: Comparison of the PLP2–Ub complex structure to the structure of apo PLP2.
PLP2 from the PLP2–Ub complex is shown in pink, while the associated Ub molecule is in
yellow. The apo PLP2 is represented in gray. The zinc atoms are shown in spheres. PDB
codes: PLP2–Ub complex – to be deposited , apo PLP2 – 4YPT.
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4.3.5 Structural comparison of MHV PLP2–Ub to other known CoV
PLP–Ub complexes
Prior to determining the structure of the MHV PLP2–Ub complex, the structures
of SARS-CoV PLpro–Ub and MERS-CoV PLpro–Ub complexes were published [34,
79,120]. In all three complexes, the Ub molecules bind PLPs via the same canonical
surface formed by the thumb-palm-fingers domains. The structures of these three
complexes were superimposed to compare the binding of ubiquitin molecules to the
three di↵erent PLPs (Figure 4.8). The catalytic cores of PLPs align well with the
major di↵erence being present in the fingers domain. The RMSDs of MHV PLP2 to
SARS-CoV PLpro and MERS-CoV PLpro are 1.9 Å (280 aligned Ca atoms) and 2.7
Å (253 aligned Ca atoms), respectively. The conformation of the fingers domains is
similar in SARS-CoV PLpro and MHV PLP2; however, the fingers domain of MERS-
CoV PLpro is very di↵erent from the other two PLPs (Figure 4.8A). A substantial
shift in the position of the bound Ub molecule in the MERS-CoV PLpro–Ub complex
is also observed (Figure 4.8B). The fingers domain of PLPs has been shown to be
highly flexible and may play a significant role in the substrate (Ub, ISG15) recognition
[34,70].
In the interface between MHV PLP2 and Ub, there are five charged residues from
Ub (R42, K48, E51, R72 and R74 ) that form extensive electrostatic interactions with
MHV PLP2 (Table 4.2 and Figure 4.5). The electrostatic surface potential analysis of
MHV PLP2 reveals several charged patches of PLP2 that match the charged residues
of Ub (Figure 4.9). However, the electrostatic surface analyses of SARS-CoV PLpro
and MERS-CoV PLpro do not reveal the similar patterns of charge matching (Figure
4.9). The presence of the extensive electrostatic interactions between MHV PLP2
and Ub, which are missing in the SARS-CoV PLpro–Ub and MERS-CoV PLpro–Ub
complexes, may explain the much lower Km of MHV PLP2 with Ub compared to
SARS-CoV PLpro and MERS-CoV PLpro (Table 2.2).
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Fig. 4.8.: Comparison of the X-ray structures of MHV PLP2–Ub (blue) to SARS-CoV
PLpro–Ub (pink) and MERS-CoV PLpro–Ub (green) complexes. (A) Structural comparison
of the PLPs in the three complexes shown in stereoview. The Ub molecules are omitted from
the structure for clarity. (B) Structural comparison of the Ub molecules in the complexes
shown in stereoview. PLPs are shown in transparency for better visualization. The zinc
atoms are represented in spheres. PDB codes: MHV PLP2–Ub, to be deposited, SARS-CoV
PLpro–Ub, 4MM3, MERS-CoV PLpro–Ub, 4RF0.
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Fig. 4.9.: Electropotential surface potential of MHV PLP2 in comparison to SARS-CoV
PLpro and MERS-CoV PLpro. Side chains of charged residues from Ub that are involved
in the interaction with PLPs are shown in sticks. These residues include R42, K48, E51,
R72 and R74. CoV PLPs are in electrostatic surface representation. The electrostatic
surface was calculated with the APBS plug-in in PyMOL [124], and is rendered in blue and
red to represent positive and negative electrostatic potentials, respectively. The settings
were +4kBT/e for positive maximum and -4kBT/e for the negative maximum.
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4.3.6 Structure-guided mutagenesis of PLP2 to decouple its multiple en-
zymatic activities
Combining the information from the MD stimulation (Section 4.3.1) and the X-ray
crystal structure of the PLP2–Ub complex (Section 4.3.3), residues that are involved
in the Ub-binding interface but far away from the active site were identified. These
residues were then targeted for mutagenesis in order to selectively disrupt the DUB
activity of PLP2. The goal was to design mutants with intact protease activity and
decreased DUB activity. However, mutants with altered deISGylating activity could
not be predicted since the interaction between PLP2 and ISG15 is unknown yet.
Purification of PLP2 mutants
Mutations were introduced to the expression vector following the procedure de-
scribed in Section 4.2.6. A series of PLP2 mutants were then expressed and purified
according to the procedure in Section 4.2.6. The SDS-PAGE gel in Figure 4.10 shows
the purity of the PLP2 mutants after purification. Most PLP2 mutants were judged
to be pure prior to kinetic characterization.
Kinetic properties of PLP2 mutants
Activity assays at one substrate concentration. The activities of PLP2 mu-
tants were characterized and compared to WT PLP2. Assays were performed as
described in Section 2.2.5 with three di↵erent substrates (RLRGG-AMC, Ub-AMC
and ISG15-AMC). The activities of the mutants were normalized to that of WT
PLP2. Figure 4.11 presents a summary of the activities of the mutants. Overall, the
mutants can be divided into four groups (Groups I–IV) given the changes in their
DUB and deISGylating activities (Figure 4.11).
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Fig. 4.10.: SDS-PAGE of purified PLP2 mutants. 4 mg of protein was loaded into each
well except for mutants I304A, F290A, Y302F and V313A, where the amount of protein
loaded was not quantitated. Mutants I304A, F290A, Y302F and V313A were run separately.


































































































































































Mutants in the Group I show a decrease in both DUB and deISGylating activi-
ties. These mutants include F290R, F290A, R281A, E279A, I304A, D285A, D285R,
Y302F and V313A. First, F290 has been identified to interact with the hydropho-
bic core of Ub that is formed by I44 and V70 (Figure 4.5D and Figure 4.12A). Most
CoVs have conserved hydrophobic residues at this position (Figure 4.15). Mutation of
the corresponding residues in SARS-CoV PLpro and MERS-CoV PLpro have shown
that this residue is important in Ub-binding [34, 79,120]. In order to disrupt the hy-
drophobic interaction, F290 was mutated to alanine (F290A, to check the importance
of the aromatic ring) and arginine (F290R, to introduce a charge to the hydrophobic
pocket). As expected, both mutants showed a significantly decrease in DUB activity.
However, the protease activity of F290A is low, while the F290R mutant seems to
maintain intact protease activity.
D285 is involved in a water-mediated H-bonding interaction with Ub as revealed
from the X-ray crystal structure of the complex (Figure 4.5). In contrast, it was
predicted to interact with the side chain of K48 from Ub through a salt-bridge in-
teraction based on the MD simulations (Table 4.2). To investigate the importance of
D285 in Ub-binding, it was mutated to both alanine (D285A) and arginine (D285R).
Both mutants, D285A and D285R, showed a significant decrease in the DUB activity,
but their protease activities are also low, at less than 50% of WT. Therefore, these
two mutants were not worth pursuing further.
Residues I304 and V313 were identified via the X-ray structure to interact with the
hydrophobic patch of Ub that is formed by F45 and A46 (Figure 4.12B). Mutation
of I304 and V313 to alanines both showed decrease in DUB activity. However, the
introduction of the mutation appeared to a↵ect the overall stability of the protein
as the protease activity also diminished. Therefore, this mutant was also not worth
pursuing in further studies.
E279 was shown to interact with the side chain of K48 through a salt-bridge based
on X-ray crystal structure. This salt-bridge interaction seems to play a role in Ub-
binding as the E279A mutant loses 50% of its DUB activity. However, the mutation
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also a↵ected the protease activity of the protein. Finally, the R281A mutant displayed
normal protease activity (88%) with only a small decrease in DUB activity (69%).
However, its deISGylating activity is significantly reduced (4%). Based on these
properties, the R281A mutant was characterized further and further discussion on
this mutant is presented in Section 4.3.7.
Fig. 4.12.: Hydrophobic interactions between PLP2 and Ub. (A) The packing of F290 from
PLP2 against I44-V70 patch from Ub. (B) The packing of I304-V313-F270 from PLP2
against F45-A46 patch from Ub. (C) The packing of the PLP2 fingers domain around
Y302. Ub is shown as cartoon in yellow, and residues involved in interactions are shown as
a space-filling view (C-green, O-red, N-blue, H-gray).
Mutants in Group II are R253E/R257A, R253A/R257A and F270A. They have
normal or increased DUB activity but significantly decreased deISGylating activities,
while the protease activity of these mutants remains intact. Both the MD simulation
and the crystal structure of the complex showed that R253 and R257 form salt-bridge
interactions with E51 of Ub (Figure 4.5C). However, it is surprising that mutations
at R253 and R257 to either remove the salt-bridge interaction (R253A/R257A) or
introduce repelling charge (R253E/R257A) did not disrupt its DUB activity. On
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the other hand, although it was predicted that F270 may be involved in hydrophobic
interaction with the F45-A46 hydrophobic core of Ub, the mutation of F270 to alanine
(F270A) does not seem to a↵ect its DUB activity at all, suggesting that the aromatic
ring is not essential in the hydrophobic interaction. It is interesting that all these three
mutant displayed significantly diminished deISGylating activity. It is not clear why
the mutation at residues R253, R257 and F270 would result in significantly decrease
of the deISGylating activity. Knowledge of how PLP2 interacts with ISG15 may be
helpful in answering these questions. However, these mutants could serve as tools to
study the role of the deISGylating activity during virus infection.
Mutants in Group III display decreased DUB activity but increased deISGylating
activity. These mutants include I249R, D250A and D250R. Although the protease
activity of mutants I249R and D250A increased, D250R lost more than 50% of the
protease activity compared to WT. The structures indicate that D250 forms an elec-
trostatic interaction with R42 from Ub (Table 4.2 and Figure 4.5C). The moderate
decrease in DUB activity of D250A and the significant decrease in DUB activity of
D250R implied the importance of D250 in Ub binding. Corresponding residues of
D250 in MHV PLP2 are either aspartic or glutamic acid in other CoVs (Figure 4.15),
except MERS-CoV PLpro (arginine) and IBV PLP2 (tryptophan). In fact, E168 in
SARS-CoV PLpro, which corresponds to D250 in MHV PLP2, has been shown to
be important for interacting with Ub [120]. However, the observation that MERS-
CoV PLpro also has a comparable level of DUB activity indicates that this enzyme
may interact with Ub in a di↵erent manner, as suggested by Figure 4.8 [61]. The
impaired protease activity of D250R may come from the repelling e↵ect between the
introduced arginine residue and R72 of Ub, as D250 of PLP2 is located close to the
active site and has interactions with R72 (Table 4.2 and Figure 4.6). The reason
that I249R also showed a significant decrease in DUB activity may be due to the
introduction of the arginine residue to the vicinity of R42 from Ub. While the DUB
activity of I249R has decreased, it is surprising to observe that I249R displayed a
huge increase in its deISGylating activity. The corresponding residue of Ub R42 is
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W123 in ISG15 (Figure 4.13). Perhaps, the mutation of I249 to arginine enables the
formation of a cation-⇡ interaction between the arginine residue and W123 of ISG15,
thus increasing the deISGylating activity of the I249R mutant. Cation-⇡ interactions
have been shown to be common among structures in Protein Data Bank, and may
contribute to protein-protein interactions as much as conventional interactions, such
as H-bonds and salt bridges [125]. The increased deISGylating activity of the I249R
mutant enables the determination of the Km value with ISG15-AMC to be 1.4 mM,
which was not determinable in the case of WT PLP2 (Table 4.4). The D250R also
showed increased deISGylating activity, implying that an arginine residue at position
249 or 250 is beneficial for deISGylating activity. Notably, the corresponding residue
of I249 in SARS-CoV PLpro is an arginine, and SARS-CoV PLpro is much more
e cient as a deISGylating enzyme than as a DUB (Table 2.2).
Fig. 4.13.: Sequence alignment of Ub and ISG15 from human and mouse origins. R42
of Ub and the corresponding residue W123 in ISG15 are shaded in orange. Accession
numbers: Human Ub, 1ubq; Mouse Ub, P62991; Human ISG15, AAH09507; Mouse ISG15,
AAI09347. The figure was generated by ESPript [126].
Mutants in Group IV, Y302A and R281E, are essentially inactive. These two
mutants are structurally unstable as supported by temperature inactivation studies,
where the activities of Y302A and R281E showed significant decreases in activity over
time when incubated at 30 C. The alternative mutants, Y302F and R281A, and WT
PLP2 did not show notable decreases in activity during incubation (Figure 4.14). The
di↵erences in the thermostability of Y302F and Y302A indicates that the presence of
an aromatic ring at this position is important, yet the H-bonding interaction between
Y302 and Ub, as predicted by MD simulation, is not crucial for the binding and
processing of Ub (Table 4.2). Given the packing around the Y302 residue (Figure
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4.12C), the removal of the aromatic ring may compromise the proteins stability and
thus its enzymatic activity. Interestingly, the multiple sequence alignment of various
PLPs reveals that residues at this position are conserved as mainly aromatic or in one
case a methionine (Figure 4.15). On the other hand, the di↵erences in the activities
of R281A and R281E suggests that the replacement of arginine with glutamic acid
at this position may introduce an electrostatic clash into this region of the protein,
compromising both stability and activity of the mutant.
Fig. 4.14.: Temperature inactivation of PLP2 mutants Y302A and R281E. The activities
of WT PLP2 and four PLP2 mutants (Y302F, Y302A, R281A and R281E) were measured
after incubation at 30 C for di↵erent time periods, and then normalized to the activity at
0min. 50 mM RLRGG-AMC was used as substrate in the activity assay.
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Fig. 4.15.: Sequence alignment of various coronaviral PLP2. Group 1, HCoV-229E and
HCoV-NL63; group 2, MHV, SARS-CoV, MERS-CoV, HCoV-OC43, and HCoV-HKU1;
group 3, IBV. The BL2 loop residues are boxed in green. Purple stars indicate the catalytic
triad residues. Orange ovals indicate residues of MHV PLP2 that may be involved in
important interactions with Ub. Accession numbers: MHV PLP2, P0C6V0; SARS-CoV
PLpro, AEA10816.1; MERS-CoV PLpro, YP 007188578.1; HCoV-OC43, NP 937947.21;
HCoV-HKU1, YP 460024.1; HCoV-229E, AGT21365.1; HCoV-NL63, AFD98832.1; IBV,
P0C6V5.1. The alignment was performed using Clustal Omega. The figure was generated
using ESPript. Same residues are shaded in red, and conserved residues are shown in red.
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Kinetics characterization of some representative mutants. Since the initial
kinetic characterization was performed using only a single substrate concentration,
it does not provide information about whether the di↵erence in activity comes from
changes in kcat or Km. Therefore, a more complete steady-state kinetics study was
performed on some interesting mutants, where the rates of the mutant PLP2 catalyzed
reactions as a function of varied substrate concentration were measured and the data
were fit to equations as described in Section 2.2.5. The results are summarized in
Table 4.4. As expected, all mutants could not be saturated by RLRGG-AMC at the
concentrations tested. As for their activities with Ub-AMC, R253A/R257A and I249R
have Km values comparable to WT PLP2, while the kcat of R253A/R257A is slightly
higher than WT PLP2, and the kcat of I249R is less than half of that for WT PLP2.
The Km values of mutants F290R, R281A and E279A were unable to be determined,
which suggests that the mutation of these residues leads to the disruption of the
interaction between the PLP2 mutant and Ub. As for the deISGylating activity,
the Km values of E279A (1.1 ± 0.4 mM) and I249R (1.4 ± 0.5 mM) were able to
be determined whereas they could not be determined for WT PLP2 and mutants
F290R, R281A and R253A/R257A. When the kcat/Km or kapp values (as determined
from the kinetics studies) of the mutants are compared to WT PLP2, it is noticed
that the di↵erences in activities are consistent to what have been observed when the
activities were measured at a single substrate concentration (Table 4.5). Therefore, it
is concluded that although the activity measurement at one substrate concentration is
not a comprehensive method for activity characterization, it does serve as a convenient
and reliable substitute to quickly evaluate the activities of the mutants in comparison
to WT PLP2.
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kcat/Km (mM-1 min-1) 0.0019a 31.3± 7.6 0.7± 0.01
kcat (min-1) – 44.4± 6.0 –
Km (mM) – 1.4± 0.3 –
F290R
kcat/Km (mM-1 min-1) 0.0019a 2.2± 0.1 0.094a
kcat (min-1) – – –
Km (mM) – – –
R281A
kcat/Km (mM-1 min-1) 0.0018a 21.3± 0.3 0.029a
kcat (min-1) – – –
Km (mM) – – –
E279A
kcat/Km (mM-1 min-1) 0.0013a 15.5± 0.2 0.2± 0.09
kcat (min-1) – – 0.2± 0.05
Km (mM) – – 1.1± 0.4
R253A/R257A
kcat/Km (mM-1 min-1) 0.0027a 38.5± 7.7 0.015a
kcat (min-1) – 58.8± 6.6 –
Km (mM) – 1.5± 0.3 –
I249R
kcat/Km (mM-1 min-1) 0.0184a 11.9± 2.4 16.4± 7.2
kcat (min-1) – 15.1± 1.7 23.1± 5.6
Km (mM) – 1.3± 0.2 1.4± 0.5



















































































































































































































































Processing of polyubiquitin chains. The activity assay with the substrate Ub-
AMC is only an approximation of the DUB activity of PLP2, as the bond that gets
cleaved upon hydrolysis of Ub-AMC is not an isopeptide bond. Therefore, polyubiqui-
tin chains cleavage assays were performed to further evaluate the DUB activity of some
interesting mutants. Enzymes were incubated with K48-Ub4 or K63-Ub4 at 25 C for
10 min (or 5 min) and 60 min prior to analysis of the reaction products via SDS-
PAGE gels. As shown in Figure 4.16, for mutants R281A, E279A, R253A/R257A,
F290R, D250A and D250R, their polyubiquitin processing activity agreed with the
results from the Ub-AMC hydrolysis assay. However, for mutant I249R, the activity
assay showed that it has decreased activity toward Ub-AMC while the polyubiquitin
processing assay suggested that its activity is comparable to WT. Cell-based assays
also showed that the DUB activity of I249 is comparable to WT or even increased
(data not shown, personal communication with Professor Susan Baker). The di↵erent
results from the enzymatic assay and the ubiquitin chains cleavage assay highlight
the importance of utilizing multiple assays to evaluate the substrate specificity profile
of the mutants.
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Fig. 4.16.: Processing of polyubiquitin chains by PLP2 mutants. K48-Ub4 and K63-Ub4
were used for the assay. The final concentration of PLP2 enzymes and Ub chains in the
reaction are 20 nM and 2 mM respectively. The reaction was incubated at 25 C for di↵erent
amount of time before running on the gel.
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4.3.7 Kinetic and thermodynamic characterization of the R281A PLP2
mutant
Temperature-dependent inactivation of the R281A mutant
As presented in the previous section, the kinetic characterization showed that the
R281A mutant maintains intact protease activity and displays some decrease in DUB
activity while its deISGylating is almost completely lost. The kinetics characterization
of R281A agreed well with the results generated at a single substrate concentration
(Table 4.4), and it also revealed that the Km of R281A with Ub has increased, which
was not determinable with the range of substrate concentrations used (Table 4.4 and
4.5). However, the polyubiquitin chains processing assay at 25 C also showed that
R281A cleaves K48-Ub4 and K63-Ub4 almost as e cient as WT, which is inconsistent
with the cell-based assay performed by our collaborators, where R281A was found to
have a notable decrease in its DUB activity (data not shown, personal communica-
tion with Professor Susan Baker). Since cells in the cell-based assay were cultured
at 37 C, we also performed the polyubiquitin chains processing assay at 37 C, and
observed that R281A exhibits significant decrease in its DUB activity in comparison
to WT (Figure 4.17). Interestingly, when a temperature inactivation experiment was
conducted at 30 C using the RLRGG-AMC substrate in the assay, no inactivation of
R281A was observed (Figure 4.14). In consistent with this result, the cell-based assay
showed that the protease activity of R281A is comparable to WT (data not shown).
Therefore, it seems that the temperature-dependent inactivation phenomena only oc-
curred to the DUB activity of R281A, but not its protease activity. When combined
with the observation that the Km value of R281A with Ub-AMC increased compared
to WT, it indicates that the mutation of R281 to alanine a↵ects its interaction with
Ub, which ultimately leads to a reduction in DUB activity.
To further investigate the e↵ects of temperature on the protein stability when
the R281A mutation was introduced, the thermal stability of the R281A mutant was
determined and compared to WT through the determination of the melting tempera-
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Fig. 4.17.: The processing of Ub chains by R281A at 37 C. K48-Ub4 and K63-Ub4 were
used for the assay. The final concentration of PLP2 enzymes and Ub chains in the reaction
are 20 nM and 2 mM respectively. The reaction was incubated at 37 C for 10 min and 60
min before running on the gel.
tures (Tm). Melting temperatures were determined using circular dichroism (CD) by
measuring CD signals at 220 nm as a function of temperature and the temperature
at the first derivative peak corresponds to Tm of the protein (Figure 4.18). The Tm
of the R281A mutant was determined to be 41.4 ± 0.9  C, which is close to that of
WT PLP2, 43.4 ± 1.1  C. This result supports the observation that mutant enzyme
is not temperature-sensitive, which is di↵erent from the results for the Ubl2 mutant
discussed in Chapter 5.
Overall, the mutation of residue R281 to alanine does not compromise the thermal
stability of PLP2. Therefore, the protease activity of R281A is comparable to WT.
However, the mutation seems to a↵ect the interaction strength between PLP2 and
Ub in a temperature-dependent manner, and the DUB activity of the R281A mutant
thereby decreases with the elevation of temperature.
The R281A mutant lost the deISGylating activity
It is interesting that the R281A mutant results in almost a complete loss of the
deISGylating activity. From the structure of the PLP2–Ub complex, it is observed
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Fig. 4.18.: CD melting curves of WT PLP2 and the R281A mutant. The thermal stability
of WT and the R281A mutant was determined by measuring the CD signal at 220 nm as
a function of temperature. Three independent experiments were performed for both WT
PLP2 (gray) and the R281A mutant (black). Welch two sample t-test (RStudio) suggests
that di↵erence in Tm is not significant (p = 0.07).
that the side chain of R281 resides at the bottom of the fingers domain and it forms
an H-bond interaction with the backbone of A46 (Figure 4.19 A and B). Structural
superposition of the ISG15 and Ub molecules in the complex reveals that the corre-
sponding residue of A46 of Ub in ISG15 is a glutamic acid, and this glutamic acid
may form an electrostatic interaction with the side chain of R281 from PLP2 (Fig-
ure 4.19C). This glutamic acid residue is conserved in ISG15 from both mouse and
human origins (Figure 4.19D). The potential salt-bridge interaction between R281 of
PLP2 and E127 of ISG15 may be critical in the binding of ISG15. Thus, when R281
is substituted with alanine, the interaction likely no longer exists, resulting in weak
binding and therefore low deISGylating activity in the R281A mutant.
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Fig. 4.19.: Structural role of PLP2 R281 in ubiquitin binding. (A) Overall structure of
PLP2-CS-Ub complex. Domains are color coded: Ub in yellow, Ubl2 domain of PLP2
in purple, thumb domain in orange, palm domain in blue, and fingers domain in green.
Residue R281 of PLP2 is located far away from the active site. (B) Interaction between
R281 of PLP2 with Ub. The side chain amine groups of R281 form H-bonding interactions
with the backbone carbonyl of A46 from Ub. The 2Fo-Fc map (gray) is contoured at
2s. (C) Potential interaction between R281 of MHV PLP2 and E127 of ISG15. ISG15
(shown in salmon color) is superimposed to Ub in the structure of PLP2–Ub complex. (D)
Sequence alignment of Ub and ISG15 from human and mouse generated by Clustal Omega.
A46 of Ub and its corresponding residue (Glu) in ISG15 are shaded in yellow. Accession
numbers: Human Ub, 1ubq; Mouse Ub, P62991; Human ISG15, AAH09507; Mouse ISG15,
AAI09347. Figure is created using ESPript [126].
The R281A mutant MHV virus is viable and attenuated
Excitingly, our collaborators, Dr. Susan Baker and Dr. Anna Mielech at Loyola
University Chicago, were able to generate the R281A mutant MHV virus through a
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reverse genetics system [127]. The R281A mutant virus was found to be viable and
attenuated. Since these data were generated by our collaborators, the details of the
results are not presented here. Briefly, the growth kinetics of R281A mutant MHV
virus in DBT (delayed brain tumor) and BMM (bone marrow macrophage) cells were
found to be comparable to WT. The R281A mutant MHV virus induced high-levels
of IFNa production in BMM cells while the WT virus did not. Moreover, C57BL/6
mice infected with the R281A mutant MHV virus survived while those infected with
WT virus succumbed to death. More importantly, the R281A mutant MHV virus
protected mice from the challenge of WT virus. That is, when mice that were initially
infected with R281A mutant virus initially were later re-infected with the WT virus,
the mice no longer succumbed to death. Furthermore, their results suggested that
the high-level production of IFN is important for R281A-induced protection of mice.
In contrast, infection of mice with the D250A mutant virus, which shows a decrease
in DUB activity but an increase in protease and deISGylating (Discussed in Section
4.3.6), cause death to the mice. The contrasting mutant virus results suggest that the
loss of deISGylating activity is critical for the attenuated pathogenesis of the R281A
mutant virus, and is crucial for protective immunity.
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4.3.8 Unsuccessful attempts to crystallize covalent PLP2–Ub complex
Ub derivatives with C-terminal thiol-reactive groups, such as Ubal, Ub-VME,
and Ub-Br3, have been widely used to covalently modify proteases with catalytic
Cys, which can then be crystallized for the structure determination of protease-Ub
complex [71, 98, 99, 118, 119]. Recently, it was reported that Ub-Prg can also be
used to modify proteases with catalytic Cys, and the crystal structure of CCHFV
vOTU modified by Ub-Prg was published [117]. Therefore, an attempt was made
to synthesize Ub-Prg and to use it to modify PLP2 for the generation of covalent
PLP2–Ub complex.
Synthesis of Ub-Prg
Figure 4.20 illustrates the reaction scheme for the synthesis of Ub-Prg. Briefly, the
synthesis of Ub-Prg takes advantage of the intein fusion technology, where a fusion
protein with the first 75 aa of Ub was fused to the N-terminus of intein followed
by a chitin binding domain (CBD) so that the protein can bind to chitin beads.
The process begins with an N-S shift when the side chain of a Cys residue from
intein nucleophilically attacks the C-terminal carbonyl of Ub to form a thiol-ester
intermediate. Since the intein used in this case is mutated, the splicing would be
trapped at this step. The thioester intermediate can then be reacted with MESNa,
which has a free thiol group, to liberate Ub-MESNa. Because the Intein-CBD portion
of the fusion protein is bound to the chitin beads, only Ub-MESNa is released and
can be eluted from the column. The purity of Ub-MESNa can be assessed through
SDS-PAGE analysis (Figure 4.21). Since the thiol-ester group of Ub-MESNa is easily
hydrolyzed, it is necessary to keep the pH below 8. Finally, proparglymine with
the terminal alkyne group was used to nucleophilically attack the thiol-ester of Ub-
MESNa to generate Ub-Prg.
139
Fig. 4.20.: Synthesis of Ub-Prg.
Modification of PLP21525-1911 by Ub-Prg
Before the large scale modification of PLP21525-1911 by Ub-Prg, a small scale test
was performed to evaluate the modification e ciency of PLP2 by Ub-Prg. Briefly,
di↵erent molar ratios of PLP2 versus Ub-Prg were incubated at room temperature
(RT) for 10 min; then the samples were analyzed on SDS-PAGE. As shown in Figure
4.22, as the amount of Ub-Prg increased, more and more PLP2 was modified to form
the PLP2–Ub complex. However, 100% modification of PLP2 could not be achieved
possibly due to the oxidation of the catalytic cysteine, which has been observed in the
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Fig. 4.21.: SDS-PAGE analysis of Ub-MESNa purity on 10% SDS-PAGE gel.
unbound structure of PLP2 (Figure 3.8C). In order to reach the maximal modification
of PLP2 with the minimal amount of Ub-Prg, the optimal molar ratio of PLP2 versus
Ub-Prg is 1:1. For large scale modification, PLP2 was mixed with Ub-Prg at 1:1 molar
ratio and the mixture was incubated at RT for 30 min with gentle shaking.
Fig. 4.22.: Modification of PLP2 by Ub-Prg. Di↵erent molar ratios of PLP2 versus Ub-Prg
was incubated at RT for 10 min prior to resolving on 10% SDS-PAGE gel.
Ion-exchange chromatography to separate PLP2–Ub from PLP2
Since 100% modification of PLP2 could not be achieved, it was necessary to sepa-
rate modified PLP2 from unmodified PLP2 in order to obtain pure PLP2–Ub complex
for crystallization. Due to the small di↵erence in MW, 43.5 kDa (PLP2) versus 52.1
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kDa (PLP2-Ub), these two species could not be separated by size exclusion chro-
matography. Therefore, ion-exchange chromatography was attempted. Both cation
exchange (Mono S) and anion exchange (Mono Q) chromatography were attempted.
However, as shown in Figure 4.23, it was di cult to completely separate PLP2–Ub
complex from unmodified PLP2 in either case. Nonetheless, fractions with higher
purity of PLP2–Ub were pooled and dialyzed for crystallization. Unfortunately, ex-
tensive attempts to crystallize PLP2–Ub purified in this manner were unsuccessful
(Table 4.6).
Summary of attempts to crystallize PLP2–Ub complex
Extensive e↵orts were committed to the crystallization of PLP2–Ub complex, as
summarized in Table 4.6. Basically, two main approaches were attempted to generate
complex. First, covalent modification of PLP2 using Ub-Prg, an Ub derivative that
contains a C-terminal thiol-reactive group, was pursued. Since the N-terminal DPUP
domain has been shown to be flexible, two constructs of PLP2 (PLP21525-1911 with
the DPUP domain and PLP21608-1911 without the DPUP domain (PLP2-4DPUP))
were used for modification with Ub-Prg. Unfortunately, crystals of either complex
could not be obtained. The other approach attempted was to generate a non-covalent
complex using mono Ub and PLP2 with the catalytic Cys to Ser mutation (C194S).
Similarly, two constructs of PLP2 were used: PLP21525-1911-C194S and PLP21608-1911-
C194S. Although the crystallization of PLP21525-1911-C194S–Ub turned out to be un-
successful, crystals of PLP21608-1911-C194S–Ub complexes were eventually obtained,
which indicated that the DPUP domain may be detrimental to the crystallization
of the PLP2–Ub complex. This stands in contrast to the crystallization of the apo
protein (Chapter 3), where only the construct with the DPUP domain (PLP21525-1911)
was able to grow high di↵raction quality crystals, but not the construct without the
DPUP domain (PLP21608-1911).
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Fig. 4.23.: Ion-exchange chromatography to separate PLP2–Ub complex from unmodified
PLP2. (A) Cation exchange chromatography – Mono S. The very left lane is the sample
after modification. Fractions in the orange box were pooled. And the lane on the very right
showed the purity of the pool. (B) Anion exchange chromatography – Mono Q. Fractions
in the orange box were pooled. And the lane on the very right showed the purity of the
pool.
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Table 4.6.: Attempts to crystallization PLP2–Ub complex
DUB Ub Complex crystallizationa Result
PLP21525-1911 Ub-prg 20 screens Unsuccessful
PLP21608-1911
His-Ub-prg 14 screens Unsuccessful
(PLP2-4DPUP)
PLP21525-1911-C194S Mono Ub 9 screens Unsuccessful
PLP2-4DPUP-C194S Mono Ub 15 screens Got HIT!
a Each screen was performed in a 96-well 3-drop plate with di↵erent protein con-
centration in the drops.
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4.4 Discussion
Traditional approaches for protein functional studies include the usage of siRNA
and small molecule inhibitors. Both methods exhibit an ”all-or-nothing” property.
In the case of the siRNA approach, the use of siRNA completely knocks out protein
expression, and makes it di cult to distinguish between functional activity and other
interaction-related e↵ects. The use of a specific inhibitor outperforms the siRNA ap-
proach in the sense that it is more selective, either targeting functional activity or an
interaction, and the protein expression levels are maintained. However, for proteins
with multiple enzymatic activities, such as CoV PLP, the inhibitor approach again be-
comes non-selective and insu cient. Protein engineering can be a powerful approach
to overcome these limitations. By targeting a specific interface via mutation, a finer
control over the enzymatic activities can be achieved. The studies here demonstrate
that protein engineering is a powerful tool to selectively disrupt a specific enzymatic
activity of a protein with multiple activities. In addition, the combined results of MD
simulations and X-ray crystal structure determination indicate that both approaches
are e cient in identifying important residues at a protein-protein interface.
The role of viral DUB/deISGylating activity during virus infection has been an
important question in the virology field. Extensive studies have been attempted to
investigate the role of viral DUB activity during virus infection [65,74,79,83], which
supports the role of the viral DUB activity in the antagonism of host innate immune
responses. In contrast, few studies have been conducted to specifically evaluate the
role of the viral deISGylating activity during virus infection. Here, we report the
first example of selectively knocking out the coronaviral deISGylating activity, and
excitingly, the mutant virus seems to be significantly attenuated as a result of the
absence of the deISGylating activity.
ISG15 has been shown to possess broad antiviral activity, both in the unconjugated
form and in the form of ISG15 conjugates, which are proposed to establish an antiviral
state for the cells [66]. For instance, it is shown that the NS1 protein from influenza
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B virus can bind ISG15, thus inhibiting the ISGylation of host proteins [128]. On
the other hand, ISGylation of IRF3 has been reported to help stabilize activated
IRF3, thus up-regulating the production of IFN [129]. The mechanism of how does
coronaviruses employ their deISGylating activity to their advantage is not entirely
clear yet. Our studies suggest that the coronaviral deISGylating activity is closely
correlated to virus pathogenesis.
It is exciting that we were able to generate the R281A mutant virus that is vi-
able and attenuated. Attenuated viruses have been widely used as a type of vaccine
against infection caused by viruses such as measles, poliovirus, rubella, mumps, small-
pox, etc [130]. However, since di↵erent coronaviruses utilize di↵erent cell receptors,
the attenuated MHV virus could not be used directly as a vaccine against the infec-
tion of other coronaviruses. However, we can still apply the approach of using critical
mutations that was discovered in MHV to other coronavirus system in order to create
a similar attenuated virus for vaccine development against the corresponding coron-
avirus infection. However, due to the low sequence conservation among CoV PLPs
(around 20–30%), the corresponding residues of R281 in other CoV PLPs cannot be
inferred directly from multiple sequence alignment (Figure 4.15). Additional struc-
ture and modeling studies of the potential interactions will be needed. For example,
through modeling and structural analysis, it was predicted that the corresponding
residue of R281 in PEDV PLP2 is also an arginine (Figure 4.24A). Given the impact
of PEDV infection on the pork production industry in US, it would be significant
if a vaccine against PEDV infection could be developed. Similar prediction could
be made for MERS-CoV PLpro, where an arginine residue was also identified as the
corresponding residue of R281 in MHV PLP2 (Figure 4.24B). The development of
vaccine against MERS-CoV infection will contribute a lot to the treatment of the
ongoing MERS-CoV outbreak.
More importantly, aside from the application in vaccine development, the R281A
mutant virus we created here can be used as a valuable tool to further investigate the
role of viral DUB or deISGylating activity during virus infection. The use of a mutant
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Fig. 4.24.: Prediction of the corresponding residues of R281 in PEDV PLP2 and MERS
PLpro. (A) Homologue model of PEDV PLP2 (green) generated through Swiss Model was
superimposed to MHV PLP2 in the model of MHV PLP2-ISG15 complex, where MHV
PLP2 is in pink, and ISG15 in wheat. (B) Structure of MERS-CoV PLpro (cyan; pdb code:
4P16) was superimposed to MHV PLP2 in the model of MHV PLP2-ISG15 complex.
virus with deficiency in DUB or deISGylating activity is more likely to provide us with
direct evidence to understand the mechanisms of viral antagonism via the DUB and
deISGylating activities during virus infection. Indeed, studies by our collaborators
with the R281A mutant virus have suggested that MHV may employ its deISGylating
activity to trick the macrophage and escape the innate immune responses (Mielech,
A.M., Chen, Y. et al, in preparation).
Besides the R281A mutant, we have generated other interesting mutants that are
worthy of further exploration. For instance, it is intriguing that mutants R253E/R257A
and R253A/R257A with mutations that were originally designed to disrupt DUB ac-
tivity end up with increased DUB activity but decreased deISGylating activity. It
is also mysterious that the SARS-CoV PLpro-mimic mutant I249R acquires around
20-fold increase in its deISGylating activity, and a mutation at the neighboring po-
sition (D250A) also results in increased deISGylating activity. Understanding the
interactions between PLP2 and ISG15 will be essential to address these questions.
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CHAPTER 5. INTERPLAY BETWEEN PLP2 AND OTHER DOMAINS
WITHIN NSP3
Part of the data and the text in this chapter has been published in the Journal of
Virology with the title ”Murine Coronavirus Ubiquitin-like Domain is Important for
Papain-like Protease Stability and Viral Pathogenesis” [44].
5.1 Introduction
Coronaviral nsp3 is a large, membrane-associated protein with multiple domains.
Although several domains of nsp3 have been characterized individually, including the
ADRP domain (from SARS-CoV and HCoV-229E), the PLP domain (from SARS-
CoV, HCoV-NL63, MERS-CoV, TGEV, PEDV and IBV) and the SARS-CoV SUD
domain [33,34,40,41,48,115,131], it remains unclear how nsp3 coordinates the multiple
domains with di↵erent functions to participate in viral RNA synthesis and if there
are any concerted actions among domains.
The Ubl2 domain adjacent to CoV PLPs was first discovered when the structure of
SARS-CoV PLpro was solved in 2006 [34]. And it has been believed to be conserved
among coronaviruses [21]. Since then, several studies have been conducted to under-
stand the role of the coronaviral Ubl2 domain. As Ubl2 and PLP2 are neighboring
domains within nsp3, it is proposed that there may be some interplays between the
Ubl2 and PLP2 domains. However, results were controversial regarding whether or
not the Ubl2 domain is involved in PLP-mediated IFN antagonism. In 2009, Frie-
man and coworkers showed that the Ubl2 domain of SARS-CoV PLpro is necessary
for the IFN antagonism activity of PLpro [74]. However, in 2010, Clementz et al.
instead reported that the IFN antagonism activity of SARS-CoV PLpro is not de-
pendent on the Ubl2 domain [65]. More recently, studies with MERS-CoV PLpro
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also showed that the Ubl2 domain of MERS-CoV PLpro is not required for its IFN
antagonism activity [60]. Here, instead of evaluating the e↵ect of the Ubl2 domain on
the IFN antagonism activity, we directly investigated the role of the Ubl2 domain in
the modulation of the enzymatic activity of PLP2. Using substitution approach, we
identified site within MHV Ubl2 domain, valine 787 (numbering according to nsp3
residues), that is important for PLP2 stability and activity. Our results showed that,
valine to serine mutation at position 787 (V787S) resulted in decreased stability and
temperature-dependent inactivation of PLP2. And the corresponding mutant virus
(AM2 virus) generated through reverse genetics technique displayed remarkable atten-
uation in virulence [44]. Overall, our findings present a novel approach to manipulate
the activity of PLP2, and provide new insights for coronavirus attenuation.
The ADRP domain, also referred to as the X domain, is conserved among coron-
aviruses. It adopts macroH2A-like fold and possesses ADP-ribose-1”-monophosphatase
activity, which may play a role in virus RNA replication. Extensive structural studies
have been performed with the ADRP domain from di↵erent coronaviruses [39,49,50].
However, limited functional studies about the ADRP domain have been reported.
Studies with the ADRP domain from MHV suggested that the ADRP domain en-
hances virulence in mice with coronavirus-induced encephalitis [31]. Recently, studies
by our collaborators suggest that there may be some interactions between the PLP2
domain and the ADRP domain within MHV nsp3 (unpublished data). In order to
further investigate into this possibility, we attempted to express and purify the MHV
ADRP domain by itself, and the region of MHV nsp3 from ADRP to PLP2 (ADRP-




5.2.1 Site-directed mutagenesis to generate construct for V787S PLP2
The construct for the V787S PLP2 mutant was generated by site-directed mutage-
nesis following the procedure described in Section 4.2.2. Plasmid pEVL8-PLP21525-1911
was used as a template. Forward primers and reverse primers used are listed as below:
Forward: 5’ CAATAAGGTCGATAGCCTGTGCACCGTCGACGG 3’
Reverse: 5’ CGGTGCACAGGCTATCGACCTTATTGGCCAGC 3’
5.2.2 Expression and purification of V787S PLP2
The V787S mutant was expressed in the same way as WT PLP21525-1911 (Section
2.2.2) except that the expression was induced at 18 C overnight with 0.1 mM IPTG.
11 grams of cell pellets were harvested from 2 L of cell culture. PLP2 V787S was
purified following the procedure for WT PLP2 as described in Section 2.2.2.
5.2.3 Temperature-dependent inactivation of the V787S mutant
RLRGG-AMC assay
WT PLP2 and the V787S mutant protein were incubated at 25 C for di↵erent
time periods (0-50 min). At each time point, the specific activity of both enzymes
was measured at 25 C using a Synergy Multi-Mode Microplate Reader (BioTek) with
50 mMRLRGG-AMC as the substrate and 3 mM of each enzyme. The assay bu↵er used
contained 50 mM HEPES, pH 7.0, 0.1 mg/ml BSA and 2 mM DTT. The experiments
were performed in triplicate in a final volume of 100 ml using the 96-well Corning
Costar black microplates. Similar experiments were carried out when the enzymes
were incubated at 30 C. To analyze the kinetic data, the ratio of the reaction rate
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at time=t (Ratet) to the rate at time=0 (Rate0) was plotted on a logarithmic scale
against incubation time. Kinetic data of the V787S PLP2 incubated at 30 C were
fitted to a first-order exponential decay model (Ratet/Rate0 = e kt), from which the
inactivation rate constant kinact and half-life t1/2 were determined. The wild-type
data were fit to a line since no significant temperature inactivation was observed.
Polyubiquitin chain processing assay
K48- and K63-linked tetra-ubiquitin were purchased from LifeSensors. Reactions
were performed by incubating 2 mM of each ubiquitin chain listed above with 20
nM of WT PLP2 or the V787S mutant in bu↵er (50 mM HEPES, pH 7.0, 100 mM
NaCl, 0.1 mg/ml BSA and 2 mM DTT) at 25 C for various times ranging from 5
min to 2 hr. At the end of each time point, the reactions were quenched by the
addition of NuPAGE LDS sample bu↵er (Invitrogen). As a control, the same amount
of ubiquitin chains was incubated at 25 C without any enzyme. Similar experiments
were carried out when the reactions were incubated at 37 C. Samples were then
analyzed by SDS-PAGE using NuPAGE Novex 4-12% Bis-Tris mini gels (Invitrogen),
which were subsequently stained with Coomassie Brilliant blue and destained with
10% acetic acid for visualization.
5.2.4 Thermal melting temperature (Tm) analysis using circular dichro-
ism (CD)
Thermal melting analyses of WT PLP2 and the V787S mutant were carried
out with a Chirascan circular dichrosim (CD) spectrometer (Applied Photophysics)
equipped with a temperature control system (Quantum Northwest Inc.) by monitor-
ing the CD signal at 220 nm while increasing the temperature at a step interval of
0.4 C and at a rate of 0.5 C/min. 2 ml of protein samples at 1 mM in bu↵er with
0.1 M potassium phosphate (pH 7.5) was contained in a 10 mm quartz cell (Starna
Cells) with magnetic stirring. Thermal scans were performed in three independent
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experiments for both WT and the V787S mutant. The melting temperatures (Tm)
were calculated as the first derivative peak using the program SigmaPlot.
5.2.5 Expression study of the ADRP domain and ADRP-PLP2
Constructs
The ADRP domain from MHV nsp3 (residue 1299-1522 of pp1ab) with a N-
terminal octo-histidine tag connected via a TEV cleavage site was codon-optimized
for E. coli expression, and synthesized and cloned to pET11a vector by Bio Basic
Inc (Toronto, Canada). The construct of ADRP-PLP2 (residue 1299-1911 of MHV
pp1ab) was generated in the same way.
Expression study
Plasmids pET11a-ADRP or pET11a-ADRP-PLP2 were transformed into E. coli
strain BL21 (DE3) cells for protein expression study. Cells were grown in 2X YT
media (16 g Tryptone, 10 g Yeast Extract, 5 g NaCl, pH 7.5) or LB media (10 g
Tryptone, 5 g Yeast Extract, 10 g NaCl, pH 7.5) supplemented with 50 mg/ml carb.
The expression of protein was induced at 18 C for overnight with varied concentration
of IPTG (0, 0.1, 0.5 and 1.0 mM). 5 ml of cells were grown under each condition.
After induction, cells were harvested and directly stored at -80 C. To perform auto-
induction of ADRP or ADRP-PLP2 expression, cells were grown at 25 C for 24 hours
in 5 ml of super LB media (3 g KH2PO4, 6 g Na2HPO4, 20 g Tryptone, 5 g Yeast
Extract, 5 g NaCl, pH 7.2) supplemented with 0.2 % lactose, 0.6 % glycerol, 0.05 %
glucose and 50 mg/ml carb.
To lyse the cells, the cells were resuspended in 350 ml of lysis bu↵er (20 mM Tris
pH 7.5, 500 mM NaCl, 20 mM imidazole, 5 mM bME, 1 mg/ml lysozyme, DNase),
then incubated at 30 C for an hour with gentle shaking, followed by centrifugation at
16,100 relative centrifugal force (rcf) at 4 C for 10 min. The clarified lysate was then
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transferred to a clean eppendorf tube and its concentration was measured through
Bradford assay. As for the pellet, it was first washed in H2O through one resuspension-
centrifugation cycle, and finally resuspended in 1 ml of H2O. For evaluation, 10 mg
of clarified lysate and 10 ml of resuspended pellet were loaded onto SDS-PAGE gels.
Two same SDS-PAGE gels were prepared: one for coomassie stain, and the other for
western blot analysis with anti-His antibody (see below).
Western blot analysis
For western blot analysis, the protein samples were transferred from the SDS-
PAGE gel to PDVF membrane at 4 C in 1X transfer bu↵er (25 mM Tris-HCl, 192
mM glycine, 10% methanol, 0.01% SDS). Upon rinse with 1X TBST bu↵er (50 mM
Tris base, 150 mM NaCl, 0.05% Tween 20), the membrane was blocked at 4 C for
overnight in 5% dry milk solution prepared in 1X TBST bu↵er. Then the membrane
was washed three times in 1X TBST bu↵er with 5 minutes for each wash. After
that, the membrane was incubation with HRP-conjugated anti-His antibody from
GenScript (1:1000 dilution in 1X TBST bu↵er) at room temperature for an hour,
followed by three washes with 1X TBST bu↵er. Finally, the membrane was incubated
with SuperSignal West Dura Extended Duration substrate (ThermoFisher Scientific)
for 5 minutes, and imaged using the FluorChem E imaging system from ProteinSimple
with ”Chemi with Markers” setting.
5.3 Resutls
5.3.1 Importance of MHV Ubl2 domain in the stability of MHV PLP2
Purification of the V787S mutant
His-tagged V787S PLP2 was first purified using a Ni2+-charged a nity column.
Upon cleavage of the His-tag by TEV protease, the protein was passed through an-
other Ni2+-charged a nity column to separate His-tag cleaved V787S PLP2 from
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uncleaved V787S PLP2. Finally, His-tag cleaved V787S PLP2 was further purified
through gel filtration. Protein purity throughout the purification process was an-
alyzed by SDS-PAGE (Figure 5.1). Statistics of the purification is summarized in
Table 5.1.
Fig. 5.1.: Purification of the V787S mutant.
Temperature-dependent inactivation of the V787S mutant
To investigate potential e↵ects of the V787S mutation on the protease activity
of PLP2, we performed temperature-dependent activity assay using WT PLP2 as a
control (WT PLP2 was expressed and purified according to Sections 2.2.2). When
the enzymes were incubated at 25 C prior to activity measurement, the activities of
the V787S mutant and WT PLP2 were comparable, and their activities remained
constant regardless of the incubation time (Figure 5.2). However, when the enzymes
were incubated at 30 C prior to activity measurement, the activity of the V787S
mutant decreased as the incubation time increased, while the activity of WT PLP2
remained constant (Figure 5.2). The kinetic data for the V787S mutant incubated
at 30 C were then fit to a first-order exponential decay model (Ratet/Rate0=e kt),
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Table 5.1.: Statistics of PLP2 V787S purification.
Sample
Total Protein Total Specific Activity Fold Yield
(mg)1 Units2 (Units/mg) Purification (%)
Lysate 600 0.25 0.0004 1.00 100
HisTrap Pool 107 0.21 0.0020 5.00 86
Superdex-75 Pool 69 0.19 0.0027 6.75 76
1 The amount of protein obtained from 2 L of cell culture.
2 Unit (mmol/min): mmol of products produced per minute under following assay
conditions - 50 mM RLRGG-AMC, 3 mM enzyme in assay bu↵er containing 50
mM HEPES, pH 7.0, 0.1 mg/ml BSA and 2mM DTT.
which resulted in an inactivation rate constant kinact of 0.025 ± 0.001 min-1 and a
half-time (t1/2) of 27.7 ± 1.1 min.
Next, we performed temperature-dependent polyubiquitin chains cleavage assay
to study the e↵ect of the V787S mutant on the deubiquitinating activity of PLP2.
K48-Ub4 and K63-Ub4 were used for the assay. WT PLP2 or the V787S mutant were
incubated with the ubiquitin chains at 25 C or 37 C for di↵erent time lengths. As
shown in Figure 5.3 A and B, the V787S mutant cleaved ubiquitin chains as e ciently
as WT PLP2 at 25 C. However, when the assay was performed at 37 C, the V787S
mutant showed notable decrease in its ability to cleave the ubiquitin chains compared
to WT PLP2 (Figure 5.3 C and D).
Tm analysis of the V787S mutant
To explore the e↵ect of the V787S mutation on the thermal stability of PLP2, we
then performed experiments to measure the melting temperature (Tm) of the V787S
mutant and WT PLP2. Circular dichroism (CD) signals at 220 nm were measured as
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Fig. 5.2.: Temperature-dependent inactivation of V787S mutant PLP2 in comparison to
WT PLP2. The specific activity of WT PLP2 and the V787S mutant were measured after
incubation at 25 C and 30 C for di↵erent time periods. The specific activities were then
normalized to the activity at 0 min (Ratet/Rate0: rate at time t over initial rate). Kinetic
data for the V787S mutant incubated at 30 C were fit to a first-order exponential decay
model (Ratet/Rate0=e kt). The y-axis is represented in logarithmic scale.
a function of temperature. The temperature at the first derivative peak corresponds
to Tm of the protein. Tm of WT PLP2 was determined to be 45.6 ± 0.5  C, while
Tm of the V787S mutant was 38.8 ± 0.5  C, 6.8 C lower than that of WT PLP2
(Figure 5.4). Therefore, the V787S mutant exhibits diminished thermostability, which
explains previously observed the temperature-dependent inactivation of the V787S
mutant.
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Fig. 5.3.: Temperature-dependent decrease in the V787S mutant’s ability to process polyu-
biquitin chains. The ability of the V787S mutant to process K48- and K63-linked tetra-
ubiquitin chains was evaluated at 25 C and 37 C with WT PLP2 as a positive control.
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Fig. 5.4.: CD melting curves of WT PLP2 and the V787S mutant. The thermal stability
of WT and V787S mutant PLP2 was determined by measuring the CD signal at 220 nm
as a function of temperature at a step interval of 0.4 C and at a rate of 0.5 C/min. Three
independent experiments were performed for both WT PLP2 (grey) and the V787S mutant
(black). Welch two sample t-test (RStudio) shows that di↵erence in Tm is significant (p <
0.0001).
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5.3.2 Attempts to express and purify ADRP and ADRP-PLP2
Expression study of the ADRP domain
Protein expression was induced at 18 C with 0, 0.1, 0.5 or 1.0 mM of IPTG with
either 2X YT (Figure 5.5A) or LB (Figure 5.5B) as the growth media. Auto-induction
of ADRP expression was also attempted. The molecular weight of the ADRP domain
with His tag is 26 kDa. From the SDS-PAGE analysis (Figure 5.5 A and B), it
seems that, in both cases, the ADRP protein did get over-expressed, but most of
the proteins went into the inclusion body. To further check if there is trace amount
of ADRP in the clarified lysate, western blot analysis was performed with anti-His
antibody. Surprisingly, the result suggested that the ADRP protein in the soluble
fraction was truncated as the His-tagged proteins in the lysate have smaller molecular
weight than the His-tagged proteins in the pellet (Figure 5.5C).
Expression study of ADRP-PLP2
The expression study of ADRP-PLP2 was carried out in the same way as the
process described for ADRP. The molecular weight of ADRP-PLP2 with His tag
is 70 kDa. The SDS-PAGE analysis in Figure 5.5 D and E indicates that ADRP-
PLP2 is over-expressed but goes into the inclusion body. Yet it seems that there
may be a trace amount of ADRP-PLP2 in the soluble fraction. To explore into this
possibility, western blot analysis was performed with anti-His antibody. As shown in
Figure 5.5F, it appears that a trace amount of ADRP-PLP2 is present in the soluble
fraction. However, attempt to purify ADRP-PLP2 from large scale expression (4 L
of cell culture) turned out to be unsuccessful with the fractions eluted with Bu↵er B
being very dirty with no protein band standing out 4YPT(data not shown).
Apparently, more work remains to be done in order to optimize the expression of
ADRP and ADRP-PLP2. Nonetheless, the initial study shows that a trace amount of
ADRP-PLP2 is soluble while soluble ADRP protein by itself appears to be truncated.
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These results suggest that the ADRP protein by itself is easy to get truncated, yet
the presence of the PLP2 domain protects ADRP from truncation, implying possible
interaction between ADRP and PLP2.
Fig. 5.5.: Expression study of ADRP and ADRP-PLP2. (A-C) Expression study of ADRP.
SDS-PAGE analysis of protein expressed from cells grown in 2X YT (A) or LB (B) media,
and the western blot analysis of protein expressed from cells grown in 2X YT media using
anti-His antibody. All cells were induced at 18 C with varied concentration of IPTG. 1,
no IPTG; 2, 0.1 mM IPG; 3, 0.5 mM IPTG; 4, 1.0 mM IPTG; 5, autoinduction. (D-F)
Expression study of ADRP-PLP2 was performed in the same way as the ADRP study. A
positive control was included for western blot analysis (F). The unit of the marker is kDa.
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5.4 Discussion
Here, through in vitro activity assay with recombinant proteins, we showed that
the Ubl2 mutant, V787S, displayed temperature-dependent inactivation of its protease
and deubiquitinating activities. And the CD melting experiments revealed that the
V787S mutant had decreased thermal stability. Interestingly, our collaborators have
further shown that the V787S mutant viruses (AM2 viruses) replicate as e ciently
as WT viruses at 37 C, but generate smaller plaques than WT viruses. However,
at higher temperatures (39.5 C and 40.5 C), the AM2 viruses are defective in repli-
cation [44]. In addition, we have also evaluated the e↵ect of the mutation on viral
pathogenesis, and showed that AM2 viruses are highly attenuated, yet replicate e -
ciently to elicit protective immunity. And immunization with AM2 viruses protected
mice against challenge with WT viruses [44]. In addition to the V787S mutant, an-
other Ubl2 mutant, V785S, has also been found to be temperature sensitive, while not
as severe as the V787S mutant. Overall, the discovery of an Ubl2 mutant virus with
attenuated virulence opens up a new direction towards virus attenuation for vaccine
development.
To understand the mechanism of the destabilizing mutant, we mapped residue
V787 onto the structure of MHV PLP2 (Chapter 3, pdb code 4YPT) and noticed
that V787 resides on a beta-sheet of the Ubl2 domain. The side chain of V787
faces towards the core of Ubl2 and participates in the formation of the hydrophobic
core of Ubl2 (Figure 5.6). When valine 787 is mutated to serine, the introduction
of a polar side chain disturbs the formation of the hydrophobic core, rendering the
overall destabilization of the neighboring PLP2 catalytic domain at elevated temper-
ature. Interestingly, sequence alignment of several coronaviral Ubl2 domain reveals
that residues at position 787 are conserved across coronaviruses as valine, leucine or
isoleucine (Figure 5.7). It indicates that the destabilizing e↵ect of the V787S muta-
tion on MHV PLP2 we observed here may be universal to other coronaviruses. On the
other hand, while residues at position 785 are mostly conserved as valine or isoleucine,
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it is lysine in IBV PLpro. This suggests that residues at position 785 is not as con-
served as residues at position 787. When we mapped residue V785 onto the structure
of PLP2, we noticed that V875 is involved in the edge of the hydrophobic core. This
is consistent with our observation that the temperature sensitive phenomenon of the
V785S mutant is not as severe as the V787S mutant [44].
Fig. 5.6.: X-ray structure of the MHV and SARS-CoV Ubl2 domains. A superposition
of the Ubl2 domains with MHV PLP2 (blue, PDB code 4YPT) and SARS-CoV PLpro
(orange, PDB code 2FE8) is shown as a stereoview with an RMSD of 0.7 Å. Side chains
of MHV Ubl2 residues V785 and V787, and their corresponding residues in SARS-CoV are
shown as sticks.
Fig. 5.7.: Sequence alignment of Ubl2 domains from representative coronaviruses. V785
and V787 from MHV are indicated with arrows. The structural information of MHV Ubl2
is shown on the top.
Previous studies with SARS-CoV PLpro showed that the Ubl2 domain is necessary
for the expression and purification of the protein (unpublished data). In the case of
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MHV PLP2, we found that the removal of the Ubl2 domain compromised the stability
and activity of PLP2, as supported by the low yield and activity after Ni column
purification (Table 5.2). However, with MERS-CoV PLpro, it has been shown by
a colleague, Jozlyn Clasman, that the removal of Ubl2 domain has no e↵ect on the
activity and stability of the enzyme (Clasman, J. R. et al, in preparation). Altogether,
it suggests that the Ubl2 domain may play di↵erent role in the regulation of the
neighboring PLP domain in di↵erent coronavirus systems. More studies are needed
to fully elucidate the function of the Ubl2 domain in coronavirus replication. It
would be informative to generate a variant form of virus with no Ubl2 domain and
investigate the consequence of infection with the virus variant.
Table 5.2.: Expression and purification of PLP2 with di↵erent truncation.
Construct Induction Yield (mg/ml)1 Stability v/E (min-1)2
PLP23 0.1 mM IPTG, 25 C for 6hr 50 Stable 0.10
PLP2-d13 0.1 mM IPTG, 18 C O/N 159 Stable 0.10
PLP2-d23 0.1 mM IPTG, 18 C O/N 7.8 Unstable 0.50
1 The amount of proteins (mg) obtained from 2 L of cell culture after Ni HisTrap
column.
2 Activity of the enzyme was measured with 50 mM of RLRGG-AMC as the substrate.
3 PLP2 is the five-domain construct (DPUP-Ubl2-PLP2) crystallized in Chapter 3.
PLP2-d1 is the construct without the N-terminal DPUP domain, while PLP2-d2 is
the construct with only the catalytic core of PLP2, no DPUP or Ubl2 domain is
included.
Interestingly, the presence of Ubl domains is not unique to coronaviral nsp3.
Ubl domains have been found to be common elements in ubiquitin-specific proteases
(USP) [132,133]. They play roles in the regulation of protease activity through di↵er-
ent mechanisms [133]. For example, the Ubl domain in USP14 helps the localization
of USP14 at the proteasome, thus facilitates catalysis. However, in the case of USP4,
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the Ubl domain mimics ubiquitin and inhibits catalysis. USP7 has five consecutive
Ubl domains at the C-terminus. The last two Ubl domains help the activation of
USP7 by inducing conformational changes.
Here, with a mutation in the Ubl2 domain, a mutant virus (AM2) that resulted
in attenuated pathogenesis and protection in mice was generated. The attenuation
comes from the overall reduction in the activities of PLP2, including the protease
activity and the DUB activity. It was shown that V787S mutant virus was able to
replicate as e ciently as WT virus in DBT and BMM cells at 37 C. However, when
the temperature was elevated to 39.5 C, the mutant virus showed defect in replication.
When infecting mice, the V787S mutant virus displayed dramatic decreased virus titer
in the liver compared to WT virus, but not in the brain. A similar phenotype has
been observed with an MHV-A59 nsp2 mutant [134] and an MHV-JHM nsp1 mutant
virus [135]. However, it is not clear yet whether the reduction in virus titer is a result
of defective virus replication or a more rapid innate immune response that clears the
virus from the liver [44].
In Chapter 4, we found that the R281A mutant virus was also attenuated. And
it can induce protective immune response against challenge in mice. However, di↵er-
ent from the V787S mutant, R281A mutant showed comparable protease activity to
WT PLP2. Studies have shown that, when infecting mice, R281A mutant virus could
replicate as e ciently as WT, yet it got cleared rapidly, resulting in the extremely low
virus titer in the liver and spleen. Preliminary studies have suggested that WT virus
messes with the phagocytosis and apoptosis of macrophages through its deISGylat-
ing activity, and further tricks the macrophages to escape innate immune responses,
and the attenuation of the R281A virus may come from the loss of its deISGylating
activity. However, more studies are needed to understand the mechanism details of
attenuation caused by the R281A mutant virus (Mielech, A. M., Chen, Y. et al, in
preparation).
The use of live-attenuated virus as vaccine is the oldest and most e↵ective ap-
proach to fight viral diseases. Live-attenuated virus maintains its ability to replicate
164
in cells, yet does not result in diseases. And it is able to induce innate and adaptive
immune response that can provide lifelong protection. However, one major concern
with attenuated viruses is that they are associated with the potential risk of reversion
to WT virus [130]. As discussed above, both the V787S mutant virus and the R281A
mutant virus are attenuated, thus could be potential candidates for vaccine devel-
opment. As an immature guess, R281A mutant virus probably would be a better
candidate than the V787S mutant virus, because it maintains full virus replication
ability and its deficiency in the deISGylating activity seems to allow the host to react
to virus infection rapidly; while the V787S virus shows defects in replication and may
not be able to replicate e ciently to induce immune responses. Nonetheless, more
information about these two mutant viruses is needed before we can make suggestions
as to whether both viruses are desirable to be used for further vaccine development.
Such information include the reversion rate, the protective e↵ect on animal models




The zoonotic origin of coronaviruses renders future reemergence of epidemic, such
as SARS and MERS, very likely. It is important to understand the pathogenesis
of coronaviruses and develop therapeutics against coronavirus infection. Papain-like
protease is essential for the replication of coronavirus in host cell because it mediates
the processing of the N-terminal polyprotein. It is intriguing that CoV PLPs evolve
deubiquitinating and deISGylating activity in addition to its ability to process the
polyprotein. Extensive studies on PLPs from two important human coronaviruses,
SARS-CoV and MERS-CoV, have been conducted in order to investigate the prop-
erties of CoV PLP as a deubiquitinating and deISGylating enzyme. In contrast, we
are still in lack of knowledge about PLP from MHV, which has historically served as
the model system for coronavirus study.
In this study, we first purified and characterized a fraction of MHV nsp3 that
contains the catalytic core of the PLP2 domain and the preceding DPUP and Ubl2
domains (DPUP-Ubl2-PLP2). This is the largest portion of a CoV nsp3 that has
ever been kinetically and structurally characterized. Kinetic characterization of this
construct reveals that the DUB activity (Ub-AMC as the substrate) and deISGylating
activity (ISG15-AMC as the substrate) of MHV PLP2 is significantly greater than
its protease activity (RLRGG-AMC as the substrate), indicating that binding of
Ub or ISG15 is beneficial for the enzymatic activity of MHV PLP2. We will show
that MHV PLP2 is a better DUB than SARS-CoV PLpro and MERS-CoV PLpro,
with the enzyme e ciency (kcat/Km) being ⇠20 times higher than that of the latter
two. However, the deISGylating activity of MHV PLP2 is lower than that of SARS-
CoV PLpro and MERS-CoV PLpro. In addition, as shown in Chapter 2, the in
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vitro polyubiquitin chain cleavage assay suggests that, as a DUB, MHV PLP2 shows
promiscuous recognition of ubiquitin chains. The implication of this observation is
further discussed in the Discussion Section of Chapter 2.
Experimental phasing using SeMet-substituted protein was implemented to deter-
mine the structure of DPUP-Ubl-PLP2, which presents the very first and so far the
only structure of PLP from a b-coronavirus genogroup 2a virus. Although MHV PLP2
shares low sequence identity to other CoV PLPs (⇠30%), its catalytic core is struc-
turally similar to other known CoV PLP structures (⇠2.5 Å), including SARS-CoV
PLpro, MERS-CoV PLpro and TGEV PLP1, with a thumb-palm-fingers architecture
and a well-aligned Cys-His-Asp catalytic triad. However, big variation in the fingers
domain is observed, which may explain the di culty in molecular replacement using
other known CoV PLP structure as the template. On the other hand, an Ubl domain
was found to be preceding the catalytic core of PLP2 as expected. Interestingly, the
DPUP domain was identified as a new domain within MHV nsp3 from the struc-
ture determined. The DPUP domain is structurally similar to the SUD domain from
SARS-CoV, even though their sequence identity is only 10%. This observation raises
doubts towards the unique presence of the SUD domain in SARS-CoV. It highlights
structural biology as a valuable tool to understand protein functions, especially when
the sequence conservation is too low to be informative. It was reported that the SUD
domain has oligonucleotide-binding ability. However, our attempts to investigate the
ability of the DPUP domain to bind oligonucleotide turned out to be unsuccessful.
The function of the DPUP domain remains to be elucidated.
The observation that MHV PLP2 possesses both DUB and deISGylating activity
enables the usage of MHV PLP2 as a model enzyme for activity decoupling studies. To
study the role of viral DUB/deISGylating activity during virus infection, it is essential
to generate mutant viruses that are deficient in DUB or deISGylating activity but are
still capable of normal virus replication in cells. Guided by structure models of PLP2-
Ub complex generated through both molecular dynamics and X-ray crystal structure
determination, we were able to implement protein engineering to successfully disrupt
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the binding of Ub, resulting in reduced DUB activity, while maintain the protease
activity of the enzyme intact. Coincidently, some mutants also display diminished
deISGylating activity. One of the examples is the R281A mutant. For the PLP2
mutants with good protease activity but reduced DUB and/or deISGylating activity,
corresponding mutant viruses were then generated through reverse genetics by our
collaborators. Among the few viable mutant viruses generated, the R281A mutant
virus is the most exciting one because it shows attenuated pathogenesis and elicit
protective immune responses in mice. Preliminary studies with this mutant virus
suggests that the deISGylating activity of CoV PLPs, but not the DUB activity,
may be critical for the immune evasion of CoVs. This stands in contrast to most
other studies in the field where only the role of the viral DUB activity is evaluated.
Although further studies with the R281A mutant virus are still needed in order to
fully understand the role of deISGylating activity in coronavirus infection, it serves as
a proof of concept that a mutant virus with defect DUB and/or deISGylating activity
is a valuable tool for functional studies of viral DUB and/or deISGylating activity
during virus infection.
Coronaviral nsp3 is a large, multi-domain protein, which functions through the
coordinated action among the domains. In order to understand the potential interplay
between the upstream Ubl2 domain and the PLP2 domain, mutation was introduced
into the Ubl2 domain. And it was found that a V787S mutation in the Ubl2 domain
compromises the stability and activity of the PLP2 domain, resulting in temperature-
dependent inactivation of the enzyme. Excitingly, the V787S mutant virus was shown
to display attenuated pathogenesis and induced protection in mice against challenge
from WT virus. However, the role of the Ubl2 domain seems to be varied in di↵erent
coronaviruses. More discussion on the Ubl2 domain is presented in Chaper 5.
Overall, our work here demonstrates the power of utilizing structure-guided pro-
tein engineering to selectively disrupt a specific enzymatic activity. Also, it provides
supports for the concept of using mutant virus with deficient DUB and/or deISGylat-
ing activity as a tool for functional studies of viral DUB and deISGylating activity.
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Excitingly, the R281A mutant virus we generated serves as a good starting point
towards this goal. In addition, our work with the Ubl2 mutant (V787S) suggests
that there are interactions among the multiple domains within nsp3. Finally, we were
able to create two attenuated viruses, the R281 mutant virus and the Ubl2 mutant
virus, which opens up two di↵erent approaches towards virus attenuation for vaccine
development.
6.2 Further directions
6.2.1 Viral deISGylating activity
From the preliminary studies with the R281A mutant virus, it suggests that the
deISGylating activity is critical in the escaping of the innate immune responses for
coronaviruses. Further investigation is still needed to understand the mechanism of
how CoV employs its deISGylating activity in viral evasion. It would be significant
if the structure of PLP2-ISG15 complex could be determined. With that, we may
be able to provide explanation regarding the loss of deISGylating activity as a result
of Arg-to-Ala mutation at position 281. In addition, with the structure of PLP2-
ISG15 complex, the ISG15-binding interface could be identified, so are residues that
are involved in the binding of ISG15. This would provide guidance towards the
engineering to manipulate the deISGylating activity of MHV PLP2. Since ISG15 is
a molecule with two Ubl domains linked through a flexible linker, it is challenging
to crystallize a complex with ISG15. To date, only the vOTU domain from CCHFV
with ISG15 has been successfully crystalized and strcutrally-determined [136]. To
circumvent the flexibility issue of the ISG15 molecule, an alternative approach is
to only use the C-terminal domain of ISG15 for complex formation. However, in
this case, we may miss out additional interactions if a second binding site with the
N-terminal domain of ISG15 exists, such as in the case of SARS-CoV PLpro [71].
Computational model could also be used to predict interactions between PLP2 and
ISG15. However, given the high flexibility of the linker in ISG15, it may be di cult
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to generate a reliable model with the full-length ISG15 molecule. Instead, it may be
a good idea to use only the C-terminal domain of ISG15 for model generation via
MD simulation.
If deISGylating activity is a powerful weapon evolved by CoVs to bypass the host
innate immune responses, getting rid of the deISGylating activity in the virus would
probably result in attenuated virus pathogenesis. Thus it is important to apply
similar studies to other medically- or economically-important coronavirus systems,
such as MERS-CoV, PEDV and FIPV. Furthermore, since bat is the reservoir for
coronaviruses, by evaluating the deISGylating activity of the PLPs from di↵erent bat
coronaviruses, we probably could gain some insights about emerging coronaviruses.
In addition to coronavirus, arterivirus and nairovirus are also found to have deIS-
Gylating activity. This activity comes from the viral OTU domain (vOTU) encoded
by the viruses, which has a fold similar to the ovarian tumor (OTU) domain protease,
a class of deubiquitinating enzymes. Interestingly, in contrast to eukaryotic OTU do-
mains that are ubiquitin-specific, vOTU domains from artervirus and nairovirus also
have ISG15 cross-reactivity. It is intriguing to investigate why does the vOTU do-
main of the virus evolve to have deISGylating activity in addition to the DUB activity.
There are a lot of questions remained to be answered: is the deISGylating activity
of vOTU domain critical for the pathogenesis of artervirus and nairovirus? Are the
mechanisms of how deISGylating activity is involved in virus infection the same or
di↵erent among coronavirus, artervirus and nairovirus?
6.2.2 Coronaviral nsp3
The PLP domains of coronavirus are only domains within its nsp3, which is the
largest subunit in the replicase complex with multiple domains. It is interesting to
explore the interplay among the domains within nsp3 and how the interplay may
a↵ect the overall function of nsp3. Our result that a mutation in the Ubl2 domain
a↵ects the stability and activity of the PLP2 domain support the idea of domain
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interactions within nsp3. The possible interaction between the ADRP domain and
the PLP2 domain could be another evidence, yet it remains to be further evaluated.
From the in vitro ubiquitin chain cleavage assay shown in 2.11, it suggests that the
DUB activity of PLP2 in the context of the DPUP-Ubl2-PLP2 construct may display
promiscuous recognition of ubiquitin chains. Cell-based assay also indicates non-
specific deubiquitination of cellular proteins by PLP2 [44]. Similar phenomena have
been observed for SARS-CoV PLpro and MERS-CoV PLpro as well [61]. It is not
impossible that CoV PLPs indiscriminately deubiquitinate multiple host cell proteins
during virus infection. However, if specific recognition is ever to be achieved, CoV
PLPs will need some help. The help could comes from other domains of nsp3, or
other nsps, or host factors. The interaction between PLP and its help may determine
the substrate tropism, thus resulting in the various levels of pathogenesis caused
by di↵erent coronaviruses. To start the investigation of the interplays within nsp3
domains, it will be informative if the structure of full-length nsp3 can be determined.
Since nsp3 is a transmembrane protein with more than 2,000 amino acids, it would be
challenging to solve the structure of nsp3 through X-ray crystallography. However, the
rapid development of electron microscopy in the past few years provide us with new
hope. Solving the structure or topology of CoV nsp3 using electron microscopy will
move us a big step forward towards the understanding of coronavirus pathogenesis.
APPENDICES
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APPENDIX A. PROTEIN SEQUENCE
DPUP-Ubl2-PLP2 (pp1ab residues 1525-1911)
E V E A L R H D I Q L D D D A R V F V Q A N M D C L P T D W R L V N K
F D S V D G V R T I K Y F E C P G G I F V S S Q G K K F G Y V Q N G S F
K E A S V S Q I R A L L A N K V D V L C T V D G V N F R S C C V A
E G E V F G K T L G S V F C D G I N V T K V R C S A I Y K G K
V F F Q Y S D L S E A D L V A V K D A F G F D E P Q L L K Y Y T M L G
M C K W P V V V C G N Y F A F K Q S N N N C Y I N V A C L M L Q H L S
L K F P K W Q W Q E A W N E F R S G K P L R F V S L V L A K G S F K F
N E P S D S I D F M R V V L R E A D L S G A T C N L E F V C K C G V K Q
E Q R K G V D A V M H F G T L D K G D L V R G Y N I A C T C G S K L V
H C T Q F N V P F L I C S N T P E G R K L P D D V V A A N I F T G G S V
G H Y T H V K C K P K Y Q L Y D A C N V N K V S E A K G N F T D C L Y
L K N L K
Italic: DPUP domain, pp1ab residues 1525–1607
Bold: Ubl2 domain, pp1ab residues 1608–1667
Regular: PLP2 catalytic core, pp1ab residues 1668-1911
Ubl2-PLP2 (pp1ab residues 1611-1970)
V D V L C T V D G V N F R S C C V A E G E V F G K T L G S V F C D G I N
V T K V R C S A I Y K G K V F F Q Y S D L S E A D L V A V K D A F G F D
E P Q L L K Y Y T M L G M C K W P V V V C G N Y F A F K Q S N N N C Y
I N V A C L M L Q H L S L K F P K W Q W Q E A W N E F R S G K P L R F V
S L V L A K G S F K F N E P S D S I D F M R V V L R E A D L S G A T C N L
E F V C K C G V K Q E Q R K G V D A V M H F G T L D K G D L V R G Y N
I A C T C G S K L V H C T Q F N V P F L I C S N T P E G R K L P D D V V A
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A N I F T G G S V G H Y T H V K C K P K Y Q L Y D A C N V N K V S E A K
G N F T D C L Y L K N L K Q T F S S V L T T F Y L D D V K C V E Y K P D
L S Q Y Y C E S G K Y Y T K P I I K A Q F R T F E K V D G V Y T N F K L
Fig. A.1.: Plasmids of MHV PLP2 used in Chapter 2 for protein expression in E. coli cells.
ADRP (pp1ab residues 1299-1522)
V G Y G M T F S M S P F E L A Q L Y G S C I T P N V C F V K G D V I K V V
R L V N A E V I V N P A N G R M A H G A G V A G A I A E K A G S A F I K E
T S D M V K A Q G V C Q V G E C Y E S A G G K L C K K V L N I V G P D A
R G H G K Q C Y S L L E R A Y Q H I N K C D N V V T T L I S A G I F S V P T
D V S L T Y L L G V V T K N V I L V S N N Q D D F D V I E K C Q V T S V A
G T K A L S L Q L A K N L C R D V K F V T N A C S S L F S E S C F V S S Y D V
ADRP-PLP2 (pp1ab residues 1299-1911)
V G Y G M T F S M S P F E L A Q L Y G S C I T P N V C F V K G D V I K V
V R L V N A E V I V N P A N G R M A H G A G V A G A I A E K A G S A F I
K E T S D M V K A Q G V C Q V G E C Y E S A G G K L C K K V L N I V G P
D A R G H G K Q C Y S L L E R A Y Q H I N K C D N V V T T L I S A G I F S
V P T D V S L T Y L L G V V T K N V I L V S N N Q D D F D V I E K C Q V
T S V A G T K A L S L Q L A K N L C R D V K F V T N A C S S L F S E S C F
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V S S Y D V L Q E V E A L R H D I Q L D D D A R V F V Q A N M D C L P T
D W R L V N K F D S V D G V R T I K Y F E C P G G I F V S S Q G K K F G
Y V Q N G S F K E A S V S Q I R A L L A N K V D V L C T V D G V N F R S
C C V A E G E V F G K T L G S V F C D G I N V T K V R C S A I Y K G K V
F F Q Y S D L S E A D L V A V K D A F G F D E P Q L L K Y Y T M L G M C
K W S V V V C G N Y F A F K Q S N N N C Y I N V A C L M L Q H L S L K F
P K W Q W Q E A W N E F R S G K P L R F V S L V L A K G S F K F N E P S
D S I D F M R V V L R E A D L S G A T C N L E F V C K C G V K Q E Q R K
G V D A V M H F G T L D K G D L V R G Y N I A C T C G S K L V H C T Q F
N V P F L I C S N T P E G R K L P D D V V A A N I F T G G S V G H Y T H
V K C K P K Y Q L Y D A C N V N K V S E A K G N F T D C L Y L K N L K
174
APPENDIX B. TEV PROTEASE PURIFICATION
A glycerol stock of E. coli BL21 (DE3) CodonPlus-RIL cells containing the His6-
TEV(S219V)-Arg5 protease expression vector pRK793 was maintained in the Mesecar
Lab. More information about the pRK793-TEV protease expression vector is available
in [137]. A starter culture was prepared by inoculating cells from the glycerol stock
in 50 ml of LB media supplemented with 50 mg/ml of carb and 30 mg/ml of cam. The
next day, 10 ml of the starter culture was transferred to 1 L of LB media (containing
50 mg/ml of carb and 30 mg/ml of cam) for protein expression. A total of three liters
of cells were grown at 37 C until the OD at 600 nm reached 0.5. IPTG was then
added to the cell culture to a final concentration of 1 mM, and protein expression
was allowed to occur for 4 hours at 30 C. Cells were harvested by centrifugation at
4,690 ⇥ g for 20 min at 4 C. Approximately 11 g of cells could be obtained from 3 L
of culture. Harvested cells were then directly stored at -80 C.
To purify the protein, the cell pellets were first thawed and resuspended in 50
ml of lysis bu↵er (20 mM Tris pH 8.0, 100 mM NaCl, 10% glycerol). The cells
were then lysed by sonication on ice-water using a Branson Digital Sonifier at 55%
amplitude for a total of 7 min with a single cycle of 10 sec on and 10 sec o↵. The
lysed cells were then subjected to centrifugation at 28,880 ⇥ g for 30 min at 4 C. The
clarified lysate was next decanted from the pellet and incubated with Talon cobalt
resins (pre-equilibrated in lysis bu↵er, Clontech Laboratories, Inc.) at 4 C for 30
min with gentle stirring. Next, the resin–lysate mixture was poured into a 120 ml
gravity column (Bio-Rad), followed by washes with 600 ml of lysis bu↵er and 150 ml
of lysis bu↵er containing 100 mM imidazole. Then the protein was eluted with 60
ml of lysis bu↵er containing 50 mM EDTA. The eluted protein was collected into a
beaker containing 10 ml of bME at 14.3 M, followed by dialysis at room temperature
for overnight into 2 L of Bu↵er 1 (20 mM Tris pH 8.0, 200 mM NaCl, 10% glycerol,
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10 mM bME). The next morning, the dialysis bu↵er was changed to 2 L of Bu↵er 2
(20 mM Tris pH 8.0, 200 mM NaCl, 10% glycerol, 1 mM EDTA, 10 bME), and the
dialysis continued for 4 hours at room temperature. Finally, the protein was aliquoted
and directly stored at -80 C.
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APPENDIX C. RESIDUE NUMBERING
Table C.1.: Numbering of residues in di↵erent context





















1 Purified DPUP-Ubl2-PLP2 with two residual residues
at the N-terminus from the TEV cleavage site.
2 Residues in bold are the catalytic triad.
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APPENDIX D. EXPRESSION, PURIFICATION AND KINETIC
CHARACTERIZATION OF PEDV PLP2
D.1 Protein sequence
PEDV PLP2 (pp1ab residues 1630–1922)
N K S V V I K V T E D T R S V K T V K V E S T V T Y G Q Q I G P C L V N
D T V V T D N K P V V A D V V A K V V P S A N W D S H Y G F D K A G E
F HML D H T G F A F P S E V V N G R R V L K T T D N N C W V N V T C L
Q L Q F A R F R F K S A G L Q A MW E S Y C T G D V AMF V H W L Y W
L T G V D K G Q P S D S E N A L NML S K Y I V P A G S V T I E R V T H D
G C C C S K R V V T A P V V N A S V L K L G V E D G L C P H G L N Y I D
K V V V V K G T T I V V N V G K P V V A P S H L F L K G V S Y T T F L D
N G N G V A G H Y T V F D H D T GMV H D G D V F V P G D L N V S P V
T N V V V S E
D.2 Protein expression
PEDV PLP2 (amino acid 1630–1922 of polyprotein 1ab from PEDV strain Indi-
ana, GenBank: AID56702.1) was codon-optimized for E. coli expression, and synthe-
sized by Bio Basic Inc (Toronto, Canada). The gene was then inserted into pEVL8
vector following the procedure described in Section 2.2.2. Next, plasmid pEVL8-
PEDV-PLP2 was transformed into E. coli strain BL21 (DE3) electro-competent cells.
Cells were grown in 2X YT media, and protein expression was induced with 0.1 mM
IPTG at 18 C for overnight. Approximately 20 g of cells from 4 L of cell culture were
harvested by centrifugation. Harvested cells were then directly stored at -80 C.
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D.3 Protein purification
Purification of PEDV PLP2 followed the procedure described in Section 2.2.2 with
slight variation in the bu↵er composition:
Bu↵er A: 25 mM Tris, pH 7.5, 500 mM NaCl, 20 mM Imidazole, 5 mM bME
Bu↵er B: 25 mM Tris, pH 7.5, 500 mM NaCl, 500 mM Imidazole, 5 mM bME
Bu↵er C: 25 mM Tris, pH 7.5, 100 mM NaCl, 5 mM bME
Bu↵er D: 25 mM Tris, pH 7.5, 100 mM NaCl, 10 mM DTT
The protein was initially purified through a Ni column. Pool from the Ni column
was then subjected to TEV protease cleavage at a mass ratio of 50:1 (PLP2:TEV),
followed by another Ni column to separate his-tag cleaved PEDV PLP2 from un-
cleaved PLP2. Finally, his-tag cleaved PLP2 was further purified through gel filtra-
tion (Superose 6 column). Figure D.1 shows the purity of PEDV PLP2 throughout
the purification.
D.4 Kinetic characterization
To characterize the activity of PEDV PLP2, substrates RLRGG-AMC, Ub-AMC
and ISG15-AMC were used. The assays were performed following the procedure
described in Section 2.2.5. Data were generated in singular experiment. The activities
of PEDV PLP2 at di↵erent substrate concentrations were shown in Figure D.2. Table
D.1 summarize the preliminary kinetic parameters of PEDV PLP2 with the three
substrates.
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Fig. D.1.: SDS-PAGE analysis of PEDV PLP2 throughout purification. (A) The purity of
his-tagged PEDV PLP2 after Ni column. (B) The purity of his-tag cleaved PEDV PLP2
after Superose 6 column. (C) The purity of final purified PEDV PLP2 (his-tag cleaved).
10% SDS-PAGE gels were used for analysis. The protein band of PEDV PLP2 was indicated
with an red arrow.
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Fig. D.2.: Kinetics of PEDV PLP2-catalyzed hydrolysis of substrates. Cleavage of RLRGG-
AMC (A), Ub-AMC (B) and ISG15-AMC (C) by PLP21525-1911 was measured at di↵erent
substrate concentrations. For each substrate, initial velocities were calculated at every
substrate concentration and then fit to equations (see Section 2.2.5 for details).




kcat/Km (mM-1 min-1) 0.004 22.9 0.01
kcat (min-1) – 13.8 –
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